

Myalgic encephalomyelitis (or encephalopathy) / chronic fatigue syndrome: diagnosis and management

[J] Evidence reviews for monitoring and reviewing people with ME/CFS

NICE guideline <number>

Evidence reviews underpinning recommendations and research recommendations in the NICE guideline

November 2020

Draft for Consultation

*These evidence reviews were developed
by the National Guideline Centre*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2021. All rights reserved. Subject to Notice of rights.

ISBN:

Contents

Contents	4
1. Monitoring and Review	5
1.1. Review question	5
1.1.1 Introduction	5
1.1.2 Summary of the protocol	5
1.1.3 Methods and process	6
1.1.4 Effectiveness evidence	7
1.1.5 Summary of studies included in the effectiveness evidence	7
1.1.6 Summary of the effectiveness evidence	7
1.1.7 Call for evidence	7
1.1.8 Economic evidence	8
1.1.9 Economic model	8
1.1.10 Evidence statements	8
1.2. The committee’s discussion and interpretation of the evidence	9
Appendices	14
Appendix A Review protocol	14
Appendix B Literature search strategies	26
B.1 Clinical search literature search strategy	26
B.2 Health economics literature search strategy	30
Appendix C – Effectiveness evidence study selection	35
Appendix D – Effectiveness evidence	36
Appendix E – Forest plots	37
Appendix F – Effectiveness evidence	38
Appendix G – Forest plots	39
Appendix H – GRADE and/or GRADE-CERQual tables	40
Appendix I – Economic evidence study selection	41
Appendix J – Economic evidence tables	42
Appendix K - Health economic model	43
Appendix L – Excluded studies	44
References	61

1. Monitoring and Review

1.1. Review question

What is the most clinically and cost-effective method of monitoring and reviewing people with ME/CFS?

1.1.1 Introduction

ME/CFS is a chronic complex, multisystem condition. Symptoms and clinical course can fluctuate with or without treatment interventions, making it difficult to have a fixed regime for the review of people with the illness. There is no established frequency, methodology or recording of monitoring or reviewing people with ME/CFS. Furthermore, the availability of specialist services in England and Wales means that review protocols are not consistent in the two countries. There is also a lack of consistency in recommendations for the diagnosis and management of the condition across European countries. Currently people are seen in specialist services for limited periods of time (usually 6 months to a year) and then discharged back to primary care. There is no clear guidance for primary care on follow up or monitoring. The current opportunistic approach for people with ME/CFS increases the risk that people will not be seen and in particular, that people most severely affected by ME/CFS will not be reviewed.

1.1.2 Summary of the protocol

For full details see the review protocol in Appendix A.

Table 1: PICO characteristics of review question

Population	Inclusion: Adults, children and young people who are diagnosed as having ME/CFS. Exclusion: Adults, children and young people with suspected ME/CFS
Interventions and comparisons	Any monitoring or reviewing strategies. These can be compared to each other or to a suitable comparator (i.e. no monitoring/review).
Outcomes	Longest follow up available: CRITICAL OUTCOMES: <ul style="list-style-type: none">• Quality of life (any validated scales, for example, EQ-5D, SF-36)• Pain (VAS/NRS)• Fatigue/fatigability (any validated scales)• Physical functioning / exercise tolerance / ADL (any validated scales)• Cognitive functioning (any validated scales)• Sleep quality (any validated scales)• Adverse effects (any reported by the studies)• Psychological outcomes• Patient satisfaction• Benefit status/employment/school attendance/school absences• Update of diagnostic status• Comorbidities• Activity monitoring• Post exertional Malaise (PEM)/Post exertional symptom exacerbation (PESE)
Study design	<ul style="list-style-type: none">• Systematic reviews• RCTs

Non-randomised studies will be excluded unless no RCTs are found. If no RCTs are found non-randomised comparative trials will be considered (including prospective cohort studies) if they have attempted to detect, and if necessary adjust for, confounding.

1 1.1.3 Methods and process

- 2 This evidence review was developed using the methods and process described in
- 3 [Developing NICE guidelines: the manual](#). Methods specific to this review question are
- 4 described in the review protocol in appendix A and the methods document
- 5 Declarations of interest were recorded according to [NICE's conflicts of interest policy](#).
- 6

1 **1.1.4 Effectiveness evidence**

2 **1.1.1.1. Included studies**

3 A search was conducted for randomised trials and non-randomised comparative studies
4 comparing the effectiveness of monitoring and review strategies versus each other or a
5 suitable comparator (i.e. no monitoring and review).

6 No relevant studies were identified.

7 **1.1.1.2. Excluded studies**

8 See the excluded studies list in Appendix L.

9 **1.1.5 Summary of studies included in the effectiveness evidence**

10 No relevant studies were identified.

11 **1.1.6 Summary of the effectiveness evidence**

12 No evidence was identified.

13 **1.1.7 Call for evidence**

14 See the methods document for detail on the process and methods for the call for evidence.

15 The committee identified monitoring and review as an area of the scope with a lack of
16 published evidence and proposed a call for evidence to identify any relevant literature not
17 identified in the searches. Submissions were received from 42 separate organisations or
18 individuals, consisting of 508 reports or references to publications (after removal of
19 duplicates). Of the submissions considered to be potentially relevant to this review question,
20 all were excluded. For details why submitted evidence was not relevant see call for evidence
21 excluded studies list in Appendix L.

22

23

1 **1.1.8 Economic evidence**

2 **1.1.1.3. Included studies**

3 No health economic studies were included.

4 **1.1.1.4. Excluded studies**

5 No relevant health economic studies were excluded due to assessment of limited
6 applicability or methodological limitations.

7 See also the health economic study selection flow chart in Appendix I.

8 **1.1.9 Economic model**

9 This area was highlighted as a potential priority for new cost-effectiveness analysis.
10 However, no clinical evidence was found on which to base a model.

11 **1.1.10 Evidence statements**

12 **1.1.1.5. Effectiveness**

13 • No relevant published evidence was identified.

14 **1.1.1.6. Economic**

15 • No relevant economic evaluations were identified.

16

1 **1.2. The committee’s discussion and interpretation of the** 2 **evidence**

3 The committee discussed this evidence with the findings from the reviews on Information for
4 people with ME/CFS and their families and carers (report A), Information and Support for
5 health and social care professionals (report B), access to care (report C), multidisciplinary
6 care (report I) and the reports on Children and Young people (Appendix 1) and people with
7 severe ME/CFS (Appendix 2). Where relevant this is noted.

8 **1.2.1 The outcomes that matter most**

9 Quality of life, pain, fatigue/fatigability, physical functioning, cognitive functioning, sleep
10 quality, adverse effects, psychological outcomes, patient satisfaction, benefit status,
11 employment and educational attendance, diagnostic status, co-morbidities, activity
12 monitoring and post exertional symptom exacerbation were all agreed by the committee to
13 be critical outcomes for decision making.

14 These outcomes reflect the direct impact ME/CFS symptoms have on a person (specifically
15 levels of pain, fatigue, physical functioning cognitive functioning, sleep quality, psychological
16 outcomes, post exertional symptom exacerbation (PESE), and in turn the impact on quality of
17 life (specifically benefit status, employment and educational attendance).

18 The impact of the monitoring and review strategies can be measured by the outcomes listed
19 above, if a strategy is successful symptoms would be managed appropriately and the impact on
20 a person’s life would be minimised compared to a strategy (including no review) that did not
21 identify worsening symptoms.

22 The effectiveness of a strategy is also reflected in these outcomes; diagnostic status, co-
23 morbidity identification, adverse effects and patient satisfaction. Diagnostic status and
24 comorbidity review and identification are key to ensuring that someone is receiving the
25 correct intervention and management for their condition. If this is not picked up in a review
26 this would have a detrimental impact on the person.

27 Any intervention for people with ME/CFS requiring contact with health and social care
28 services is likely to affect their physical and emotional energy levels. It is key that any
29 strategy should not make people with ME/CFS worse and strategies should ensure that they
30 are able to access the service successfully. Measuring adverse effects and patient
31 satisfaction address these concerns.

32 The committee acknowledged the lack of existing objective outcome measures of
33 effectiveness of interventions for ME/CFS and the limitations of subjective measures (see
34 Professor Edwards expert testimony – Appendix 3: Expert testimonies). Only validated
35 outcome measurement scales were included in the evidence review.

36 **1.2.2 The quality of the evidence**

37 No evidence was identified in the review or the call for evidence.

38 **1.2.3 Benefits and harms**

39 The committee acknowledged there is a lack of evidence on monitoring and review
40 strategies. However, the area is important to people with ME/CFS and providing guidance on
41 monitoring and review is likely to improve the care delivered to people with ME/CFS. The
42 committee made consensus recommendations informed by their own experience and
43 evidence in other areas of the guideline.

44 Stakeholders in the scoping consultation highlighted that people with ME/CFS need to have
45 regular monitoring and scheduled reviews of their health like all other people with a long term

1 condition. This was described as an area of care that is inadequate and neglected in people
2 with ME/CFS, people are lost to follow-up and do not receive appropriate support and care.

3 The committee noted that people with ME/CFS report little or no follow up care, monitoring or
4 scheduled reviews. This is reflected in Evidence review C: Access to care and the reports on
5 children and young people with ME/CFS (Appendix 1: Children and Young people), and
6 people with severe ME/CFS (Appendix 2: People with severe ME/CFS). The majority of
7 respondents with severe ME/CFS (41/60) reported not having any regular monitoring by any
8 healthcare profession and 92% (55/60) have not had ongoing medical support for an illness
9 (related or not related to ME/CFS). Poor experience of health and social care and lack of
10 trust in health and social care services has resulted in people with ME/CFS not engaging
11 with services and not receiving appropriate care or follow-up (see Evidence review C: Access
12 to care).

13 The committee emphasised that inadequate or inappropriate follow up and review impacts
14 not only on care related to ME/CFS but screening and assessment for other conditions and
15 preventative care. This has the potential consequence of worsening of symptoms and overall
16 deterioration in health.

17 **Principles of monitoring and review**

18 The committee agreed that although all adults with ME/CFS should be seen by specialist
19 services initially to confirm diagnosis and the development of a personalised management
20 plan, most will be primarily monitored and reviewed in primary care and this was reflected in
21 the recommendations (section 1.6 Review in primary care). The committee agreed a copy of
22 the management plan should be sent to the person's GP and discharge letters from
23 specialist services should be comprehensive and have a detailed plan for monitoring and
24 review in primary care. Specialist input may be needed for some people on an ongoing basis,
25 or intermittently, but the committee are aware of the significant delays that people can
26 experience in accessing specialist services after re-referral from primary services.

27 The committee noted that written assessments, and reassessments, are important for
28 accessing disability support. A scheduled review with a healthcare professional is an
29 opportunity to provide people with ME/CFS medical evidence of disability for the purpose of
30 claiming benefits and accessing support. Access to written assessments by healthcare
31 professionals is essential in supporting communication between educational providers and a
32 child or young person's family. Evidence from assessments increases understanding of the
33 child's capabilities and provides information on adjustments to help the child or young person
34 stay in education. It is also important in providing information to a local authority about why a
35 child or young person may have reduced or no school attendance.

36 The committee noted as with any part of providing care for people with ME/CFS it is vital to
37 consider and discuss with the person the most appropriate way for them to participate in a
38 review of their care. The ME/CFS population is underserved by health and social care
39 services and this is explored in Evidence review C: Access to care and information and
40 Evidence review A: Information and support for people with ME/CFS. The committee have
41 made recommendations on accessing services (see section 1.3 of the guideline) and
42 providing information for people with ME/CFS (see section 1.4 of the guideline).

43 The committee noted that review of care may be required by more than one professional
44 depending on the person's situation, for example someone with severe or very severe
45 ME/CFS and who is immobile will need assessments for contractures, and pressure ulcers
46 as well as other more general aspects of review.

47 The committee considered that a scheduled review alongside advice on self-management
48 and advice on who to contact in periods of worsening health could help people with ME/CFS
49 to feel more supported and able to better self-manage in between reviews.

50 **Review process**

1 The committee considered that adults with ME/CFS would benefit from having a review of all
2 aspects of their care at least annually. They acknowledged that not everyone might accept
3 this but made a recommendation to offer a review at least once a year.

4 The committee were clear that scheduled reviews (for both adults, children and young
5 people) do not override the need for regular monitoring of symptoms and additional reviews
6 in response to changing needs or episodes of acute illness. ME/CFS is a fluctuating medical
7 condition that affects each person differently and can vary in symptom presentation and
8 severity during the course of a day, week or longer. The impact of fluctuations can vary
9 widely and can range from being severely debilitating to people being able to carry out most
10 aspects of daily living. Additional monitoring and reviews may be needed for people with
11 severe or very severe ME/CFS.

12 The committee added specific examples to the recommendations for children and young
13 people. The committee discussed the needs of children and young people with ME/CFS
14 recognising that additional scheduled reviews may be necessary. They noted that when
15 children and young people reach developmental milestones the understanding of their
16 condition and management changes. During significant life changes (e.g. school and college
17 transitions, exam periods) more emotional and practical support may be required. After
18 considering this the committee recommended that children and young people are offered a
19 review of their care every six months.

20 The committee members working with children and young people with ME/CFS agreed that
21 the process for monitoring and review is different from adults and needs to address the
22 changing needs of children and young people as they develop. Supportive models of care,
23 with primary care working alongside a specialist centre was described as one model of care
24 that worked well. The committee members agreed that scheduled reviews for children and
25 young people should be carried out by or overseen by a paediatrician with expertise in
26 ME/CFS.

27 With particular reference to scheduled reviews, the committee observed that healthcare
28 professionals should understand they are unlikely to see people at their worst because of the
29 debilitating impact of their symptoms. These may prevent people from leaving their home,
30 and if they have cognitive difficulties they may wait until they are able to speak and explain
31 clearly before contacting services. Making contact with services can cause symptoms to
32 worsen and people may not have the energy to expend on communication even when health
33 or social care professionals are receptive. They may not contact professionals once they
34 have improved for fear of making their symptoms worse. A comment in the report on People
35 with severe ME/CFS (Appendix 2: People with severe ME/CFS) illustrates this, “any doctor
36 visit makes me ill (even a home visit), so it is only worthwhile for a specific purpose.”

37 **Content of a scheduled review**

38 The committee reflected on the evidence (see Evidence review B: Information for health and
39 social care professionals and Dr Muirhead’s related expert testimony in appendix 3) that
40 health care professionals lack the knowledge and training to confidently manage the care of
41 people with ME/CFS and agreed to provide guidance on areas that should be considered
42 during a scheduled review. The committee considered this could also be a useful resource
43 for carers and families when monitoring a person’s symptoms and health between scheduled
44 reviews (see evidence report A: information for people with ME/CFS).

45 The committee were hesitant to recommend specific tools or checklists, as evidence for their
46 use in the monitoring and review of people with ME/CFS has not been reviewed. They noted
47 there are scales being developed to use with people with ME/CFS to evaluate symptoms.

48 The committee agreed that as a minimum providing guidance of areas to assess would
49 ensure that relevant topics are discussed with people with ME/CFS. The committee
50 considered this guidance works best as a framework. A list could make a consultation

1 constrained and rigid and not responsive to the person and their needs. A list that takes a
2 long time to complete may be counterproductive, people with ME/CFS may find the time and
3 energy to complete a long assessment prohibitive and even damaging to their health. In
4 addition, the committee were aware that primary care consultation appointments are
5 commonly limited to 10 minutes and any assessment has to be realistic within these time
6 frames.

7 The committee were keen to reinforce that any review of care should be personalised taking
8 into account the person's own experience of ME/CFS. The committee observed it was
9 important that any review or assessment should not be done in isolation and there should be
10 access to the person's management plan and this should be reviewed with the person
11 considering the assessment.

12 The committee used their experience of undertaking assessments and reviews to
13 recommend areas for discussion under the following headings.

14 **Current condition and self-management**

15 People should be asked about changes in their condition and the impact of any changes
16 including what can and cannot be achieved. This is important to assess if someone has
17 experienced any flares or relapses and if their condition is worsening impacting on their life. It
18 is important to look at any self-management strategies, in particular those for energy
19 management to see if the strategies are effective or need revising.

20 **Symptoms**

21 As well as asking about someone's current condition the committee considered it was
22 important to ask directly about current symptoms and if these had changed or if any new
23 ones has developed. Then the current management of symptoms should be assessed to see
24 if any changes are needed. This is also important to assess if any new symptoms have been
25 attributed to ME/CFS but need further investigation for other causes and conditions.

26 **Current support**

27 The committee noted that when people are asked how they are managing, they may respond
28 they are managing well, for example carrying out activities of daily living, but not explain that
29 these are only possible with support from family members. The committee considered this
30 was particularly relevant in children and young people that may require considerable support
31 from their parents but need further questioning to assess accurately how they are managing.
32 This is important in identifying how much support a family may need. The committee were
33 aware that the level of care provided by family members is often unrecognised or are they
34 seen as partners in the healthcare team.

35 **Emotional and social wellbeing**

36 The committee considered that as part of any assessment someone should be asked about
37 their emotional and social wellbeing and the impact of ME/CFS on their lives.

38 **Any future plans**

39 People should be asked if they are considering any changes in their lives, or there are any
40 expected challenges anticipated. This can support effective planning with the aim of
41 preventing any flares and relapses.

42 The committee discussed how other areas of health can be forgotten when reviewing
43 someone with ME/CS. Aspects of care such as bone health and skin care may be neglected
44 if there is a focus on specific disease processes only. This is particularly pertinent to people
45 with ME/CFS and reduced mobility who should be assessed for osteoporosis, pressure sores
46 and these NICE guidelines are referenced in the recommendations.

1 In addition to this list the committee wanted to raise awareness that if the scheduled review
2 identified any issues for concern related to a person's ME/CFS then a referral to their contact
3 in specialist team should be made. The committee noted that some of the symptoms of
4 ME/CFS are similar to other those in other conditions and can be erroneously put down to
5 ME/CFS (for example, dizziness). They were aware of conditions that had been undiagnosed
6 or misdiagnosed and as a consequence treatment had been neglected causing harm. The
7 committee made a recommendation in the suspecting ME/CFS section of the guideline
8 raising the awareness of the possibility of other conditions. The committee made a similar
9 recommendation here to remind health care professionals to refer any issues identified in the
10 scheduled review to appropriate specialists for evaluation.

11 **1.2.4 Cost effectiveness and resource use**

12 No economic evidence on monitoring and reviewing people with ME/CFS was found.

13 There was no quantitative evidence for the frequency of review and so cost effectiveness is
14 uncertain.

15 ME/CFS is often a fluctuating condition and the impact on quality of life is considerable.¹⁵⁴ In
16 the committee's experience and in line with the qualitative evidence, a lack of monitoring can
17 be a barrier to the effective management of ME/CFS. Therefore, the committee agreed that
18 offering follow up yearly for adults and twice yearly for children would be important for
19 assessing worsening or changing of symptoms and modifying the patients' care plan and
20 would be commensurate with other long-term conditions.

21 An analysis of general practice records found that people with ME/CFS have an average of 7
22 GP consultations a year,⁹⁷ so these recommendations are unlikely to have a substantial
23 resource impact. However, the qualitative evidence in this guideline suggests that some
24 people with ME/CFS, including those with severe or very severe ME/CFS, do not get a
25 clinical review routinely, so for some this will be a change in practice.

26 The committee decided that it would be helpful to provide guidance on topics that may need
27 review for people with ME/CFS.

28

29

1 Appendices

2 Appendix A Review protocol

3 **Table 2: Review protocol for monitoring and review**

ID	Field	Content
	Scope	Monitoring and review
	Draft review questions	What is the most clinically and cost-effective method of reviewing people with ME/CFS? What is the most clinically and cost-effective method of monitoring people with ME/CFS?
0.	PROSPERO registration number	-
1.	Review title	What is the most clinically and cost-effective method of monitoring/reviewing people with ME/CFS?
2.	Review question	What is the most clinically and cost-effective method of monitoring/reviewing people with ME/CFS?
3.	Objective	To identify the most clinically and cost effective form of monitoring/reviewing to improve outcomes in adults and children with a diagnosis of ME/CFS.
4.	Searches	The following databases will be searched: <ul style="list-style-type: none"> • Cochrane Central Register of Controlled Trials (CENTRAL) • Cochrane Database of Systematic Reviews (CDSR) • Embase

		<ul style="list-style-type: none"> • MEDLINE • Cinahl <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> • English language studies • Human studies • Letters and comments are excluded. <p>Other searches:</p> <ul style="list-style-type: none"> • Inclusion lists of relevant systematic reviews will be checked by the reviewer. <p>The searches may be re-run 6 weeks before final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review.</p>
5.	Condition or domain being studied	ME / CFS
6.	Population	<p>Inclusion: Adults, children and young people who are diagnosed as having ME/CFS.</p> <p>Exclusion: Adults, children and young people with suspected ME/CFS</p>
7.	Intervention/Exposure/Test	

8.	Comparator/Reference standard/Confounding factors	Any monitoring/reviewing strategies evaluated by the eligible literature. These can be compared to each other or to a suitable comparator (i.e. no monitoring/review).
9.	Types of study to be included	<ul style="list-style-type: none"> • Systematic reviews • RCTs <p>Non-randomised studies will be excluded unless no RCTs are found. If no RCTs are found non-randomised comparative trials will be considered (including prospective cohort studies) if they have attempted to detect, and if necessary adjust for, confounding.</p>
10.	Other exclusion criteria	<p>Non-English language studies.</p> <p>Conference abstracts will be excluded as it is expected there will be sufficient full text published studies available.</p>
11.	Context	N/A
12.	Primary outcomes (critical outcomes)	<p>Longest follow up available:</p> <p>CRITICAL OUTCOMES:</p> <ul style="list-style-type: none"> • Quality of life (any validated scales, for example, EQ-5D, SF-36) • Pain (VAS/NRS) • Fatigue (any validated scales) • Physical functioning / exercise tolerance / ADL (any validated scales) • Cognitive functioning (any validated scales) • Sleep quality (any validated scales) • Adverse effects (any reported by the studies) • Psychological outcomes • Patient satisfaction • Benefit status/employment/school attendance/school absences

		<ul style="list-style-type: none"> • Update of diagnostic status • Comorbidities • Activity monitoring • post exertional symptom exacerbation
13.	Secondary outcomes (important outcomes)	<ul style="list-style-type: none"> • Care needs • Impact on the carer/family
14.	Data extraction (selection and coding)	<p>EndNote will be used for reference management, sifting, citations and bibliographies. Titles and/or abstracts of studies retrieved using the search strategy and those from additional sources will be screened for inclusion.</p> <p>The full text of potentially eligible studies will be retrieved and will be assessed for eligibility in line with the criteria outlined above.</p> <p>10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer.</p> <p>An in-house developed database; EviBase, will be used for data extraction. A standardised form is followed to extract data from studies (see Developing NICE guidelines: the manual section 6.4) and for undertaking assessment of study quality. Summary evidence tables will be produced including information on: study setting; study population and participant demographics and baseline characteristics; details of the intervention and control interventions; study methodology' recruitment and missing data rates; outcomes and times of measurement; critical appraisal ratings.</p>
15.	Risk of bias (quality) assessment	Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual .

		<p><u>For Intervention reviews the following checklist will be used according to study design being assessed:</u></p> <ul style="list-style-type: none"> • <u>Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS)</u> • <u>Randomised Controlled Trial: Cochrane RoB (2.0)</u> <p>10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:</p> <p>papers were included /excluded appropriately</p> <p>a sample of the data extractions</p> <p>correct methods are used to synthesise data</p> <p>a sample of the risk of bias assessments</p> <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p>
16.	Strategy for data synthesis	<p>Where possible, data will be meta-analysed. Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5) to combine the data given in all studies for each of the outcomes stated above. A fixed effect meta-analysis, with weighted mean differences for continuous outcomes and risk ratios for binary outcomes will be used, and 95% confidence intervals will be calculated for each outcome.</p> <p>Heterogeneity between the studies in effect measures will be assessed using the I² statistic and visually inspected. We will consider an I² value greater than 50% indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented using random-effects.</p>

		<p>GRADE pro will be used to assess the quality of each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome.</p> <p>If the population included in an individual study includes children aged under 12, it will be included if the majority of the population is aged over 12, and downgraded for indirectness if the overlap into those aged less than 12 is greater than 20%.</p> <p>Publication bias is tested for when there are more than 5 studies for an outcome. Other bias will only be taken into consideration in the quality assessment if it is apparent.</p> <p>Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome.</p> <p>If sufficient data is available to make a network of treatments, WinBUGS will be used for network meta-analysis.</p>
17.	Analysis of sub-groups	<p>Stratification:</p> <ul style="list-style-type: none"> • Age: children vs young people vs adults • Severity: severe vs not severe <p>Subgroups to investigate if heterogeneity is present:</p> <ul style="list-style-type: none"> • post infectious onset / no post infectious onset • Duration of illness (<3 months symptoms/3-36 months/>36 months) • Gender • When study was done (pre 2000/post 2000)

18.	Type and method of review	<input checked="" type="checkbox"/> Intervention <input type="checkbox"/> Diagnostic <input type="checkbox"/> Prognostic <input type="checkbox"/> Qualitative <input type="checkbox"/> Epidemiologic <input type="checkbox"/> Service Delivery <input type="checkbox"/> Other (please specify)		
19.	Language	English		
20.	Country	England		
21.	Anticipated or actual start date	01/01/20		
22.	Anticipated completion date	01/01/21		
23.	Stage of review at time of this submission	Review stage	Started	Completed
		Preliminary searches	<input checked="" type="checkbox"/>	<input type="checkbox"/>
		Piloting of the study selection process	<input checked="" type="checkbox"/>	<input type="checkbox"/>

		Formal screening of search results against eligibility criteria	<input type="checkbox"/>	<input type="checkbox"/>
		Data extraction	<input type="checkbox"/>	<input type="checkbox"/>
		Risk of bias (quality) assessment	<input type="checkbox"/>	<input type="checkbox"/>
		Data analysis	<input type="checkbox"/>	<input type="checkbox"/>
24.	Named contact	<p>5a. Named contact National Guideline Centre</p> <p>5b Named contact e-mail</p> <p>5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and the National Guideline Centre</p>		
25.	Review team members	<p>From the National Guideline Centre:</p> <ul style="list-style-type: none"> • Dr Kate Kelley [Guideline lead] • Ms Maria Smyth [Senior systematic reviewer] 		

		<ul style="list-style-type: none"> • Ms Melina Vasileiou [Systematic reviewer] • Dr Richard Clubbe [Systematic reviewer] • Dr Karin van Bart [Systematic reviewer] • Mr David Wonderling [Health economist] • Ms Agnes Cuyas [Information specialist] • Ms Kate Ashmore [Project manager]
26.	Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.
27.	Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.
28.	Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of <u>Developing NICE guidelines: the manual</u> . Members of the guideline committee are available on the NICE website: [NICE guideline webpage].
29.	Other registration details	
30.	Reference/URL for published protocol	
31.	Dissemination plans	NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:

		<ul style="list-style-type: none"> • notifying registered stakeholders of publication • publicising the guideline through NICE's newsletter and alerts • issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.
32.	Keywords	
33.	Details of existing review of same topic by same authors	N/A
34.	Current review status	<input checked="" type="checkbox"/> Ongoing <input type="checkbox"/> Completed but not published <input type="checkbox"/> Completed and published <input type="checkbox"/> Completed, published and being updated <input type="checkbox"/> Discontinued
35..	Additional information	N/A
36.	Details of final publication	www.nice.org.uk

1 Table 3: Health economic review protocol

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2004, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).³¹⁹</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. • If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included. <p>Where there is discretion</p> <p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to</p>

include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2004 or later but that depend on unit costs and resource data entirely or predominantly from before 2004 will be rated as 'Not applicable'.
- Studies published before 2004 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

1

2

Appendix B Literature search strategies

- 2 This literature search strategy was used for the following review question:
- 3 • What is the most clinically and cost-effective method of monitoring and reviewing people
4 with ME/CFS?
- 5 The literature searches for this review are detailed below and complied with the methodology
6 outlined in *Developing NICE guidelines: the manual*.³¹⁹
- 7 For more information, please see the Methodology review published as part of the
8 accompanying documents for this guideline.

B.1.9 Clinical search literature search strategy

- 10 Searches were constructed using a PICO framework where population (P) terms were
11 combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are
12 rarely used in search strategies for interventions as these concepts may not be well
13 described in title, abstract or indexes and therefore difficult to retrieve.
- 14 Searches for patient views were run in Medline (OVID), Embase (OVID), CINAHL, and
15 PsycINFO (ProQuest).

16 **Table 4: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 23 June 2020	Exclusions
Embase (OVID)	1974 – 23 June 2020	Exclusions
The Cochrane Library (Wiley)	Cochrane Reviews to 2020 Issue 6 of 12 CENTRAL to 2020 Issue 6 of 12	None
CINAHL, Current Nursing and Allied Health Literature (EBSCO)	Inception – 23 June 2020	None
PsycINFO (ProQuest)	Inception – 23 June 2020	Exclusions
Epistemonikos (The Epistemonikos Foundation)	Inception - 23 June 2020	None

17 Medline (Ovid) search terms

1.	Fatigue Syndrome, Chronic/
2.	chronic* fatigue*.ti,ab.
3.	((fatigue* adj2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*)).ti,ab.
4.	((myalgic or post infection* or postinfection*) adj (encephalomyelitis or encephalopathy)).ti,ab.
5.	((ME adj CFS) or (CFS adj ME) or CFIDS or PVFS).ti,ab.
6.	(Systemic Exertion Intolerance Disease or SEID).ti,ab.
7.	((CFS adj SEID) or (SEID adj CFS) or (ME adj CFS adj SEID) or (ME adj SEID) or (SEID adj ME)).ti,ab.
8.	((Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome or POTS) adj6 (CFS or chronic* fatigue* or ME or myalgic or SEID or systemic exertion)).ti,ab.

9.	((Post-exertional or postexertional) adj2 malaise).ti,ab.
10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia or neurasthenia).ti,ab.
11.	((atypical or simulating or resembling) adj poliomyelitis).ti,ab.
12.	((chronic adj2 epstein Barr virus) or CEBV or CAEBV or chronic mononucleosis).ti,ab.
13.	xenotropic murine leukemia virus-related virus.ti,ab.
14.	effort syndrome*.ti,ab.
15.	((akureyri or iceland or tapanui or royal free or royal free hospital) adj disease*) or ((yuppie or yuppy or tapanui) adj flu)).ti,ab.
16.	or/1-15
17.	letter/
18.	editorial/
19.	news/
20.	exp historical article/
21.	Anecdotes as Topic/
22.	comment/
23.	case report/
24.	(letter or comment*).ti.
25.	or/17-24
26.	randomized controlled trial/ or random*.ti,ab.
27.	25 not 26
28.	animals/ not humans/
29.	exp Animals, Laboratory/
30.	exp Animal Experimentation/
31.	exp Models, Animal/
32.	exp Rodentia/
33.	(rat or rats or mouse or mice).ti.
34.	or/27-33
35.	16 not 34
36.	limit 35 to English language

1 Embase (Ovid) search terms

1.	chronic fatigue syndrome/
2.	chronic* fatigue*.ti,ab.
3.	(fatigue* adj2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*)).ti,ab.
4.	((myalgic or post infection* or postinfection*) adj (encephalomyelitis or encephalopathy)).ti,ab.
5.	((ME adj CFS) or (CFS adj ME) or CFIDS or PVFS).ti,ab.
6.	(Systemic Exertion Intolerance Disease or SEID).ti,ab.
7.	((CFS adj SEID) or (SEID adj CFS) or (ME adj CFS adj SEID) or (ME adj SEID) or (SEID adj ME)).ti,ab.
8.	((Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome or POTS) adj6 (CFS or chronic* fatigue* or ME or myalgic or SEID or systemic exertion)).ti,ab.
9.	((Post-exertional or postexertional) adj2 malaise).ti,ab.
10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia or neurasthenia).ti,ab.

11.	((atypical or simulating or resembling) adj poliomyelitis).ti,ab.
12.	((chronic adj2 epstein Barr virus) or CEBV or CAEBV or chronic mononucleosis).ti,ab.
13.	xenotropic murine leukemia virus-related virus.ti,ab.
14.	effort syndrome*.ti,ab.
15.	((akureyri or iceland or tapanui or royal free or royal free hospital) adj disease*) or ((yuppie or yuppy or tapanui) adj flu)).ti,ab.
16.	or/1-15
17.	letter.pt. or letter/
18.	note.pt.
19.	editorial.pt.
20.	case report/ or case study/
21.	(letter or comment*).ti.
22.	or/17-21
23.	randomized controlled trial/ or random*.ti,ab.
24.	22 not 23
25.	animal/ not human/
26.	nonhuman/
27.	exp Animal Experiment/
28.	exp Experimental Animal/
29.	animal model/
30.	exp Rodent/
31.	(rat or rats or mouse or mice).ti.
32.	or/24-31
33.	16 not 32
34.	limit 33 to English language

1 Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Fatigue Syndrome, Chronic] this term only
#2.	chronic* fatigue*.ti,ab
#3.	(fatigue* near/2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*)):ti,ab
#4.	((myalgic or post infection* or postinfection*) near/1 (encephalomyelitis or encephalopathy)):ti,ab
#5.	((ME near/1 CFS) or (CFS near/1 ME) or CFIDS or PVFS):ti,ab
#6.	(Systemic Exertion Intolerance Disease or SEID):ti,ab
#7.	((CFS near/1 SEID) or (SEID near/1 CFS) or (ME near/1 CFS near/1 SEID) or (ME near/1 SEID) or (SEID near/1 ME)):ti,ab
#8.	(Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome or POTS)
#9.	((Post-exertional or postexertional) near/2 malaise):ti,ab
#10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia or neurasthenia):ti,ab
#11.	((atypical or simulating or resembling) near/1 poliomyelitis):ti,ab
#12.	((chronic epstein Barr virus) or CEBV or CAEBV or chronic mononucleosis):ti,ab
#13.	xenotropic murine leukemia virus-related virus:ti,ab
#14.	effort syndrome*.ti,ab
#15.	((akureyri or iceland or tapanui or "royal free" or "royal free hospital") near/1 disease*):ti,ab

#16.	((yuppie or yuppy or tapanui) near flu):ti,ab
#17.	(or #1-#16)

1 CINAHL (EBSCO) search terms

S1.	(MH "Fatigue Syndrome, Chronic")
S2.	chronic* fatigue*
S3.	(fatigue* n2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*))
S4.	((myalgic or post infection* or postinfection*) and (encephalomyelitis or encephalopathy))
S5.	((ME and CFS) or (CFS and ME) or CFIDS or PVFS)
S6.	(Systemic Exertion Intolerance Disease or SEID)
S7.	((CFS and SEID) or (SEID and CFS) or (ME and CFS and SEID) or (CFS and ME and SEID) or (ME and SEID) or (SEID and ME))
S8.	((Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome) and (CFS or chronic* fatigue* or ME or myalgic or SEID or systemic exertion))
S9.	((Post-exertional or postexertional) n2 malaise)
S10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia)
S11.	((atypical or simulating or resembling) and poliomyelitis)
S12.	(chronic epstein Barr virus or chronic mononucleosis)
S13.	xenotropic murine leukemia virus-related virus
S14.	effort syndrome*
S15.	((akureyri or iceland or tapanui or royal free or royal free hospital) and disease*) or ((yuppie or yuppy or tapanui) and flu))
S16.	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15

2 PsycINFO (ProQuest) search terms

1.	(((chronic* fatigue*) OR (fatigue* NEAR2 (disorder* OR syndrome* OR post viral OR postviral OR immune dysfunction* OR post infection* OR postinfection*)) OR ((myalgic OR post infection* OR postinfection*) NEAR1 (encephalomyelitis OR encephalopathy)) OR ((ME NEAR1 CFS) OR (CFS NEAR1 ME) OR CFIDS OR PVFS) OR (Systemic Exertion Intolerance Disease OR SEID) OR ((CFS NEAR1 SEID) OR (SEID NEAR1 CFS)) OR ((ME NEAR1 CFS NEAR1 SEID) OR (ME NEAR1 SEID) OR (SEID NEAR1 ME)) OR ((Orthostatic intolerance OR postural orthostatic tachycardia syndrome OR postural tachycardia syndrome OR POTS) NEAR6 (CFS OR chronic* fatigue* OR ME OR myalgic OR SEID OR systemic exertion)) OR (neurasthenic neuroses OR epidemic neuromyasthenia OR neurataxia OR neuroasthenia OR neurasthenia) OR ((atypical OR simulating OR resembling) NEAR1 poliomyelitis)) OR (((chronic NEAR2 epstein Barr virus) OR CEBV OR CAEBV OR chronic mononucleosis) OR (xenotropic murine leukemia virus-related virus) OR (effort syndrome*)) OR ((akureyri OR iceland OR tapanui OR royal free OR royal free hospital) NEAR1 disease*) OR ((yuppie OR yuppy OR tapanui) NEAR1 flu) OR MAINSUBJECT.EXACT.EXPLODE("Chronic Fatigue Syndrome")) AND (stpe.exact("Scholarly Journals") AND la.exact("ENG") AND po.exact("Human") NOT (me.exact("Empirical Study" OR "Quantitative Study" OR "Longitudinal Study" OR "Clinical Trial" OR "Qualitative Study" OR "Prospective Study" OR "Followup Study" OR "Literature Review" OR "Retrospective Study" OR "Systematic Review" OR "Meta Analysis") AND po.exact("Human"))
----	---

3 Epistemonikos search terms

1.	(advanced_title_en:((advanced_title_en:((chronic* fatigue* syndrome*) OR (fatigue* syndrome* OR fatigue* disorder* OR postviral fatigue* OR post viral fatigue* OR fatigue* immune dysfunction OR post infection fatigue* OR postinfection fatigue*)) OR (encephalomyelitis OR encephalopathy) OR ("ME/CFS" OR "CFS/ME" OR "CFIDS"
----	--

<p>OR "PVFS") OR (Systemic Exertion Intolerance Disease OR SEID) OR ((CFS AND SEID) OR (SEID AND CFS) OR (ME AND CFS AND SEID) OR (ME AND SEID) OR (SEID AND ME)) OR (Orthostatic intolerance OR postural orthostatic tachycardia syndrome OR postural tachycardia syndrome OR POTS) OR ((Post-exertional OR postexertional) AND malaise) OR (neurasthenic neuroses OR epidemic neuromyasthenia OR neurataxia OR neuroasthenia OR neurasthenia) OR (atypical poliomyelitis OR simulating poliomyelitis OR resembling poliomyelitis) OR (chronic epstein Barr virus OR CEBV OR CAEBV OR chronic mononucleosis) OR (xenotropic murine leukemia virus-related virus) OR (effort syndrome*) OR (akureyri OR iceland disease OR tapanui OR royal free disease) OR (yuppie flu OR yuppy flu OR tapanui flu)) OR advanced_abstract_en:((chronic* fatigue* syndrome*) OR (fatigue* syndrome* OR fatigue* disorder* OR postviral fatigue* OR post viral fatigue* OR fatigue* immune dysfunction OR post infection fatigue* OR postinfection fatigue*)) OR (encephalomyelitis OR encephalopathy) OR ("ME/CFS" OR "CFS/ME" OR "CFIDS" OR "PVFS") OR (Systemic Exertion Intolerance Disease OR SEID) OR ((CFS AND SEID) OR (SEID AND CFS) OR (ME AND CFS AND SEID) OR (ME AND SEID) OR (SEID AND ME)) OR (Orthostatic intolerance OR postural orthostatic tachycardia syndrome OR postural tachycardia syndrome OR POTS) OR ((Post-exertional OR postexertional) AND malaise) OR (neurasthenic neuroses OR epidemic neuromyasthenia OR neurataxia OR neuroasthenia OR neurasthenia) OR (atypical poliomyelitis OR simulating poliomyelitis OR resembling poliomyelitis) OR (chronic epstein Barr virus OR CEBV OR CAEBV OR chronic mononucleosis) OR (xenotropic murine leukemia virus-related virus) OR (effort syndrome*) OR (akureyri OR iceland disease OR tapanui OR royal free disease) OR (yuppie flu OR yuppy flu OR tapanui flu)))) OR advanced_abstract_en:((advanced_title_en:((chronic* fatigue* syndrome*) OR (fatigue* syndrome* OR fatigue* disorder* OR postviral fatigue* OR post viral fatigue* OR fatigue* immune dysfunction OR post infection fatigue* OR postinfection fatigue*)) OR (encephalomyelitis OR encephalopathy) OR ("ME/CFS" OR "CFS/ME" OR "CFIDS" OR "PVFS") OR (Systemic Exertion Intolerance Disease OR SEID) OR ((CFS AND SEID) OR (SEID AND CFS) OR (ME AND CFS AND SEID) OR (ME AND SEID) OR (SEID AND ME)) OR (Orthostatic intolerance OR postural orthostatic tachycardia syndrome OR postural tachycardia syndrome OR POTS) OR ((Post-exertional OR postexertional) AND malaise) OR (neurasthenic neuroses OR epidemic neuromyasthenia OR neurataxia OR neuroasthenia OR neurasthenia) OR (atypical poliomyelitis OR simulating poliomyelitis OR resembling poliomyelitis) OR (chronic epstein Barr virus OR CEBV OR CAEBV OR chronic mononucleosis) OR (xenotropic murine leukemia virus-related virus) OR (effort syndrome*) OR (akureyri OR iceland disease OR tapanui OR royal free disease) OR (yuppie flu OR yuppy flu OR tapanui flu)) OR advanced_abstract_en:((chronic* fatigue* syndrome*) OR (fatigue* syndrome* OR fatigue* disorder* OR postviral fatigue* OR post viral fatigue* OR fatigue* immune dysfunction OR post infection fatigue* OR postinfection fatigue*)) OR (encephalomyelitis OR encephalopathy) OR ("ME/CFS" OR "CFS/ME" OR "CFIDS" OR "PVFS") OR (Systemic Exertion Intolerance Disease OR SEID) OR ((CFS AND SEID) OR (SEID AND CFS) OR (ME AND CFS AND SEID) OR (ME AND SEID) OR (SEID AND ME)) OR (Orthostatic intolerance OR postural orthostatic tachycardia syndrome OR postural tachycardia syndrome OR POTS) OR ((Post-exertional OR postexertional) AND malaise) OR (neurasthenic neuroses OR epidemic neuromyasthenia OR neurataxia OR neuroasthenia OR neurasthenia) OR (atypical poliomyelitis OR simulating poliomyelitis OR resembling poliomyelitis) OR (chronic epstein Barr virus OR CEBV OR CAEBV OR chronic mononucleosis) OR (xenotropic murine leukemia virus-related virus) OR (effort syndrome*) OR (akureyri OR iceland disease OR tapanui OR royal free disease) OR (yuppie flu OR yuppy flu OR tapanui flu))))))</p>
--

B.2.1 Health economics literature search strategy

- 2 Health economic evidence was identified by conducting a broad search relating to ME/CFS
- 3 population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated
- 4 after March 2015) and the Health Technology Assessment database (HTA – this ceased to
- 5 be updated after March 2018), with no date restrictions. NHS EED and HTA databases are

- 1 hosted by the Centre for Research and Dissemination (CRD). Additional searches were run
- 2 on Medline and Embase for health economics.

3 Table 5: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	2014 – 30 June 2020	Exclusions Health economics studies
Embase	2014 –30 June 2020	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - 2003 – 31 March 2018 NHSEED - 2003 to 31 March 2015	None

4

5 Medline (Ovid) search terms

1.	Fatigue Syndrome, Chronic/
2.	chronic* fatigue*.ti,ab.
3.	((fatigue* adj2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*)).ti,ab.
4.	((myalgic or post infection* or postinfection*) adj (encephalomyelitis or encephalopathy)).ti,ab.
5.	((ME adj CFS) or (CFS adj ME) or CFIDS or PVFS).ti,ab.
6.	(Systemic Exertion Intolerance Disease or SEID).ti,ab.
7.	((CFS adj SEID) or (SEID adj CFS) or (ME adj CFS adj SEID) or (ME adj SEID) or (SEID adj ME)).ti,ab.
8.	((Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome or POTS) adj6 (CFS or chronic* fatigue* or ME or myalgic or SEID or systemic exertion)).ti,ab.
9.	((Post-exertional or postexertional) adj2 malaise).ti,ab.
10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia or neurasthenia).ti,ab.
11.	((atypical or simulating or resembling) adj poliomyelitis).ti,ab.
12.	((chronic adj2 epstein Barr virus) or CEBV or CAEBV or chronic mononucleosis).ti,ab.
13.	xenotropic murine leukemia virus-related virus.ti,ab.
14.	effort syndrome*.ti,ab.
15.	((akureyri or iceland or tapanui or royal free or royal free hospital) adj disease*) or ((yuppie or yuppy or tapanui) adj flu)).ti,ab.
16.	or/1-15
17.	letter/
18.	editorial/
19.	news/
20.	exp historical article/
21.	Anecdotes as Topic/
22.	comment/
23.	case report/
24.	(letter or comment*).ti.
25.	or/17-24
26.	randomized controlled trial/ or random*.ti,ab.

27.	25 not 26
28.	animals/ not humans/
29.	exp Animals, Laboratory/
30.	exp Animal Experimentation/
31.	exp Models, Animal/
32.	exp Rodentia/
33.	(rat or rats or mouse or mice).ti.
34.	or/27-33
35.	16 not 34
36.	limit 35 to English language
37.	Economics/
38.	Value of life/
39.	exp "Costs and Cost Analysis"/
40.	exp Economics, Hospital/
41.	exp Economics, Medical/
42.	Economics, Nursing/
43.	Economics, Pharmaceutical/
44.	exp "Fees and Charges"/
45.	exp Budgets/
46.	budget*.ti,ab.
47.	cost*.ti.
48.	(economic* or pharmaco?economic*).ti.
49.	(price* or pricing*).ti,ab.
50.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
51.	(financ* or fee or fees).ti,ab.
52.	(value adj2 (money or monetary)).ti,ab.
53.	or/37-52
54.	36 and 53

1 Embase (Ovid) search terms

1.	chronic fatigue syndrome/
2.	chronic* fatigue*.ti,ab.
3.	(fatigue* adj2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*)).ti,ab.
4.	((myalgic or post infection* or postinfection*) adj (encephalomyelitis or encephalopathy)).ti,ab.
5.	((ME adj CFS) or (CFS adj ME) or CFIDS or PVFS).ti,ab.
6.	(Systemic Exertion Intolerance Disease or SEID).ti,ab.
7.	((CFS adj SEID) or (SEID adj CFS) or (ME adj CFS adj SEID) or (ME adj SEID) or (SEID adj ME)).ti,ab.
8.	((Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome or POTS) adj6 (CFS or chronic* fatigue* or ME or myalgic or SEID or systemic exertion)).ti,ab.
9.	((Post-exertional or postexertional) adj2 malaise).ti,ab.
10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia or neurasthenia).ti,ab.

11.	((atypical or simulating or resembling) adj poliomyelitis).ti,ab.
12.	((chronic adj2 epstein Barr virus) or CEBV or CAEBV or chronic mononucleosis).ti,ab.
13.	xenotropic murine leukemia virus-related virus.ti,ab.
14.	effort syndrome*.ti,ab.
15.	((akureyri or iceland or tapanui or royal free or royal free hospital) adj disease*) or ((yuppie or yuppy or tapanui) adj flu)).ti,ab.
16.	or/1-15
17.	letter.pt. or letter/
18.	note.pt.
19.	editorial.pt.
20.	case report/ or case study/
21.	(letter or comment*).ti.
22.	or/17-21
23.	randomized controlled trial/ or random*.ti,ab.
24.	22 not 23
25.	animal/ not human/
26.	nonhuman/
27.	exp Animal Experiment/
28.	exp Experimental Animal/
29.	animal model/
30.	exp Rodent/
31.	(rat or rats or mouse or mice).ti.
32.	or/24-31
33.	16 not 32
34.	limit 33 to English language
35.	health economics/
36.	exp economic evaluation/
37.	exp health care cost/
38.	exp fee/
39.	budget/
40.	funding/
41.	budget*.ti,ab.
42.	cost*.ti.
43.	(economic* or pharmaco?economic*).ti.
44.	(price* or pricing*).ti,ab.
45.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
46.	(financ* or fee or fees).ti,ab.
47.	(value adj2 (money or monetary)).ti,ab.
48.	or/35-47
49.	34 and 48

1 NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Fatigue Syndrome, Chronic
#2.	(chronic fatigue or fatigue syndrome*)


#3.	((myalgic adj (encephalomyelitis or encephalopathy)))
#4.	((((ME adj CFS) or (CFS adj ME)))
#5.	(post viral fatigue or post viral syndrome* or viral fatigue syndrome* or PVFS)
#6.	#1 OR #2 OR #3 OR #4 OR #5
#7.	(neurasthenic neuroses or epidemic neuromyasthenia or post infectious encephalomyelitis or neurataxia or neuroasthenia)
#8.	((((atypical or simulating or resembling) adj poliomyelitis))
#9.	(chronic epstein Barr virus or chronic mononucleosis)
#10.	(xenotropic murine leukemia virus-related virus)
#11.	((((chronic fatigue and immune dysfunction syndrome*) or cfids or chronic fatigue-fibromyalgia syndrome* or chronic fatigue disorder* or Systemic Exertion Intolerance Disease or SEID or effort syndrome or post infectious fatigue))
#12.	(((((akureyri or iceland or tapanui or royal free or royal free hospital) adj disease*) or ((yuppie or yuppy or tapanui) adj flu)))
#13.	#7 OR #8 OR #9 OR #10 OR #11 OR #12
#14.	#6 or #13

1

2

1 Appendix C – Effectiveness evidence study selection

Figure 1: Flow chart of clinical study selection for the review of monitoring and review



2

3

1 **Appendix D – Effectiveness evidence**

2 None.

3

1 **Appendix E – Forest plots**

2 None.

3

1 **Appendix F – Effectiveness evidence**

2 None.

3

1 **Appendix G – Forest plots**

2 None.

3

1 **Appendix H – GRADE and/or GRADE-CERQual tables**


2 None.

3

4

1 Appendix I – Economic evidence study selection

Figure 2: Flow chart of health economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language

NB. Two papers were included in both the non-pharma and the multidisciplinary care reviews, in parallel with the review of clinical effectiveness.

1 **Appendix J – Economic evidence tables**

2 None.

3

1 **Appendix K - Health economic model**

2 No original economic modelling was undertaken.

3

1 Appendix L – Excluded studies

2 Clinical studies

3 Table 6: Studies excluded from the clinical review

Study	Exclusion reason
Allen 2008 ¹⁰	Incorrect study design - not an intervention study (literature review and expert opinion on the treatment/care of women with ME/CFS during pregnancy/postpartum period)
Brown 1999 ⁵⁷	Incorrect study design - not an intervention study (describes a treatment programme used at a hospital)
Bryan 1992 ⁵⁸	Incorrect study design - not an intervention study (describes an approach to treatment/management and monitoring/review in people with ME/CFS)
Christley 2012 ⁹⁰	Incorrect study design - not an intervention study (literature review on reproductive and pregnancy related issues and management in people with ME/CFS)
Jason 1994 ²¹⁵	Incorrect study design - not an intervention study (case study describing the use of a symptom rating scale to monitor fluctuation in symptoms over time)
Jason 2000 ²¹²	Incorrect study design - not an intervention study (describes a model which aims to measure illness stage/progression in people with ME/CFS)
Jason 2009 ²¹⁶	Incorrect study design - non-comparative study with no relevant outcomes (study used activity log to examine patterns, intensity and qualitative nature of activity in people with ME/CFS)
Kuehn 2018 ²⁵⁴	Incorrect study design - not a research article (news article describing ME/CFS)
Roor 2020 ³⁸⁵	Incorrect study design (assesses efficacy of intervention on the validity of cognitive performance measure results)
Ross 2004 ³⁸⁶	Incorrect study design/intervention - no relevant monitoring/reviewing interventions (systematic review on interventions, patient characteristics, neuropsychological test reliability and comorbid psychiatric conditions in people with ME/CFS)
Tillett 2000 ⁴⁵⁶	Incorrect study design - not an intervention study (study examines school attendance, management, and nature of follow-up in a cohort of school children diagnosed with ME/CFS)
Weatherburn 2007 ⁴⁹⁹	Incorrect study design - non-comparative study and no relevant outcomes (study examining the feasibility of teleconference distance review in a group of patients with ME/CFS)

4 A call for evidence was sent out for three review questions for which the committee
5 anticipated that there would be limited published evidence. Some articles were submitted
6 with a clear indication of which of the three review questions they related to, but for many
7 there was no clear indication. Regardless, all articles were assessed for eligibility for
8 inclusion in all three reviews and one main table was created for all studies/articles submitted
9 that were subsequently excluded. For some articles, there were multiple reasons for
10 exclusion across the three review questions. The exclusion reason listed is the main reason
11 for exclusion from the review that the article was judged to be most relevant to. For example,
12 a quantitative study on the effectiveness of an intervention in people diagnosed with ME/CFS
13 was considered to be most relevant to the experiences of interventions question, but the
14 review protocol specified only qualitative studies to be included, so the main reason for
15 exclusion would be incorrect study design. Some articles were relevant to the guideline in
16 general, but did not specifically attempt to answer any of the three review questions.

1 **Table 7: Studies excluded from call for evidence**

Study	Exclusion reason
Action for ME 2001 ²	Incorrect study design (quantitative survey)
Action for ME 2014 ³⁴⁵	No relevant themes
Action for ME 2019 Results from our big survey ¹ (unpublished)	Incorrect study design (quantitative survey)
Action for ME and Association of Young People with ME (UK) 2008 ³	Incorrect study design (qualitative survey)
Adamowicz 2014 ⁴	Systematic review with different PICO
Adamson ⁵ (unpublished)	Incorrect study design (cohort)
Adedeji 2012 ⁶	Study/article does not address any of the call for evidence review questions
Adelakun ⁷	No useable data - qualitative data reported as most frequently occurring words
Ahmed 2020 ⁸	Incorrect study design (systematic review; no qualitative data)
All-Party Parliamentary Group on ME 2010 ⁹	Not a qualitative study
Allwright 2019 ¹¹	No relevant themes
Anderson 1997 ¹³	Mixed method study design with no extractable themes
Anderson ¹² (unpublished)	Incorrect study design (qualitative)
Anon ⁴²⁹	Incorrect study design (quantitative survey)
Anon ³⁹⁸	Incorrect study design (non-comparative intervention study)
Anon ¹⁴	Incorrect study design (non-comparative intervention study with quantitative outcomes)
Anon 2013 ³⁴⁶ (unpublished)	Incorrect study design (quantitative survey)
Anon 2015 ⁹⁵	Trial registry record; no results posted
Anon 2015 ³⁹⁹	Incorrect study design (quantitative)
Anon 2015 ¹⁵	Unable to obtain
Anon 2016 ²⁸ (unpublished)	Letter/commentary/expert opinion
Anon 2016 ³⁷²	Study/article does not address any of the call for evidence review questions
Anon 2017 ¹⁵²	Study/article does not address any of the call for evidence review questions
Anon 2018 ³⁶³	Not research article
Antcliff 2019 ¹⁶	Incorrect population (HCPs)
Antiel 2011 ¹⁷	Incorrect interventions (no intervention)
Armstrong 2012 ¹⁸	Study/article does not address any of the call for evidence review questions
Arnold 2015 ¹⁹	Incorrect study design (RCT)
Ates 2016 ²⁰	Study/article does not address any of the call for evidence review questions
Augusto 2018 ²¹	Study/article does not address any of the call for evidence review questions
BACME 2019 ²²	Incorrect population (survey of CFS/ME services)
Balaguru 2012 ²³	Study/article does not address any of the call for evidence review questions
Baos 2019 ²⁴	RCT protocol

Study	Exclusion reason
Baraniuk 2017 ²⁶	Study/article does not address any of the call for evidence review questions
Baraniuk 2018 ²⁵	Study/article does not address any of the call for evidence review questions (BMJ best practice)
Barnden 2016 ²⁷	Study/article does not address any of the call for evidence review questions
Bazelmans 2004 ²⁹	Incorrect population (therapists)
Bazelmans 2005 ³⁰	Incorrect study design (quantitative)
Bazilevskaya 2006 ³¹	Study/article does not address any of the call for evidence review questions
Beasant ³² (unpublished)	Incorrect study design (qualitative)
Belgian Ministry of Social Affairs, Public Health and Environment 2000 ³³	Guidelines including systematic review of the evidence (unclear source of data on patient experience of CBT)
Bell 2016 ³⁴	Letter/commentary/expert opinion
Berkovitz 2009 ³⁵	Incorrect interventions (no intervention)
Blease 2017 ³⁶	Incorrect study design (review article)
Blout 2015 ³⁷	Incorrect study design (quantitative)
Blue Ribbon for the Awareness of Myalgic Encephalomyelitis 2010 ³⁸ (unpublished)	Incorrect study design (quantitative survey; no qualitative data)
Boneva 2019 ³⁹	Incorrect interventions (no intervention)
Bould 2011 ⁴¹	Review
Bould 2013 ⁴⁰	Not relevant to any call for evidence questions
Bowers 2019 ⁴²	Study/article does not address any of the call for evidence review questions
Brigden ⁴⁶ (unpublished)	Incorrect study design (qualitative)
Brigden 2018 ⁴⁵	No intervention
Brigden 2018 ⁴³	No relevant themes
Brigden 2016 ⁴⁴	RCT protocol
Bringsli 2014 ⁴⁷	Incorrect study design (quantitative survey)
Bristol CFS/ME Service ⁴⁹	Incorrect study design (survey)
Bristol CFS/ME Service ⁴⁸ (unpublished)	Incorrect study design (qualitative)
Britain 2019 ⁵⁰	Conference abstract
Brooks 2011 ⁵¹	Incorrect study design (quantitative)
Broughton 2017 ⁵²	Incorrect interventions (specialist services rather than specific interventions)
Brouwers 2002 ⁵³	Incorrect study design (RCT)
Brown 2012 ⁵⁵	Study/article does not address any of the call for evidence review questions
Brown 2005 ⁵⁶	Study/article does not address any of the call for evidence review questions
Brown 2015 ⁵⁴	Study/article does not address any of the call for evidence review questions
Buchachenko 2013 ⁶³	Study/article does not address any of the call for evidence review questions

Study	Exclusion reason
Buchachenko 2005 ⁶¹	Study/article does not address any of the call for evidence review questions
Buchachenko 2006 ⁶²	Study/article does not address any of the call for evidence review questions
Buchachenko 2017 ⁶⁰	Study/article does not address any of the call for evidence review questions
Buchachenko 2019 ⁵⁹	Study/article does not address any of the call for evidence review questions
Burgess 2012 ⁶⁴	Incorrect study design (RCT)
Burke 1986 ⁶⁵	Study/article does not address any of the call for evidence review questions
Butland 1982 ⁶⁶	Study/article does not address any of the call for evidence review questions
Calello 2018 ⁶⁷	Study/article does not address any of the call for evidence review questions
Carpenter 2013 ⁶⁸	Study/article does not address any of the call for evidence review questions
Carruthers 2011 ⁷¹	Study/article does not address any of the call for evidence review questions
Carruthers 2012 ⁷⁰	Study/article does not address any of the call for evidence review questions
Carruthers 2003 ⁶⁹	Guidelines
Casanova 2011 ⁷²	Study/article does not address any of the call for evidence review questions
Castro-Marrero 2016 ⁷⁴	Incorrect study design (RCT)
Castro-Marrero 2017 ⁷³	Study/article does not address any of the call for evidence review questions
Cella 2011 ⁷⁶	Incorrect study design (quantitative)
Cella 2011 ⁷⁵	Incorrect study design (quantitative)
Centers for Disease Control and Prevention 2019 ⁷⁷	Study/article does not address any of the call for evidence review questions
CFS/ME National Outcomes Database Team 2016 ⁷⁸	Incorrect study design (non-comparative observational study)
CFS/ME Service for South Yorkshire and North Derbyshire 2019 ⁷⁹	Incorrect study design (quantitative survey)
CFS/ME Service for South Yorkshire and North Derbyshire ⁸⁰	Incorrect study design (quantitative survey)
CFS/ME Working Group 2002 ⁸¹ (unpublished)	No relevant themes
Chaudhuri 2003 ⁸⁸	Study/article does not address any of the call for evidence review questions
Chalder 1993 ⁸³	Study/article does not address any of the call for evidence review questions
Chalder 2010 ⁸⁴	Incorrect study design (RCT)
Chalder 2010 ⁸²	Incorrect study design (review, not qualitative)
Chalder 2015 ⁸⁵	Incorrect study design (quantitative)
Chan 2019 ⁸⁶	Not a qualitative study
Chang 2012 ⁸⁷	Incorrect interventions (no intervention)

Study	Exclusion reason
Childs 2019 ⁸⁹	Incorrect study design (quantitative survey); no qualitative data
Chu 2018 ⁹¹	Study/article does not address any of the call for evidence review questions
Claypoole 2007 ⁹²	Incorrect interventions (no intervention)
Cleare 2004 ⁹³	Incorrect study design (quantitative)
Cliff 2019 ⁹⁴	Study/article does not address any of the call for evidence review questions
Cockshell 2010 ⁹⁶	Incorrect interventions (no intervention)
Collin 2018 ¹⁰¹	Study/article does not address any of the call for evidence review questions
Collin 2017 ⁹⁹	Incorrect study design (non-comparative cohort study)
Collin 2017 ⁹⁷	Incorrect study design (case-control)
Collin 2017 ⁹⁸	Study/article does not address any of the call for evidence review questions
Collin 2016 ¹⁰²	Study/article does not address any of the call for evidence review questions
Collin 2015 ¹⁰³	Study/article does not address any of the call for evidence review questions
Collin 2012 ¹⁰⁴	Incorrect study design (quantitative survey)
Collin 2011 ¹⁰⁰	Study/article does not address any of the call for evidence review questions
Comhaire 2018 ¹⁰⁵	Incorrect study design (quantitative)
Cook 2017 ¹⁰⁶	Incorrect interventions (no intervention)
Cooper 2019 ¹⁰⁷	No relevant themes (qualitative data on an ME/CFS service, not specific interventions)
Corsius 2019 ¹⁰⁸	Report summary; full report in Dutch
Costa 1995 ¹⁰⁹	Study/article does not address any of the call for evidence review questions
Crawford 2010 ¹¹¹	Study/article does not address any of the call for evidence review questions
Crawford 2012 ¹¹⁰	Letter/commentary/expert opinion
Crawford 2012 ¹¹²	Study advertisement
Crawley 2018 ¹¹⁸	Not relevant to monitoring/review question
Crawley 2013 ¹¹⁵	Incorrect interventions
Crawley 2013 ¹¹³	No relevant outcomes
Crawley 2011 ¹¹⁷	No intervention
Crawley 2009 ¹¹⁴	Study/article does not address any of the call for evidence review questions
Crawley 2009 ¹¹⁶	Study/article does not address any of the call for evidence review questions
Crowhurst 2005 ¹¹⁹	Letter/commentary/expert opinion
Crowhurst 2007 ¹²⁰	No relevant themes
Currell ¹²¹	No relevant themes (qualitative data on a specialist service, not specific interventions)
DARPA 2017 ¹²²	Study/article does not address any of the call for evidence review questions
Davenport 2010 ¹²⁷	Incorrect study design (conceptual model; not qualitative)
Davenport 2019 ¹²³	Study/article does not address any of the call for evidence review questions

Study	Exclusion reason
Davenport 2011 ¹²⁵	Study/article does not address any of the call for evidence review questions
Davenport 2011 ¹²⁴	Incorrect study design (quantitative)
Davenport 2019 ¹²⁶	Letter/commentary/expert opinion
Davies 2008 ¹²⁸	Study/article does not address any of the call for evidence review questions
Dawes 2019 ¹⁵³	Executive summary of an excluded survey
Deale 2001 ¹³⁶	Incorrect study design (RCT)
Deale 1998 ¹³⁵	Incorrect study design (quantitative)
Deale 1997 ¹³⁴	Incorrect study design (RCT)
De Becker 2000 ¹³⁰	Study/article does not address any of the call for evidence review questions
De Becker 2001 ¹²⁹	Study/article does not address any of the call for evidence review questions
de Carvalho 2011 ¹³¹	Study/article does not address any of the call for evidence review questions
Deftereos 2016 ¹³⁷	Incorrect population (expert clinicians)
de Lange 2008 ¹³²	Incorrect study design (quantitative)
DeLuca 2004 ¹³⁸	Incorrect interventions (no intervention)
de Vega 2017 ¹³³	Study/article does not address any of the call for evidence review questions
Devasahayam 2012 ¹³⁹	Study/article does not address any of the call for evidence review questions
Diao 2017 ¹⁴⁰	Study/article does not address any of the call for evidence review questions
Dobson 2007 ¹⁴¹	Study/article does not address any of the call for evidence review questions
Dougall 2014 ¹⁴²	Incorrect study design (RCT)
Doukrou 2019 ¹⁴³	Incorrect study design (no qualitative data)
Dowsett 1997 ¹⁴⁴	Study/article does not address any of the call for evidence review questions
Duyn 2017 ¹⁴⁵	Study/article does not address any of the call for evidence review questions
Dyda 2018 ¹⁴⁶	Study/article does not address any of the call for evidence review questions
Effective Health Care Program: Agency for Healthcare Research and Quality ¹⁴⁷	Systematic review protocol
Emerge Australia 2018 ¹⁴⁸	Incorrect study design (quantitative survey)
Emerge Australia 2019 ¹⁴⁹	Incorrect study design (quantitative survey)
Encephalitis Society 2017 ¹⁵⁰	Study/article does not address any of the call for evidence review questions (website information)
Eroshenko 2004 ¹⁵¹	Study/article does not address any of the call for evidence review questions
Falk Hvidberg 2015 ¹⁵⁴	Incorrect interventions (no intervention)
Faulkner 2016 ¹⁵⁵	Letter/commentary/expert opinion
Fisher 2013 ¹⁵⁶	No relevant themes
Fisk 1994 ¹⁵⁷	Not relevant to any call for evidence questions

Study	Exclusion reason
Flo 2014 ¹⁵⁸	Incorrect study design (quantitative)
Fluge 2019 ¹⁶⁰	Incorrect study design (RCT)
Fluge 2015 ¹⁶¹	Incorrect study design (quantitative)
Fluge 2016 ¹⁵⁹	Study/article does not address any of the call for evidence review questions
Forward ME Survey 2019 ³³⁶	Incorrect study design (survey)
Franklin 2018 ¹⁶²	Incorrect study design (quantitative)
Fukuda 2016 ¹⁶³	Incorrect study design (RCT)
Garner 2019 ¹⁶⁴	Study/article does not address any of the call for evidence review questions
Geraghty 2018 ¹⁶⁸	Incorrect study design (narrative review)
Geraghty 2016 ¹⁷⁰	Incorrect study design (debate article)
Geraghty 2019 ¹⁶⁹	Incorrect study design (literature review)
Geraghty 2019 ¹⁶⁶	Letter/commentary/expert opinion
Geraghty 2017 ¹⁶⁵	Incorrect study design (analysis of quantitative survey data)
Geraghty 2019 ¹⁶⁷	Study/article does not address any of the call for evidence review questions
Ghatineh 2017 ¹⁷¹	Review of an RCT
Gielissen 2007 ¹⁷²	Study/article does not address any of the call for evidence review questions
Gieré 2016 ¹⁷³	Study/article does not address any of the call for evidence review questions
Gilder 2018 ¹⁷⁴	Study/article does not address any of the call for evidence review questions
Gladwell 2013 ¹⁷⁵	Incorrect study design (survey)
Goedendorp 2009 ¹⁷⁶	Study/article does not address any of the call for evidence review questions
Haig-Ferguson 2019 ¹⁷⁷	No relevant themes
Haig-Ferguson 2009 ¹⁷⁸	No relevant themes
Halapy 2017 ¹⁷⁹	Letter/commentary/expert opinion
Harada 1999 ¹⁸⁰	Study/article does not address any of the call for evidence review questions
Haywood 2012 ¹⁸²	Study/article does not address any of the call for evidence review questions
Haywood 2014 ¹⁸¹	Systematic review with different PICO
Heald 2019 ¹⁸³	Study/article does not address any of the call for evidence review questions
Healthwatch Trafford 2017 ¹⁸⁵	No relevant themes
Healthwatch Lancashire 2017 ¹⁸⁴	Different focus to review question
Heins 2013 ¹⁸⁷	Incorrect study design (quantitative)
Heins 2013 ¹⁸⁶	Incorrect study design (quantitative)
Heins 2011 ¹⁸⁸	Incorrect study design (quantitative)
Heins 2010 ¹⁸⁹	Incorrect study design (quantitative)
Hives 2017 ¹⁹⁰	Incorrect study design (diagnostic accuracy study)
Hodges 2018 ¹⁹¹	Incorrect interventions (no intervention)

Study	Exclusion reason
Holtzman 2019 ¹⁹²	Study/article does not address any of the call for evidence review questions
Hughes 2002 ¹⁹⁴	Review article
Hughes 2018 ¹⁹³	Study/article does not address any of the call for evidence review questions
Huibers 2004 ¹⁹⁵	Incorrect population (some met criteria for CFS, some did not and results not reported separately)
Ickmans 2014 ¹⁹⁶	Incorrect interventions (no intervention)
ICNIRP Project Group 2017 ¹⁹⁷	Study/article does not address any of the call for evidence review questions
Ingman 2016 ²⁰⁰	Incorrect study design (quantitative)
Ingman ¹⁹⁹	Unable to obtain
Ingman ¹⁹⁸	Unable to obtain
Institute of Medicine 2015 ²⁰¹	Study/article does not address any of the call for evidence review questions
ISRCTN Registry 2015 ²⁰²	Study/article does not address any of the call for evidence review questions
Jackson 2012 ²⁰³	Study/article does not address any of the call for evidence review questions
Janse 2019 ²⁰⁴	Prognostic study looking at predictors of outcome of CBT - none relevant to CFE questions
Janse 2019 ²⁰⁶	Incorrect study design (non-randomised quantitative study)
Janse 2018 ²⁰⁸	Incorrect study design (RCT)
Janse 2017 ²⁰⁵	Incorrect study design (RCT)
Janse 2016 ²⁰⁷	Incorrect population (idiopathic chronic fatigue); incorrect study design (RCT)
Janse 2015 ²⁰⁹	RCT protocol
Jason 2006 ²¹¹	Study/article does not address any of the call for evidence review questions
Jason 2008 ²¹⁷	Study/article does not address any of the call for evidence review questions
Jason 2009 ²¹⁰	Incorrect study design (quantitative)
Jason 2009 ²¹³	Study/article does not address any of the call for evidence review questions
Jason 2015 ²¹⁸	Review article
Jason 2018 ²¹⁴	Not relevant to any call for evidence question
Jelinek 2001 ²¹⁹	Study/article does not address any of the call for evidence review questions
Jenkins 2005 ²²⁰	Study/article does not address any of the call for evidence review questions
Jones 2012 ²²¹	Incorrect study design (quantitative)
Josev 2019 ²²²	Incorrect interventions (no intervention)
Juutilainen 2018 ²²³	Study/article does not address any of the call for evidence review questions
Kapitein 2015 ²²⁴	Study/article does not address any of the call for evidence review questions
Kasevich 2002 ²²⁵	Study/article does not address any of the call for evidence review questions
Keller 2014 ²²⁶	Incorrect interventions (no intervention)

Study	Exclusion reason
Kempke 2013 ²²⁷	Study/article does not address any of the call for evidence review questions
Kenyon 2019 ²²⁸	Incorrect study design (quantitative)
Kim 2019 ²²⁹	Study/article does not address any of the call for evidence review questions
Kindlon 2011 ²³⁷	Letter/commentary/expert opinion
Kindlon 2017 ²³¹	Letter/commentary/expert opinion
Kindlon 2009 ²³⁰	Letter/commentary/expert opinion
Kindlon 2010 ²³⁹	Letter/commentary/expert opinion
Kindlon 2010 ²⁴¹	Letter/commentary/expert opinion
Kindlon 2011 ²³³	Letter/commentary/expert opinion
Kindlon 2012 ²³⁴	Letter/commentary/expert opinion
Kindlon 2012 ²³⁵	Letter/commentary/expert opinion
Kindlon 2015 ²³²	Letter/commentary/expert opinion
Kindlon 2015 ²⁴⁰	Letter/commentary/expert opinion
Kindlon 2015 ²⁴²	Letter/commentary/expert opinion
Kindlon 2011 ²³⁶	Letter/commentary/expert opinion
Kindlon 2009 ²³⁸	Letter/commentary/expert opinion
Kingdon 2018 ²⁴³	Study/article does not address any of the call for evidence review questions
Knoester 2019 ²⁴⁴	Study/article does not address any of the call for evidence review questions
Knoop 2008 ²⁴⁹	Incorrect study design (RCT)
Knoop 2007 ²⁴⁸	Incorrect study design (quantitative)
Knoop 2007 ²⁴⁶	Incorrect study design (quantitative)
Knoop 2007 ²⁴⁵	Incorrect study design (quantitative)
Knoop 2008 ²⁴⁷	Incorrect study design (RCT)
Knudsen 2011 ²⁵⁰	Study/article does not address any of the call for evidence review questions
Kodama 2013 ²⁵¹	Study/article does not address any of the call for evidence review questions
Kreyberg 2007 ²⁵²	Guidelines
Kreyberg 2007 ²⁵³	Incorrect population (nursing staff)
Lacerda 2018 ²⁵⁵	Study/article does not address any of the call for evidence review questions
Lacerda 2019 ²⁵⁶	No relevant themes
LaManca 1998 ²⁵⁷	Incorrect interventions (no intervention)
Lapp 2019 ²⁵⁸	Letter/commentary/expert opinion
Larun 2014 ²⁵⁹	Incorrect study design (systematic review of RCTs)
Leaman 1997 ²⁶⁰	Study/article does not address any of the call for evidence review questions
Leone 2006 ²⁶²	Not relevant to any call for evidence question
Lewis 2013 ²⁶³	Incorrect interventions (no intervention)
Lien 2019 ²⁶⁴	Study/article does not address any of the call for evidence review questions
Light 2009 ²⁶⁵	Incorrect study design (quantitative)

Study	Exclusion reason
Lincolnshire Partnership 2019 ²⁶⁶	Qualitative data in the form of quotes - no thematic analysis
Liu 2018 ²⁶⁷	Study/article does not address any of the call for evidence review questions
Lloyd 2012 ²⁶⁹	Incorrect study design (quantitative)
Lloyd 2012 ²⁶⁸	Incorrect study design (RCT)
Loades 2016 ²⁷³	Systematic review with different PICO
Loades 2019 ²⁷⁰ (unpublished)	Incorrect population (already diagnosed with ME/CFS); incorrect study design (cross-sectional epidemiological study with no interventions)
Loades 2019 ²⁷⁴	Incorrect study design (qualitative); also excluded from experiences of interventions review due incorrect population (healthcare professionals)
Loades 2019 ²⁷¹	Incorrect study design (quantitative)
Loades 2018 ²⁷²	Study/article does not address any of the call for evidence review questions
Loy 2016 ²⁷⁵	Incorrect study design (quantitative)
Lyshevski 2001 ²⁷⁶	Study/article does not address any of the call for evidence review questions
Maes 2006 ²⁷⁹	Study/article does not address any of the call for evidence review questions
Maes 2009 ²⁸⁰	Study/article does not address any of the call for evidence review questions
Maes 2012 ²⁸¹	Study/article does not address any of the call for evidence review questions
Marshall 1997 ²⁸²	Not relevant to any call for evidence question
Marshall 1996 ²⁸³	Incorrect study design (quantitative)
Mathew 2009 ²⁸⁴	Study/article does not address any of the call for evidence review questions
May 2010 ²⁸⁵	Study/article does not address any of the call for evidence review questions
McCourt 2019 ²⁸⁶	Study/article does not address any of the call for evidence review questions
McDermott 2006 ²⁸⁷	Study/article does not address any of the call for evidence review questions
McGregor 2016 ²⁸⁸	Study/article does not address any of the call for evidence review questions
McGregor 2019 ²⁸⁹	Study/article does not address any of the call for evidence review questions
McManimen 2016 ²⁹¹	Study/article does not address any of the call for evidence review questions
McManimen 2019 ²⁹⁰	Incorrect study design (qualitative)
McPhee 2019 ²⁹²	Qualitative section was related to information given to patients about possible harms, data about harm was quantitative
ME Action 2019 ²⁶¹	Incorrect study design (survey)
ME/cvs Vereniging 2016 ²⁹³	Report summary; full report in Dutch
Meeus 2015 ²⁹⁴	Incorrect study design (RCT)
ME Group 2019 ²⁷⁸	No qualitative findings/data analysis reported
ME Group 2014 ²⁷⁷	No qualitative findings/data analysis reported

Study	Exclusion reason
Melamed 2019 ²⁹⁵	Study/article does not address any of the call for evidence review questions
Mihelicova 2016 ²⁹⁶	Study/article does not address any of the call for evidence review questions
Miller 2015 ²⁹⁷	Study/article does not address any of the call for evidence review questions
Millions Missing Canada 2017 ²⁹⁸	Incorrect study design (quantitative survey)
Missen 2012 ²⁹⁹	No relevant outcomes
Moneghetti 2018 ³⁰⁰	Incorrect interventions (no intervention)
Montoya 2018 ³⁰¹	Incorrect study design (RCT)
Montoya 2013 ³⁰²	Incorrect study design (RCT)
Moore 2000 ³⁰³	Study/article does not address any of the call for evidence review questions
Moore 2015 ³⁰⁴	Study/article does not address any of the call for evidence review questions
Morens 2019 ³⁰⁵	Study/article does not address any of the call for evidence review questions
Morris 2014 ³⁰⁶	Study/article does not address any of the call for evidence review questions
Murdock 2017 ³⁰⁷	Study/article does not address any of the call for evidence review questions
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Advisory Committee 2019 ³⁰⁸	Study/article does not address any of the call for evidence review questions
Nacul 2011 ³¹¹	Study/article does not address any of the call for evidence review questions
Nacul 2011 ³¹²	Study/article does not address any of the call for evidence review questions
Nacul 2018 ³¹³	Study/article does not address any of the call for evidence review questions
Nacul 2019 ³¹⁰	Study/article does not address any of the call for evidence review questions
Nacul 2019 ³⁰⁹	Study/article does not address any of the call for evidence review questions
Nagy-Szakal 2018 ³¹⁴	Study/article does not address any of the call for evidence review questions
Natelson 2017 ³¹⁶	Study/article does not address any of the call for evidence review questions
Natelson 2017 ³¹⁵	Study/article does not address any of the call for evidence review questions
National Centers for Environmental Information ³¹⁷	Study/article does not address any of the call for evidence review questions
National Collaborating Centre for Primary Care 2007 ³¹⁸	Study/article does not address any of the call for evidence review questions
Naviaux 2016 ³²¹	Study/article does not address any of the call for evidence review questions
Naviaux 2017 ³²⁰	Study/article does not address any of the call for evidence review questions
Newberry 2018 ³²²	Study/article does not address any of the call for evidence review questions

Study	Exclusion reason
Newton 2010 ³²³	Study/article does not address any of the call for evidence review questions
NHS North Bristol 2019 ³²⁴	No relevant themes (qualitative data on specialist services, not specific interventions)
Nijhof 2014 ³²⁸	Incorrect study design (quantitative)
Nijhof 2013 ³²⁷	Incorrect study design (quantitative)
Nijhof 2012 ³²⁵	Incorrect study design (RCT)
Nijhof 2011 ³²⁶	RCT protocol
Norfolk and Suffolk Service 2009 ³²⁹	Unable to obtain (web link unavailable)
Norris 2017 ³³⁰	Incorrect study design (cross-sectional analysis of quantitative data)
Ocon 2012 ³³¹	Study/article does not address any of the call for evidence review questions
Odoom 2018 ³³²	Study/article does not address any of the call for evidence review questions
Office for National Statistics 2018 ³³³	Not relevant to any call for evidence questions
Ojo-Amaize 1994 ³³⁴	Study/article does not address any of the call for evidence review questions
Oliver 2018 ³³⁵	Incorrect study design (quantitative survey)
PACE Trial participant dataset ³³⁷	Study/article does not address any of the call for evidence review questions
Packer 1997 ³³⁸	Study/article does not address any of the call for evidence review questions
Pakpoor 2017 ³³⁹	Study/article does not address any of the call for evidence review questions
Parslow 2018 ³⁴¹	No relevant themes
Parslow 2017 ³⁴³	Incorrect study design (qualitative)
Parslow 2017 ³⁴²	Systematic review with different PICO
Parslow 2015 ³⁴⁰	Incorrect study design (qualitative; assessed for monitoring and review question)
Pastula 2014 ³⁴⁴	Study/article does not address any of the call for evidence review questions
Patrick Neary 2008 ³⁴⁷	Incorrect interventions (no intervention)
Peci 2015 ³⁴⁸	Study/article does not address any of the call for evidence review questions
Peckerman 2003 ³⁴⁹	Study/article does not address any of the call for evidence review questions
Pemberton 2014 ³⁵¹	No relevant themes
Pemberton 2014 ³⁵⁰	No relevant themes
Peterson 1991 ³⁵⁶	Not relevant to any call for evidence question
Peterson 1994 ³⁵⁷	Incorrect interventions (no intervention)
Perrin 1993 ³⁵³	Review; study/article does not address any of the call for evidence review questions
Perrin 1998 ³⁵⁴	Incorrect study design (non-randomised quantitative study)
Perrin 2011 ³⁵⁵	Incorrect study design (non-randomised quantitative study)
Pheby 2009 ³⁵⁸	Incorrect study design (survey) and no useable data

Study	Exclusion reason
Physios for M.E ³⁵⁹ (unpublished)	Incorrect study design (qualitative)
Plascencia-Villa 2016 ³⁶⁰	Study/article does not address any of the call for evidence review questions
Polli 2019 ³⁶¹	Incorrect study design (quantitative)
Polo 2019 ³⁶²	Incorrect study design (no qualitative data)
Prins 2005 ³⁶⁴	Incorrect study design (quantitative)
Prins 2001 ³⁶⁵	Incorrect study design (RCT)
Prokhorov 2016 ³⁶⁶	Study/article does not address any of the call for evidence review questions
Puri 2011 ³⁶⁷	Incorrect study design (diagnostic accuracy study)
Quarmby 2007 ³⁶⁸	Incorrect study design (quantitative)
Raine 2004 ³⁶⁹	Incorrect population (GPs)
Rand Corporation ³⁷⁰	Study/article does not address any of the call for evidence review questions
Rawlins 2008 ³⁷¹	Study/article does not address any of the call for evidence review questions
Regland 2015 ³⁷³	Incorrect study design (quantitative)
Reynolds 2014 ³⁷⁴	Incorrect interventions (no intervention)
Richardson 2002 ³⁷⁵	Review article
Rimes 2014 ³⁷⁶	Incorrect study design (quantitative)
Roberts 2016 ³⁷⁹	Study/article does not address any of the call for evidence review questions
Roberts 2009 ³⁷⁷	Incorrect study design (quantitative)
Roberts 2018 ³⁷⁸	Study/article does not address any of the call for evidence review questions
Roe ³⁸⁰	No relevant themes (qualitative data on a specialist service, not specific interventions)
Roerink 2017 ³⁸³	Study/article does not address any of the call for evidence review questions
Roerink 2017 ³⁸¹	Incorrect study design (RCT)
Roerink 2015 ³⁸²	RCT protocol
Roma 2019 ³⁸⁴	Incorrect interventions (no intervention)
Rowe 2019 ³⁸⁷	No relevant themes
Rowe 2017 ³⁸⁸	Review article
Ruggieri 2017 ³⁸⁹	Study/article does not address any of the call for evidence review questions
Santini 2018 ³⁹⁰	Study/article does not address any of the call for evidence review questions
Šarić 2016 ³⁹¹	Study/article does not address any of the call for evidence review questions
Scheeres 2009 ³⁹²	Study/article does not address any of the call for evidence review questions
Scheeres 2008 ³⁹⁴	Incorrect study design (quantitative)
Scheeres 2008 ³⁹³	Incorrect study design (quantitative)
Scheeres 2007 ³⁹⁵	Study/article does not address any of the call for evidence review questions
Schmalting 2019 ³⁹⁶	Study/article does not address any of the call for evidence review questions

Study	Exclusion reason
Schweitzer 1995 ³⁹⁷	Not relevant to any call for evidence question
Severens 2004 ⁴⁰⁰	Letter/commentary/expert opinion
Shakespeare 2017 ⁴⁰¹	Study/article does not address any of the call for evidence review questions
Shan 2018 ⁴⁰²	Study/article does not address any of the call for evidence review questions
Sharpe 1991 ⁴⁰⁴	Study/article does not address any of the call for evidence review questions
Sharpe 2015 ⁴⁰³	Incorrect study design (RCT)
Shukla 2015 ⁴⁰⁵	Incorrect study design (quantitative)
Shungu 2012 ⁴⁰⁶	Study/article does not address any of the call for evidence review questions
Smith 2014 ⁴⁰⁸	Incorrect study design (systematic review of RCTs)
Smith 2013 ⁴⁰⁹	Systematic review with different PICO
Smith 2015 ⁴⁰⁷	Incorrect study design (systematic review of RCTs)
Snell 2013 ⁴¹⁰	Study/article does not address any of the call for evidence review questions
Snounou 2019 ⁴¹¹	Incorrect study design (qualitative)
Solomon-Moore 2019 ⁴¹²	Incorrect study design (baseline cross-sectional data from an RCT)
Stahl 2014 ⁴¹³	Incorrect study design (quantitative)
Staud 2017 ⁴¹⁵	Incorrect study design (RCT)
Staud 2018 ⁴¹⁴	Incorrect study design (quantitative)
Steffen 2002 ⁴¹⁶	Study/article does not address any of the call for evidence review questions
Stevellink 2019 ⁴¹⁷	Study/article does not address any of the call for evidence review questions
Stevens 2018 ⁴¹⁸	Study/article does not address any of the call for evidence review questions
Stevens 2010 ⁴¹⁹	Incorrect study design (case study)
Stoll 2017 ⁴²⁰	Systematic review with different PICO
Stordeur 2008 ⁴²¹	Study/article does not address any of the call for evidence review questions
Strassheim 2018 ⁴²²	Study/article does not address any of the call for evidence review questions
Strawbridge 2019 ⁴²³	Not relevant to any call for evidence question
Strayer 2012 ⁴²⁴	Incorrect study design (RCT)
Strbak 2011 ⁴²⁵	Study/article does not address any of the call for evidence review questions
Stulemeijer 2005 ⁴²⁶	Incorrect study design (RCT)
Sumathipala 2008 ⁴²⁷	Incorrect population (medically unexplained symptoms)
Sunnquist 2018 ⁴²⁸	Incorrect study design (quantitative)
Suvorov 1998 ⁴³⁰	Study/article does not address any of the call for evidence review questions
Swinscow 1997 ⁴³¹	Study/article does not address any of the call for evidence review questions
Taylor 2004 ⁴³⁴	Incorrect study design (RCT)
Taylor 2019 Leeds and York CFS/ME Service ⁴³³ (unpublished)	No qualitative data

Study	Exclusion reason
Taylor 2016 ⁴³²	Study/article does not address any of the call for evidence review questions
Teitelbaum 2001 ⁴³⁵	Incorrect study design (RCT)
Terzi 2016 ⁴³⁶	Study/article does not address any of the call for evidence review questions
The 2010 ⁴⁴⁹	Incorrect study design (RCT)
The 2007 ⁴⁵⁰	Incorrect study design (RCT)
The Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee 1997 ⁴⁴⁸	Not relevant to any call for evidence questions
The 25% ME Group 2010 ⁴³⁷	Different focus to review question
The 25% ME Group 2014 ⁴³⁸ (unpublished)	Report on a research presentation; no qualitative data from people with ME/CFS
The 25% ME Group 2004 ⁴⁴⁷	Incorrect study design (quantitative survey)
The 25% ME Group 2000 ⁴⁴⁴	Incorrect study design (quantitative survey)
The 25% ME Group 2001 ⁴³⁹	Incorrect study design (quantitative survey)
The 25% ME Group ⁴⁴⁶	Article; no qualitative data from people with ME/CFS
The 25% ME Group 2002 ⁴⁴³ (unpublished)	Incorrect study design (quantitative survey)
The 25% ME Group 2017 ⁴⁴¹	Not relevant to any call for evidence questions
The 25% ME Group 2018 ⁴⁴⁰	Not relevant to any call for evidence questions
The 25% ME Group 2001 ⁴⁴²	Incorrect study design (quantitative survey)
The 25% ME Group 2016 ⁴⁴⁵	Study/article does not address any of the call for evidence review questions (newsletter)
The ME Association 2010 ⁴⁵¹	Incorrect study design (quantitative survey)
The ME Association 2015 ⁴⁵²	Survey including quantitative and qualitative data, but no analysis on the qualitative data
The Neurological Alliance 2019 ⁴⁵³	Incorrect study design (quantitative survey)
Thomas 2009 ⁴⁵⁴	Incorrect interventions (no intervention)
Tiersky 2001 ⁴⁵⁵	Incorrect study design (quantitative)
Timbol 2019 ⁴⁵⁷	No relevant themes
Togo 2015 ⁴⁵⁸	Incorrect interventions (no intervention)
Trabal 2012 ⁴⁵⁹	Study/article does not address any of the call for evidence review questions
Tummers 2013 ⁴⁶²	Incorrect study design (quantitative)
Tummers 2012 ⁴⁶¹	Incorrect study design (RCT)
Tummers 2010 ⁴⁶⁰	Incorrect study design (quantitative)
Twisk 2014 ⁴⁶⁷	Letter/commentary/expert opinion
Twisk 2017 ⁴⁶⁴	Letter/commentary/expert opinion
Twisk 2018 ⁴⁶³	Report summary; full report in Dutch
Twisk 2015 ⁴⁶⁶	Study/article does not address any of the call for evidence review questions
Twisk 2015 ⁴⁶⁵	Incorrect study design (review article)
Van Campen 2018 ⁴⁶⁸	Incorrect interventions (no intervention)
Van Campen 2018 ⁴⁷⁰	Study/article does not address any of the call for evidence review questions

Study	Exclusion reason
Van Campen 2019 ⁴⁶⁹	Incorrect study design (quantitative)
Van Den Eede 2011 ⁴⁷¹	Study/article does not address any of the call for evidence review questions
Van Der Schaaf 2015 ⁴⁷³	RCT protocol
Van Der Schaaf 2017 ⁴⁷²	Study/article does not address any of the call for evidence review questions
Van Der Werf 2002 ⁴⁷⁴	Study/article does not address any of the call for evidence review questions
Van Konynenburg 2010 ⁴⁷⁵	Conference abstract
Van Kuppeveld 2010 ⁴⁷⁶	Study/article does not address any of the call for evidence review questions
VanNess 2007 ⁴⁷⁷	Incorrect interventions (no intervention)
VanNess 2010 ⁴⁷⁸	Incorrect intervention (exercise test)
Velleman 2016 ⁴⁷⁹	Incorrect population (siblings) and no relevant themes
Vercoulen 1996 ⁴⁸¹	Incorrect study design (RCT)
Vercoulen 1996 ⁴⁸⁰	Study/article does not address any of the call for evidence review questions
Vermeulen 2010 ⁴⁸²	Study/article does not address any of the call for evidence review questions
Vermeulen 2014 ⁴⁸³	Study/article does not address any of the call for evidence review questions
Vernon 2004 ⁴⁸⁴	Unable to obtain
Verspaandonk 2015 ⁴⁸⁵	Incorrect study design (quantitative)
Vink 2017 ⁴⁸⁶	Incorrect study design (quantitative)
Vink 2018 ⁴⁸⁹	Review of an RCT
Vink 2018 ⁴⁸⁸	Incorrect study design (reanalysis of a Cochrane review); no qualitative data
Vink 2019 ⁴⁹⁰	Review article
Vink 2019 ⁴⁸⁷	Incorrect study design (reanalysis of a Cochrane review); no qualitative data
Wallis 2016 ⁴⁹²	Study/article does not address any of the call for evidence review questions
Wallis 2018 ⁴⁹¹	Incorrect study design (quantitative)
Wang 2017 ⁴⁹⁴	Study/article does not address any of the call for evidence review questions
Watt 2012 ⁴⁹⁵	Incorrect study design (quantitative)
Wearden 2006 ⁴⁹⁸	Study/article does not address any of the call for evidence review questions
Wearden 2010 ⁴⁹⁶	Incorrect study design (RCT)
Wearden 2013 ⁴⁹⁷	Incorrect study design (prognostic)
Webb 2011 ⁵⁰⁰	No relevant themes
Werbach 2000 ⁵⁰¹	Incorrect study design (literature review)
White 2007 ⁵⁰⁴	RCT protocol
White 2011 ⁵⁰³	Incorrect study design (RCT)
White 2013 ⁵⁰²	Study/article does not address any of the call for evidence review questions
Whitehead 2009 ⁵⁰⁵	Study/article does not address any of the call for evidence review questions

Study	Exclusion reason
Whitehead 2002 ⁵⁰⁶	Study/article does not address any of the call for evidence review questions
Wiborg 2010 ⁵⁰⁸	Incorrect study design (reanalysis of RCTs)
Wiborg 2014 ⁵¹⁰	Incorrect study design (quantitative)
Wiborg 2015 ⁵⁰⁹	Incorrect study design (RCT)
Wiborg 2011 ⁵⁰⁷	Incorrect study design (quantitative)
Wieczorek 2017 ⁴⁹³	Study/article does not address any of the call for evidence review questions
Wilshire 2018 ⁵¹⁴	Incorrect study design (reanalysis of an RCT)
Wilshire 2019 ⁵¹³	Letter/commentary/expert opinion
Wilshire 2017 ⁵¹¹	Incorrect study design (critical commentary and reanalysis of an RCT)
Wilshire 2017 ⁵¹²	Letter/commentary/expert opinion
Worm-Smeitink 2019 ⁵¹⁶	Incorrect study design (RCT)
Worm-Smeitink 2017 ⁵¹⁵	Study/article does not address any of the call for evidence review questions
Worm-Smeitink 2016 ⁵¹⁷	Incorrect study design (quantitative)
Yorkshire Fatigue Clinic 2019 ³⁵²	Incorrect study design (survey)
Zablotskii 2016 ⁵¹⁸	Study/article does not address any of the call for evidence review questions
Zablotskii 2018 ⁵¹⁹	Study/article does not address any of the call for evidence review questions
Zhi 2017 ⁵²⁰	Study/article does not address any of the call for evidence review questions
Zielinski 2019 ⁵²¹	Study/article does not address any of the call for evidence review questions

1 Health economic studies

2 Published health economic studies that met the inclusion criteria (relevant population,
3 comparators, economic study design, published 2004 or later and not from non-OECD
4 country or USA) but that were excluded following appraisal of applicability and
5 methodological quality are listed below. See the health economic protocol for more details.

6 None.

7

1 References

- 2 1. Action for ME. Results from our Big Survey [Unpublished]. 2019.
- 3 2. Action for ME. Severely neglected: M.E. in the UK. Membership survey. London.
4 Action for ME, 2001.
- 5 3. Action for ME, Association of Young People with ME. Action for M.E. and AYME
6 survey 2008 - results. 2008. Available from: <https://afme.wordpress.com/> Last
7 accessed: 29/11/2019.
- 8 4. Adamowicz JL, Caikauskaite I, Friedberg F. Defining recovery in chronic fatigue
9 syndrome: A critical review. *Quality of Life Research*. 2014; 23(9):2407-2416
- 10 5. Adamson J, Ali S, Santhouse A, Wessely S, Chalder T. Routine clinic outcomes after
11 cognitive behavior therapy (CBT) and graded exercise therapy (GET) from South
12 London and Maudsley NHS Trust & King's College London service compared to trials
13 of CBT and GET respectively [Unpublished].
- 14 6. Adedeji AO, Okonko IO, Adu FD. Sabin and wild type polioviruses from children who
15 presented with acute flaccid paralysis in Nigeria. *African Health Sciences*. 2012;
16 12(3):345-354
- 17 7. Adelakun S, Meriwoode J. An evaluation of CFS/ME group members' experience of
18 engaging in a self management treatment programme in an NHS specialist CFS/ME
19 service in the UK. *Specialist Occupational Therapist Sussex-wide CFS/ME Service*,
20 2019.
- 21 8. Ahmed SA, Mewes JC, Vrijhoef H. Assessment of the scientific rigour of randomized
22 controlled trials on the effectiveness of cognitive behavioural therapy and graded
23 exercise therapy for patients with myalgic encephalomyelitis/chronic fatigue
24 syndrome: A systematic review. *Journal of Health Psychology*. 2020; 25(2):240-255
- 25 9. All-Party Parliamentary Group on ME. Inquiry into NHS Service Provision for
26 ME/CFS. 2010. Available from: [https://www.meassociation.org.uk/wp-](https://www.meassociation.org.uk/wp-content/uploads/2013/02/APPG-Report-v3.pdf)
27 [content/uploads/2013/02/APPG-Report-v3.pdf](https://www.meassociation.org.uk/wp-content/uploads/2013/02/APPG-Report-v3.pdf)
- 28 10. Allen PR. Chronic fatigue syndrome: implications for women and their health care
29 providers during the childbearing years. *Journal of Midwifery & Women's Health*.
30 2008; 53(4):289-301; quiz 399
- 31 11. Allwright E, Murihead N. Understanding the role of the general practitioner in caring
32 for patients with myalgic encephalomyelitis/chronic fatigue syndrome in the
33 community. 2019.
- 34 12. Anderson E, Parslow R, Hollingworth W, Mills N, Beasant L, Gaunt D et al. Testing
35 the feasibility of recruiting adolescents with CFS/ME to internet-delivered therapy:
36 internal pilot within a randomised controlled trial investigating online cognitive
37 behavioural therapy (Fatigue In Teenagers on the interNET in the NHS – "FITNET-
38 NHS") compared to skype-delivered activity management for adolescents with
39 CFS/ME [Unpublished].
- 40 13. Anderson JS, Ferrans CE. The quality of life of persons with chronic fatigue
41 syndrome. *Journal of Nervous and Mental Disease*. 1997; 185(6):359-367
- 42 14. Anonymous. Evaluating the effects of change in the content and format of a lifestyle
43 management group on standardized outcome measures of chronic fatigue
44 syndrome/myalgic encephalomyelitis. University of Surrey.

- 1 15. Anonymous. Neuropsychological performance in myalgic encephalomyelitis/chronic
2 fatigue syndrome (ME/CFS) and Gulf war illness (GWI). Implications for interventions
3 and patient management. [Submission for Doctoral level Qualification in Counselling
4 Psychology]. 2015.
- 5 16. Antcliff D, Keenan AM, Keeley P, Woby S, McGowan L. Survey of activity pacing
6 across healthcare professionals informs a new activity pacing framework for chronic
7 pain/fatigue. *Musculoskeletal Care*. 2019; 17(4):335-345
- 8 17. Antiel RM, Caudill JS, Burkhardt BE, Brands CK, Fischer PR. Iron insufficiency and
9 hypovitaminosis D in adolescents with chronic fatigue and orthostatic intolerance.
10 *Southern Medical Journal*. 2011; 104(8):609-611
- 11 18. Armstrong CW, McGregor NR, Sheedy JR, Buttfeld I, Butt HL, Gooley PR. NMR
12 metabolic profiling of serum identifies amino acid disturbances in chronic fatigue
13 syndrome. *Clinica Chimica Acta*. 2012; 413(19-20):1525-1531
- 14 19. Arnold LM, Blom TJ, Welge JA, Mariutto E, Heller A. A randomized, placebo-
15 controlled, double-blinded trial of duloxetine in the treatment of general fatigue in
16 patients with chronic fatigue syndrome. *Psychosomatics*. 2015; 56(3):242-253
- 17 20. Ates K, Carlak HF, Ozen S. Magnetic field exposures due to underground power
18 cables: A simulation study. *Proceedings of the 2nd World Congress on Electrical
19 Engineering and Computer Systems and Science*. 2016:EEE 133
- 20 21. Augusto CRA, Navia CE, de Oliveira MN, Nepomuceno AA, Fauth AC, Kopenkin V et
21 al. Relativistic proton levels from region AR 12673 (GLE #72) and the heliospheric
22 current sheet as a sun–earth magnetic connection. *Publications of the Astronomical
23 Society of the Pacific*. 2018; 131(996):024401
- 24 22. BACME. CFS/ME national services survey February 2018. 2019. Available from:
25 [https://www.bacme.info/sites/bacme.info/files/BACME%20CFS%20ME%20National%
26 20services%20survey%20March19.pdf](https://www.bacme.info/sites/bacme.info/files/BACME%20CFS%20ME%20National%20services%20survey%20March19.pdf)
- 27 23. Balaguru S, Uppal R, Vaid RP, Kumar BP. Investigation of the spinal cord as a
28 natural receptor antenna for incident electromagnetic waves and possible impact on
29 the central nervous system. *Electromagnetic Biology and Medicine*. 2012; 31(2):101-
30 111
- 31 24. Baos S, Brigden A, Anderson E, Hollingworth W, Price S, Mills N et al. Investigating
32 the effectiveness and cost-effectiveness of FITNET-NHS (Fatigue In Teenagers on
33 the interNET in the NHS) compared to Activity Management to treat paediatric
34 chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (ME): Protocol for a
35 randomised controlled trial. *Trials*. 2018; 19(1):136
- 36 25. Baraniuk JN. *BMJ Best Practice: Chronic fatigue syndrome/Myalgic
37 encephalomyelitis*. 2018. Available from: [https://bestpractice.bmj.com/topics/en-
38 gb/277](https://bestpractice.bmj.com/topics/en-gb/277) Last accessed: 29/11/2019.
- 39 26. Baraniuk JN, Shivapurkar N. Exercise - induced changes in cerebrospinal fluid
40 miRNAs in Gulf War Illness, Chronic Fatigue Syndrome and sedentary control
41 subjects. *Scientific Reports*. 2017; 7:15338
- 42 27. Barnden LR, Kwiatek R, Crouch B, Burnet R, Del Fante P. Autonomic correlations
43 with MRI are abnormal in the brainstem vasomotor centre in chronic fatigue
44 syndrome. *NeuroImage Clinical*. 2016; 11:530-537

- 1 28. Barriers to access to social care for patients very severely affected by myalgic
2 encephalomyelitis (ME). Submission to APPG on ME April 19th 2016 Roundtable
3 Meeting on Social Care, chaired by Daniel Zeichner MP. 2016.
- 4 29. Bazelmans E, Prins JB, Hoogveld S, Bleijenberg G. Manual-based cognitive
5 behaviour therapy for chronic fatigue syndrome: Therapists' adherence and
6 perceptions. *Cognitive Behaviour Therapy*. 2004; 33(3):143-150
- 7 30. Bazelmans E, Prins JB, Lulofs R, van der Meer JW, Bleijenberg G, Netherlands
8 Fatigue Research Group N. Cognitive behaviour group therapy for chronic fatigue
9 syndrome: A non-randomised waiting list controlled study. *Psychotherapy and
10 Psychosomatics*. 2005; 74(4):218-224
- 11 31. Bazilevskaya GA, Makhmutov VS, Sladkova AI. Gnevyshev gap effects in solar
12 energetic particle activity. *Advances in Space Research*. 2006; 38(3):484-488
- 13 32. Beasant L, Brigden A, Anderson E, Mills N, Trist A, Crawley E. "All the programmes
14 are designed around you": Families views on graded exercise therapy for paediatric
15 CFS/ME [Unpublished].
- 16 33. Belgian Ministry of Social Affairs, Public Health and Environment. Aanbevelingen
17 betreffende de medischsociale, economische en juridische aspecten voor patienten
18 met syndroom van chronische vermoeidheid. 2000. Available from:
19 <https://tinyurl.com/belgiumreportpdf>
- 20 34. Bell DS. Prognosis of ME/CFS. 2016. Available from:
21 <https://www.omf.ngo/2016/08/01/prognosis-of-mecfs/> Last accessed: 26/11/2019.
- 22 35. Berkovitz S, Ambler G, Jenkins M, Thurgood S. Serum 25-hydroxy vitamin D levels in
23 chronic fatigue syndrome: A retrospective survey. *International Journal for Vitamin
24 and Nutrition Research*. 2009; 79(4):250-254
- 25 36. Blease C, Carel H, Geraghty K. Epistemic injustice in healthcare encounters:
26 evidence from chronic fatigue syndrome. *Journal of Medical Ethics*. 2017; 43(8):549-
27 557
- 28 37. Bloot L, Heins MJ, Donders R, Bleijenberg G, Knoop H. The process of change in
29 pain during cognitive-behavior therapy for chronic fatigue syndrome. *Clinical Journal
30 of Pain*. 2015; 31(10):914-921
- 31 38. Blue Ribbon for the Awareness of Myalgic Encephalomyelitis. Results of recent
32 patient surveys on CBT, GET, PACING, REST [Unpublished]. 2010.
- 33 39. Boneva RS, Lin JS, Wieser F, Nater UM, Ditzen B, Taylor RN et al. Endometriosis as
34 a comorbid condition in chronic fatigue syndrome (CFS): Secondary analysis of data
35 from a CFS case-control study. *Frontiers in Pediatrics*. 2019; 7:195
- 36 40. Bould H, Collin SM, Lewis G, Rimes K, Crawley E. Depression in paediatric chronic
37 fatigue syndrome. *Archives of Disease in Childhood*. 2013; 98(6):425-428
- 38 41. Bould H, Lewis G, Emond A, Crawley E. Depression and anxiety in children with
39 CFS/ME: Cause or effect? *Archives of Disease in Childhood*. 2011; 96(3):211-214
- 40 42. Bowers JR, Valentine M, Harrison V, Fofanov VY, Gillece J, Delisle J et al. Genomic
41 analyses of acute flaccid myelitis cases among a cluster in arizona provide further
42 evidence of enterovirus D68 role. *mBio*. 2019; 10(1):e02262-02218
- 43 43. Brigden A, Barnett J, Parslow RM, Beasant L, Crawley E. Using the internet to cope
44 with chronic fatigue syndrome/myalgic encephalomyelitis in adolescence: A
45 qualitative study. *BMJ Paediatrics Open*. 2018; 2:e000299

- 1 44. Brigden A, Beasant L, Hollingworth W, Metcalfe C, Gaunt D, Mills N et al. Managed
2 Activity Graded Exercise iN Teenagers and pre-Adolescents (MAGENTA) feasibility
3 randomised controlled trial: Study protocol. *BMJ Open*. 2016; 6:e011255
- 4 45. Brigden A, Parslow RM, Gaunt D, Collin SM, Jones A, Crawley E. Defining the
5 minimally clinically important difference of the SF-36 physical function subscale for
6 paediatric CFS/ME: Triangulation using three different methods. *Health & Quality of
7 Life Outcomes*. 2018; 16(1):202
- 8 46. Brigden AB, Beasant LB, Gaunt DG, Hollingworth WH, Mills NM, Solomon-Moore E
9 et al. Results of the feasibility phase of the Managed Activity Graded Exercise iN
10 Teenagers and Pre-Adolescents (MAGENTA) randomised controlled trial of
11 treatments for chronic fatigue syndrome/myalgic encephalomyelitis [Unpublished].
- 12 47. Bringsli GJ, Gilje AM, Getz Wold BK. The Norwegian ME Association National Survey
13 2014. Oslo. 2014. Available from: [http://www.me-foreningen.info/wp-](http://www.me-foreningen.info/wp-content/uploads/2016/09/ME-Nat-Norwegian-Survey-Abr-Eng-Ver.pdf)
14 [content/uploads/2016/09/ME-Nat-Norwegian-Survey-Abr-Eng-Ver.pdf](http://www.me-foreningen.info/wp-content/uploads/2016/09/ME-Nat-Norwegian-Survey-Abr-Eng-Ver.pdf)
- 15 48. Bristol CFS/ME Service. A qualitative evaluation of the Foundation Phase seminars
16 [Unpublished].
- 17 49. Bristol CFS/ME Service. Survey of patients attending NHS specialist CFS/ME
18 Services conducted April-July 2019. 2019.
- 19 50. Britain E, Muirhead NL, Finlay AY, Vyas J. The impact of myalgic
20 encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the family: measuring
21 quality of life (QOL) using the WHOQOL-BREF and from-16 questionnaires. *Journal
22 of liMER*,. 2019; 13(1):21
- 23 51. Brooks SK, Rimes KA, Chalder T. The role of acceptance in chronic fatigue
24 syndrome. *Journal of Psychosomatic Research*. 2011; 71(6):411-415
- 25 52. Broughton J, Harris S, Beasant L, Crawley E, Collin SM. Adult patients' experiences
26 of NHS specialist services for chronic fatigue syndrome (CFS/ME): A qualitative study
27 in England. *BMC Health Services Research*. 2017; 17:384
- 28 53. Brouwers FM, Van Der Werf S, Bleijenberg G, Van Der Zee L, Van Der Meer JW.
29 The effect of a polynutrient supplement on fatigue and physical activity of patients
30 with chronic fatigue syndrome: A double-blind randomized controlled trial. *QJM*. 2002;
31 95(10):677-683
- 32 54. Brown AE, Jones DE, Walker M, Newton JL. Abnormalities of AMPK activation and
33 glucose uptake in cultured skeletal muscle cells from individuals with chronic fatigue
34 syndrome. *PloS One*. 2015; 10(4):e0122982
- 35 55. Brown MM, Bell DS, Jason LA, Christos C, Bell DE. Understanding long-term
36 outcomes of chronic fatigue syndrome. *Journal of Clinical Psychology*. 2012;
37 68(9):1028-1035
- 38 56. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: An overview
39 of environmental risk factors. *Environmental Health Perspectives*. 2005; 113(9):1250-
40 1256
- 41 57. Brown S, Cox DL. Supporting pupils with chronic fatigue syndrome. *Educational
42 Psychology in Practice*. 1999; 15(3):183-189
- 43 58. Bryan CS. Managing chronic fatigue syndrome: what's practical, and what isn't.
44 *Consultant*. 1992; 32(4):33-40

- 1 59. Buchachenko A, Bukhvostov A, Ermakov K, Kuznetsov D. Nuclear spin selectivity in
2 enzymatic catalysis: A caution for applied biophysics. Archives of Biochemistry and
3 Biophysics. 2019; 667:30-35
- 4 60. Buchachenko A, Lawler RG. New possibilities for magnetic control of chemical and
5 biochemical reactions. Accounts of Chemical Research. 2017; 50(4):877-884
- 6 61. Buchachenko AL, Kouznetsov DA, Arkhangelsky SE, Orlova MA, Markarian AA. Spin
7 biochemistry: Magnetic ²⁴Mg-²⁵Mg-²⁶Mg isotope effect in mitochondrial ADP
8 phosphorylation. Cell Biochemistry and Biophysics. 2005; 43(2):243-251
- 9 62. Buchachenko AL, Kuznetsov DA, Berdinskii VL. [New mechanisms of biological
10 effects of electromagnetic fields]. Biofizika. 2006; 51(3):545-552
- 11 63. Buchachenko AL, Orlov AP, Kuznetsov DA, Breslavskaya NN. Magnetic isotope and
12 magnetic field effects on the DNA synthesis. Nucleic Acids Research. 2013;
13 41(17):8300-8307
- 14 64. Burgess M, Andiappan M, Chalder T. Cognitive behaviour therapy for chronic fatigue
15 syndrome in adults: face to face versus telephone treatment: A randomized controlled
16 trial. Behavioural and Cognitive Psychotherapy. 2012; 40(2):175-191
- 17 65. Burke HE. Handbook of magnetic phenomena. New York, NY. Van Nostrand
18 Reinhold. 1986.
- 19 66. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-
20 minute walking tests in respiratory disease. British Medical Journal (Clinical Research
21 Ed). 1982; 284(6329):1607-1608
- 22 67. Calello M. Two Virginia children diagnosed with polio-like illness AFM. 2018.
23 Available from: [https://eu.newsleader.com/story/news/2018/11/26/two-virginia-kids-
24 diagnosed-polio-like-illness-afm-cdc-virginia-department-health/2115535002/](https://eu.newsleader.com/story/news/2018/11/26/two-virginia-kids-diagnosed-polio-like-illness-afm-cdc-virginia-department-health/2115535002/) Last
25 accessed: 05/12/2019.
- 26 68. Carpenter DO. Human disease resulting from exposure to electromagnetic fields.
27 Reviews on Environmental Health. 2013; 28(4):159-172
- 28 69. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lemer AM et al.
29 Myalgic encephalomyelitis/chronic fatigue syndrome: Clinical working case definition,
30 diagnostic and treatment protocols. Journal of Chronic Fatigue Syndrome. 2003;
31 11(1):7-115
- 32 70. Carruthers BM, Van de Sande MI. Myalgic encephalomyelitis-adult & pediatric:
33 International Consensus Primer for Medical Practitioners. 2012. Available from:
34 <http://www.investinme.org/index.shtml>
- 35 71. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T
36 et al. Myalgic encephalomyelitis: International Consensus Criteria. Journal of Internal
37 Medicine. 2011; 270(4):327-338
- 38 72. Casanova C, Celli BR, Barria P, Casas A, Cote C, de Torres JP et al. The 6-min walk
39 distance in healthy subjects: Reference standards from seven countries. European
40 Respiratory Journal. 2011; 37(1):150-156
- 41 73. Castro-Marrero J, Saez-Francas N, Santillo D, Alegre J. Treatment and management
42 of chronic fatigue syndrome/myalgic encephalomyelitis: All roads lead to Rome.
43 British Journal of Pharmacology. 2017; 174(5):345-369
- 44 74. Castro-Marrero J, Saez-Francas N, Segundo MJ, Calvo N, Faro M, Aliste L et al.
45 Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on

- 1 maximum heart rate after exercise testing in chronic fatigue syndrome - A
2 randomized, controlled, double-blind trial. *Clinical Nutrition*. 2016; 35(4):826-834
- 3 75. Cella M, Chalder T, White PD. Does the heterogeneity of chronic fatigue syndrome
4 moderate the response to cognitive behaviour therapy? An exploratory study.
5 *Psychotherapy and Psychosomatics*. 2011; 80(6):353-358
- 6 76. Cella M, Stahl D, Reme SE, Chalder T. Therapist effects in routine psychotherapy
7 practice: an account from chronic fatigue syndrome. *Psychotherapy research: Journal*
8 *of the Society for Psychotherapy Research*. 2011; 21(2):168-178
- 9 77. Centers for Disease Control and Prevention. Acute flaccid myelitis. 2019. Available
10 from: [https://www.cdc.gov/acute-flaccid-myelitis/cases-in-](https://www.cdc.gov/acute-flaccid-myelitis/cases-in-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Facute-flaccid-myelitis%2Fafm-cases.html)
11 [us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Facute-flaccid-](https://www.cdc.gov/acute-flaccid-myelitis%2Fafm-cases.html)
12 [myelitis%2Fafm-cases.html](https://www.cdc.gov/acute-flaccid-myelitis%2Fafm-cases.html) Last accessed: 04/12/2019.
- 13 78. CFS/ME National Outcomes Database Team, SW London and Surrey CFS service
14 NOD local Surrey. Report on Epsom and St Helier CFS/ME service. University of
15 Bristol, 2016.
- 16 79. CFS/ME Service for South Yorkshire and North Derbyshire. CFS/ME Service for
17 South Yorkshire and North Derbyshire outcomes up to 2018/19: clinical global
18 improvement scale. 2019.
- 19 80. CFS/ME Service for South Yorkshire and North Derbyshire. Feedback after therapy:
20 Summary comparing 2016 (54 replies) and 2018 (47 replies).
- 21 81. CFS/ME Working Group. Chief medical officer report of the CFS/ME working group:
22 Annex 3 patient evidence [Unpublished]. 2002.
- 23 82. Chalder T. Assessing predictors of outcome and mediators of change in chronic
24 fatigue syndrome after cognitive behaviour therapy. *International Journal of*
25 *Behavioural Medicine*. 2010; 17(Suppl 1):228
- 26 83. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D et al.
27 Development of a fatigue scale. *Journal of Psychosomatic Research*. 1993;
28 37(2):147-153
- 29 84. Chalder T, Deary V, Husain K, Walwyn R. Family-focused cognitive behaviour
30 therapy versus psycho-education for chronic fatigue syndrome in 11- to 18-year-olds:
31 A randomized controlled treatment trial. *Psychological Medicine*. 2010; 40(8):1269-
32 1279
- 33 85. Chalder T, Goldsmith KA, White PD, Sharpe M, Pickles AR. Rehabilitative therapies
34 for chronic fatigue syndrome: A secondary mediation analysis of the PACE trial. *The*
35 *Lancet Psychiatry*. 2015; 2(2):141-152
- 36 86. Chan JSM, Ng S-M, Yuen L-P, Chan CLW. Chapter Five - Qigong exercise for
37 chronic fatigue syndrome. 'In:' Yau S-Y, So K-F, editors. *International Review of*
38 *Neurobiology*. 147: Academic Press. 2019. p. 121-153.
- 39 87. Chang CM, Warren JL, Engels EA. Chronic fatigue syndrome and subsequent risk of
40 cancer among elderly US adults. *Cancer*. 2012; 118(23):5929-5936
- 41 88. Chaudhuri A, Condon BR, Gow JW, Brennan D, Hadley DM. Proton magnetic
42 resonance spectroscopy of basal ganglia in chronic fatigue syndrome. *Neuroreport*.
43 2003; 14(2):225-228

- 1 89. Childs K, Krockakova Lerari A, Pattinson P, Smith L, Woodvine K. Parental
2 perspectives of diagnosis and management of ME/CFS in children and young people
3 [Unpublished]. 2019.
- 4 90. Christley Y, Hollins Martin CJ, Martin CR. Perinatal perspectives on chronic fatigue
5 syndrome. *British Journal of Midwifery*. 2012; 20(6):389-393
- 6 91. Chu L, Valencia IJ, Garvert DW, Montoya JG. Deconstructing post-exertional malaise
7 in myalgic encephalomyelitis/ chronic fatigue syndrome: A patient-centered, cross-
8 sectional survey. *PloS One*. 2018; 13(6):e0197811
- 9 92. Claypoole KH, Noonan C, Mahurin RK, Goldberg J, Erickson T, Buchwald D. A twin
10 study of cognitive function in chronic fatigue syndrome: The effects of sudden illness
11 onset. *Neuropsychology*. 2007; 21(4):507-513
- 12 93. Cleare AJ, Roberts A, Papadopoulos A, Chalder T, Wessely S. P.6.077 Cognitive
13 behavioural therapy normalises HPA axis dysfunction in chronic fatigue syndrome.
14 *European Neuropsychopharmacology*. 2004; 14(Suppl 3):S389
- 15 94. Cliff JM, King EC, Lee JS, Sepulveda N, Wolf AS, Kingdon C et al. Cellular immune
16 function in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *Frontiers
17 in Immunology*. 2019; 10:796
- 18 95. Clinical trial to measure the maximum HR after ReConnect® supplementation vs.
19 Placebo in CFS (ReConnect) [NCT02063126]. 2015. Available from:
20 [https://www.clinicaltrials.gov/ct2/show/NCT02063126?recrs=ae&type=Intr&cond=Cfs
21 &draw=7](https://www.clinicaltrials.gov/ct2/show/NCT02063126?recrs=ae&type=Intr&cond=Cfs&draw=7) Last accessed: 29/11/2019.
- 22 96. Cockshell SJ, Mathias JL. Cognitive functioning in chronic fatigue syndrome: A meta-
23 analysis. *Psychological Medicine*. 2010; 40(8):1253-1267
- 24 97. Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD. Health care resource use by
25 patients before and after a diagnosis of chronic fatigue syndrome (CFS/ME): A
26 clinical practice research datalink study. *BMC Family Practice*. 2017; 18(1):60
- 27 98. Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD. Trends in the incidence of
28 chronic fatigue syndrome and fibromyalgia in the UK, 2001-2013: A Clinical Practice
29 Research Datalink study. *Journal of the Royal Society of Medicine*. 2017; 110(6):231-
30 244
- 31 99. Collin SM, Crawley E. Specialist treatment of chronic fatigue syndrome/ME: A cohort
32 study among adult patients in England. *BMC Health Services Research*. 2017;
33 17(1):488
- 34 100. Collin SM, Crawley E, May MT, Sterne JA, Hollingworth W, UK CFS/ME National
35 Outcomes Database. The impact of CFS/ME on employment and productivity in the
36 UK: A cross-sectional study based on the CFS/ME national outcomes database. *BMC
37 Health Services Research*. 2011; 11:217
- 38 101. Collin SM, Heron J, Nikolaus S, Knoop H, Crawley E. Chronic fatigue syndrome
39 (CFS/ME) symptom-based phenotypes and 1-year treatment outcomes in two clinical
40 cohorts of adult patients in the UK and The Netherlands. *Journal of Psychosomatic
41 Research*. 2018; 104:29-34
- 42 102. Collin SM, Nikolaus S, Heron J, Knoop H, White PD, Crawley E. Chronic fatigue
43 syndrome (CFS) symptom-based phenotypes in two clinical cohorts of adult patients
44 in the UK and The Netherlands. *Journal of Psychosomatic Research*. 2016; 81:14-23
- 45 103. Collin SM, Nuevo R, van de Putte EM, Nijhof SL, Crawley E. Chronic fatigue
46 syndrome (CFS) or myalgic encephalomyelitis (ME) is different in children compared

- 1 to in adults: A study of UK and Dutch clinical cohorts. *BMJ Open*. 2015;
2 5(10):e008830
- 3 104. Collin SM, Sterne JA, Hollingworth W, May MT, Crawley E. Equity of access to
4 specialist chronic fatigue syndrome (CFS/ME) services in England (2008-2010): A
5 national survey and cross-sectional study. *BMJ Open*. 2012; 2:e001417
- 6 105. Comhaire F. Treating patients suffering from myalgic encephalopathy/chronic fatigue
7 syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof-of-principle
8 pilot trial. *Medical Hypotheses*. 2018; 114:45-48
- 9 106. Cook DB, Light AR, Light KC, Broderick G, Shields MR, Dougherty RJ et al. Neural
10 consequences of post-exertion malaise in myalgic encephalomyelitis/chronic fatigue
11 syndrome. *Brain, Behavior, and Immunity*. 2017; 62:87-99
- 12 107. Cooper M. North of Tyne CFS/ME service evaluation report: October 2018-January
13 2019. The New Castle Upon Tyne Hospitals NHS Foundation Trust, 2019.
- 14 108. Corsius LAMM, Crijnen BGPJM, Hogeweg AA, Kuijper JSM. Zorg voor
15 beterebehandeling bij ME. Enquête onder ME-patiënten naar hun ervaringen met
16 behandelingen bij ME. 2019. Available from: [https://www.me-
17 cvsvereniging.nl/sites/default/files/documenten/Rapport%20Zorg%20voor%20betere
18 %20behandeling.pdf](https://www.me-cvsvereniging.nl/sites/default/files/documenten/Rapport%20Zorg%20voor%20betere%20behandeling.pdf)
- 19 109. Costa DC, Tannock C, Brostoff J. Brainstem perfusion is impaired in chronic fatigue
20 syndrome. *QJM*. 1995; 88(11):767-773
- 21 110. Crawford J. Internet-based CBT for adolescents with chronic fatigue syndrome.
22 *Lancet*. 2012; 380(9841):561-562
- 23 111. Crawford JS. Effect of a demanding cognitive task on neuropsychological
24 performance in myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) and
25 Persian Gulf War illness (GWI). *Proceedings of the British Psychological Society*.
26 2010; 18(1)
- 27 112. Crawford JS, Reeves A. The patient's voice: An exploration of what aids or hinders
28 patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in the
29 counselling process? *Proceedings of the British Psychological Society*. 2012; 20(1)
- 30 113. Crawley E, Collin SM, White PD, Rimes K, Sterne JA, May MT et al. Treatment
31 outcome in adults with chronic fatigue syndrome: A prospective study in England
32 based on the CFS/ME National Outcomes Database. *QJM*. 2013; 106(6):555-565
- 33 114. Crawley E, Hunt L, Stallard P. Anxiety in children with CFS/ME. *European Child and
34 Adolescent Psychiatry*. 2009; 18(11):683-689
- 35 115. Crawley E, Mills N, Beasant L, Johnson D, Collin SM, Deans Z et al. The feasibility
36 and acceptability of conducting a trial of specialist medical care and the Lightning
37 Process in children with chronic fatigue syndrome: feasibility randomized controlled
38 trial (SMILE study). *Trials*. 2013; 14:415
- 39 116. Crawley E, Sterne JA. Association between school absence and physical function in
40 paediatric chronic fatigue syndrome/myalgic encephalopathy. *Archives of Disease in
41 Childhood*. 2009; 94(10):752-756
- 42 117. Crawley EM, Emond AM, Sterne JA. Unidentified chronic fatigue syndrome/myalgic
43 encephalomyelitis (CFS/ME) is a major cause of school absence: Surveillance
44 outcomes from school-based clinics. *BMJ Open*. 2011; 1:e000252

- 1 118. Crawley EM, Gaunt DM, Garfield K, Hollingworth W, Sterne JAC, Beasant L et al.
2 Clinical and cost-effectiveness of the Lightning Process in addition to specialist
3 medical care for paediatric chronic fatigue syndrome: Randomised controlled trial.
4 Archives of Disease in Childhood. 2018; 103(2):155-164
- 5 119. Crowhurst G. Supporting people with severe myalgic encephalomyelitis. Nursing
6 Standard. 2005; 19(21):38-43
- 7 120. Crowhurst G, Crowhurst L. A survey of severe ME patients in Norfolk and Suffolk,
8 November 2007. 2007.
- 9 121. Currell S. North of Tyne CFS/ME rehabilitation and management team: Service
10 evaluation 2017/18. The Newcastle Upon Tyne Hospitals NHS Foundation Trust.
- 11 122. DARPA. RadioBio: What role does electromagnetic signaling have in biological
12 systems? 2017. Available from: <https://www.darpa.mil/news-events/2017-02-07> Last
13 accessed: 04/12/2019.
- 14 123. Davenport TE, Lehnen M, Stevens SR, VanNess JM, Stevens J, Snell CR.
15 Chronotropic intolerance: An overlooked determinant of symptoms and activity
16 limitation in myalgic encephalomyelitis/chronic fatigue syndrome? Frontiers in
17 Pediatrics. 2019; 7:82
- 18 124. Davenport TE, Stevens SR, Baroni K, Van Ness JM, Snell CR. Reliability and validity
19 of Short Form 36 Version 2 to measure health perceptions in a sub-group of
20 individuals with fatigue. Disability and Rehabilitation. 2011; 33(25-26):2596-2604
- 21 125. Davenport TE, Stevens SR, Baroni K, Van Ness M, Snell CR. Diagnostic accuracy of
22 symptoms characterising chronic fatigue syndrome. Disability and Rehabilitation.
23 2011; 33(19-20):1768-1775
- 24 126. Davenport TE, Stevens SR, VanNess JM, Stevens J, Snell CR. Checking our blind
25 spots: Current status of research evidence summaries in ME/CFS. British Journal of
26 Sports Medicine. 2019; 53(19):1198
- 27 127. Davenport TE, Stevens SR, VanNess MJ, Snell CR, Little T. Conceptual model for
28 physical therapist management of chronic fatigue syndrome/myalgic
29 encephalomyelitis. Physical Therapy. 2010; 90(4):602-614
- 30 128. Davies S, Crawley E. Chronic fatigue syndrome in children aged 11 years old and
31 younger. Archives of Disease in Childhood. 2008; 93(5):419-421
- 32 129. De Becker P, McGregor N, De Meirleir K. A definition-based analysis of symptoms in
33 a large cohort of patients with chronic fatigue syndrome. Journal of Internal Medicine.
34 2001; 250(3):234-240
- 35 130. De Becker P, Roeykens J, Reynders M, McGregor N, De Meirleir K. Exercise
36 capacity in chronic fatigue syndrome. Archives of Internal Medicine. 2000;
37 160(21):3270-3277
- 38 131. de Carvalho Leite JC, de LDM, Killeit A, Kale S, Nacul L, McArthur M et al. Social
39 support needs for equity in health and social care: a thematic analysis of experiences
40 of people with chronic fatigue syndrome/myalgic encephalomyelitis. International
41 Journal for Equity in Health. 2011; 10:46
- 42 132. de Lange FP, Koers A, Kalkman JS, Bleijenberg G, Hagoort P, van der Meer JW et
43 al. Increase in prefrontal cortical volume following cognitive behavioural therapy in
44 patients with chronic fatigue syndrome. Brain. 2008; 131(Pt 8):2172-2180

- 1 133. de Vega WC, Herrera S, Vernon SD, McGowan PO. Epigenetic modifications and
2 glucocorticoid sensitivity in myalgic encephalomyelitis/chronic fatigue syndrome
3 (ME/CFS). *BMC Medical Genomics*. 2017; 10(1):11
- 4 134. Deale A, Chalder T, Marks I, Wessely S. Cognitive behavior therapy for chronic
5 fatigue syndrome: A randomized controlled trial. *American Journal of Psychiatry*.
6 1997; 154(3):408-414
- 7 135. Deale A, Chalder T, Wessely S. Illness beliefs and treatment outcome in chronic
8 fatigue syndrome. *Journal of Psychosomatic Research*. 1998; 45(1):77-83
- 9 136. Deale A, Husain K, Chalder T, Wessely S. Long-term outcome of cognitive behavior
10 therapy versus relaxation therapy for chronic fatigue syndrome: A 5-year follow-up
11 study. *American Journal of Psychiatry*. 2001; 158(12):2038-2042
- 12 137. Deftereos SN, Vernon SD, Persidis A. Current therapeutic strategies for myalgic
13 encephalomyelitis/chronic fatigue syndrome: Results of an online survey. *Fatigue:
14 Biomedicine, Health and Behavior*. 2016; 4(1):39-51
- 15 138. DeLuca J, Christodoulou C, Diamond BJ, Rosenstein ED, Kramer N, Ricker JH et al.
16 The Nature of Memory Impairment in Chronic Fatigue Syndrome. *Rehabilitation
17 Psychology*. 2004; 49(1):62-70
- 18 139. Devasahayam A, Lawn T, Murphy M, White PD. Alternative diagnoses to chronic
19 fatigue syndrome in referrals to a specialist service: Service evaluation survey. *JRSM
20 Short Reports*. 2012; 3:4
- 21 140. Diao YL, Sun WN, He YQ, Leung SW, Siu YM. Equivalent magnetic vector potential
22 model for low-frequency magnetic exposure assessment. *Physics in Medicine and
23 Biology*. 2017; 62(19):7905-7922
- 24 141. Dobson J. Magnetic properties of biological material. *Bioengineering and biophysical
25 aspects of electromagnetic fields*. 3rd ed: CRC Press,. 2007.
- 26 142. Dougall D, Johnson A, Goldsmith K, Sharpe M, Angus B, Chalder T et al. Adverse
27 events and deterioration reported by participants in the PACE trial of therapies for
28 chronic fatigue syndrome. *Journal of Psychosomatic Research*. 2014; 77(1):20-26
- 29 143. Doukrou M, Hiremath S, Ferin K, Jones S, Begent J, Segal T. G612(P)
30 Characterisation of population, review of service provision, and outcomes for young
31 people with chronic fatigue syndrome in a tertiary care inpatient setting. *Archives of
32 Disease in Childhood*. 2019; 104(Suppl 2):A247-A247
- 33 144. Dowsett EG, Colby J. Long-term sickness absence due to ME/CFS in UK schools: An
34 epidemiological study with medical and educational implications. *Journal of Chronic
35 Fatigue Syndrome*. 1997; 3(2):29-42
- 36 145. Duyn JH, Schenck J. Contributions to magnetic susceptibility of brain tissue. *NMR in
37 Biomedicine*. 2017; 30(4):1-37
- 38 146. Dyda A, Stelzer-Braid S, Adam D, Chughtai AA, MacIntyre CR. The association
39 between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68) - what is the
40 evidence for causation? *Euro Surveillance*. 2018; 23(3):17-00310
- 41 147. Effective Health Care Program: Agency for Healthcare Research and Quality
42 (AHRQ). Diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue
43 syndrome. U.S. Department of Health & Human Services, 2014. Available from:
44 [https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-fatigue_research-
45 protocol.pdf](https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-fatigue_research-protocol.pdf)

- 1 148. Emerge Australia. Health and wellbeing survey 2018. 2018.
- 2 149. Emerge Australia. Health and wellbeing survey 2019. 2019. Available from:
3 <https://www.emerge.org.au/health-and-wellbeing-survey-report>
- 4 150. Encephalitis Society. What is encephalitis? 2017. Available from:
5 <https://www.encephalitis.info/what-is-encephalitis> Last accessed: 29/11/2019.
- 6 151. Eroshenko E, Belov A, Mavromichalaki H, Mariatos G, Oleneva V, Plainaki C et al.
7 Cosmic-ray variations during the two greatest bursts of solar activity in the 23rd solar
8 cycle. *Solar Physics*. 2004; 224(1):345-358
- 9 152. Evidence submissions to Health Select Committee Inquiry into aspects of the work of
10 the National Institute for Health and Clinical Excellence (NICE). House of Commons,
11 2017. Available from:
12 <https://publications.parliament.uk/pa/cm200607/cmselect/cmhealth/503/503we01.htm>
- 13 153. Executive Summary from Forward ME of survey conducted by Prof. Helen Dawes.
14 2019. Available from: [http://www.merereasearch.org.uk/wp-](http://www.merereasearch.org.uk/wp-content/uploads/2019/04/Amended-Final-Consolidated-Report.pdf)
15 [content/uploads/2019/04/Amended-Final-Consolidated-Report.pdf](http://www.merereasearch.org.uk/wp-content/uploads/2019/04/Amended-Final-Consolidated-Report.pdf)
- 16 154. Falk Hvidberg M, Brinth LS, Olesen AV, Petersen KD, Ehlers L. The health-related
17 quality of life for patients with myalgic encephalomyelitis/chronic fatigue syndrome
18 (ME/CFS). *PloS One*. 2015; 10(7):e0132421
- 19 155. Faulkner G. In the expectation of recovery: Misleading medical research and welfare
20 reform. The centre for Welfare Reform, 2016. Available from:
21 [https://www.centreforwelfarereform.org/uploads/attachment/492/in-the-expectation-of-](https://www.centreforwelfarereform.org/uploads/attachment/492/in-the-expectation-of-recovery.pdf)
22 [recovery.pdf](https://www.centreforwelfarereform.org/uploads/attachment/492/in-the-expectation-of-recovery.pdf)
- 23 156. Fisher H, Crawley E. Why do young people with CFS/ME feel anxious? A qualitative
24 study. *Clinical Child Psychology and Psychiatry*. 2013; 18(4):556-573
- 25 157. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the
26 functional impact of fatigue: Initial validation of the fatigue impact scale. *Clinical*
27 *Infectious Diseases*. 1994; 18(Suppl 1):S79-83
- 28 158. Flo E, Chalder T. Prevalence and predictors of recovery from chronic fatigue
29 syndrome in a routine clinical practice. *Behaviour Research and Therapy*. 2014; 63:1-
30 8
- 31 159. Fluge O, Mella O, Bruland O, Risa K, Dyrstad SE, Alme K et al. Metabolic profiling
32 indicates impaired pyruvate dehydrogenase function in myalgic
33 encephalopathy/chronic fatigue syndrome. *JCI Insight*. 2016; 1(21):e89376
- 34 160. Fluge O, Rekeland IG, Lien K, Thurmer H, Borchgrevink PC, Schafer C et al. B-
35 Lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue
36 syndrome: A randomized, double-blind, placebo-controlled trial. *Annals of Internal*
37 *Medicine*. 2019; 170(9):585-593
- 38 161. Fluge O, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D et al. B-Lymphocyte
39 Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label
40 Phase II Study with Rituximab Maintenance Treatment. *PloS One*. 2015;
41 10(7):e0129898
- 42 162. Franklin JD, Atkinson G, Atkinson JM, Batterham AM. Peak oxygen uptake in chronic
43 fatigue syndrome/myalgic encephalomyelitis: A meta-analysis. *International Journal*
44 *of Sports Medicine*. 2018; 40(2):77-87

- 1 163. Fukuda S, Nojima J, Kajimoto O, Yamaguti K, Nakatomi Y, Kuratsune H et al.
2 Ubiquinol-10 supplementation improves autonomic nervous function and cognitive
3 function in chronic fatigue syndrome. *Biofactors*. 2016; 42(4):431-440
- 4 164. Garner R, Baraniuk JN. Orthostatic intolerance in chronic fatigue syndrome. *Journal*
5 *of Translational Medicine*. 2019; 17:185
- 6 165. Geraghty K, Hann M, Kurtev S. Myalgic encephalomyelitis/chronic fatigue syndrome
7 patients' reports of symptom changes following cognitive behavioural therapy, graded
8 exercise therapy and pacing treatments: Analysis of a primary survey compared with
9 secondary surveys. *Journal of Health Psychology*. 2017; 24(10):1318-1333
- 10 166. Geraghty K, Jason L, Sunnquist M, Tuller D, Blease C, Adeniji C. The 'cognitive
11 behavioural model' of chronic fatigue syndrome: Critique of a flawed model. *Health*
12 *Psychology Open*. 2019; 6(1):1-14
- 13 167. Geraghty KJ, Adeniji C. The importance of accurate diagnosis of ME/CFS in children
14 and adolescents: A commentary. *Frontiers in Pediatrics*. 2019; 6:435
- 15 168. Geraghty KJ, Blease C. Cognitive behavioural therapy in the treatment of chronic
16 fatigue syndrome: A narrative review on efficacy and informed consent. *Journal of*
17 *Health Psychology*. 2018; 23(1):127-138
- 18 169. Geraghty KJ, Blease C. Myalgic encephalomyelitis/chronic fatigue syndrome and the
19 biopsychosocial model: A review of patient harm and distress in the medical
20 encounter *Disability and Rehabilitation*. 2019; 41(25):3092-3102
- 21 170. Geraghty KJ, Esmail A. Chronic fatigue syndrome: Is the biopsychosocial model
22 responsible for patient dissatisfaction and harm? *British Journal of General Practice*.
23 2016; 66(649):437-438
- 24 171. Ghatineh S, Vink M. FITNET's internet-based cognitive behavioural therapy is
25 ineffective and may impede natural recovery in adolescents with myalgic
26 encephalomyelitis/chronic fatigue syndrome. A review. *Behavioral Sciences*. 2017;
27 7(3):11
- 28 172. Gielissen MF, Knoop H, Servaes P, Kalkman JS, Huibers MJ, Verhagen S et al.
29 Differences in the experience of fatigue in patients and healthy controls: Patients'
30 descriptions. *Health & Quality of Life Outcomes*. 2007; 5:36
- 31 173. Gieré R. Magnetite in the human body: Biogenic vs. anthropogenic. *Proceedings of*
32 *the National Academy of Sciences*. 2016; 113(43):11986-11987
- 33 174. Gilder SA, Wack M, Kaub L, Roud SC, Petersen N, Heinsen H et al. Distribution of
34 magnetic remanence carriers in the human brain. *Scientific Reports*. 2018; 8:11363
- 35 175. Gladwell PW, Pheby D, Rodriguez T, Poland F. Use of an online survey to explore
36 positive and negative outcomes of rehabilitation for people with CFS/ME. *Disability*
37 *and Rehabilitation*. 2014; 36(5):387-394
- 38 176. Goedendorp MM, Knoop H, Schippers GM, Bleijenberg G. The lifestyle of patients
39 with chronic fatigue syndrome and the effect on fatigue and functional impairments.
40 *Journal of Human Nutrition & Dietetics*. 2009; 22(3):226-231
- 41 177. Haig-Ferguson A, Loades M, Whittle C, Read R, Higson-Sweeney N, Beasant L et al.
42 "It's not one size fits all"; the use of videoconferencing for delivering therapy in a
43 Specialist Paediatric Chronic Fatigue Service. *Internet Interventions*. 2019; 15:43-51

- 1 178. Haig-Ferguson A, Tucker P, Eaton N, Hunt L, Crawley E. Memory and attention
2 problems in children with chronic fatigue syndrome or myalgic encephalopathy.
3 Archives of Disease in Childhood. 2009; 94(10):757-762
- 4 179. Halapy E, Parlor M. Trends in the Canadian Community Health Survey Data - 2005,
5 2010, 2014. Quest. 2017; 112(Fall)
- 6 180. Harada ND, Chiu V, Stewart AL. Mobility-related function in older adults: Assessment
7 with a 6-minute walk test. Archives of Physical Medicine and Rehabilitation. 1999;
8 80(7):837-841
- 9 181. Haywood KL, Collin SM, Crawley E. Assessing severity of illness and outcomes of
10 treatment in children with chronic fatigue syndrome/myalgic encephalomyelitis
11 (CFS/ME): A systematic review of patient-reported outcome measures (PROMs).
12 Child: Care, Health and Development. 2014; 40(6):806-824
- 13 182. Haywood KL, Staniszevska S, Chapman S. Quality and acceptability of patient-
14 reported outcome measures used in chronic fatigue syndrome/myalgic
15 encephalomyelitis (CFS/ME): A systematic review. Quality of Life Research. 2012;
16 21(1):35-52
- 17 183. Heald A, Barber L, Jones HL, Farman S, Walther A. Service based comparison of
18 group cognitive behavior therapy to waiting list control for chronic fatigue syndrome
19 with regard to symptom reduction and positive psychological dimensions. Medicine
20 (Baltimore). 2019; 98(39):e16720
- 21 184. Healthwatch Lancashire. ME/CFS report. 2017. Available from:
22 <https://www.healthwatch.co.uk/reports-library/me-cfs-patient-experience-report>
- 23 185. Healthwatch Trafford. Patient experience report: Tired of explaining: Experiences of
24 services for ME/CFS patients in Trafford and Greater Manchester. 2017. Available
25 from: [https://healthwatchtrafford.co.uk/wp-content/uploads/2015/03/Tired-of-
26 explaining-ME-CFS-Report-by-Healthwatch-Trafford.pdf](https://healthwatchtrafford.co.uk/wp-content/uploads/2015/03/Tired-of-explaining-ME-CFS-Report-by-Healthwatch-Trafford.pdf)
- 27 186. Heins MJ, Knoop H, Bleijenberg G. The role of the therapeutic relationship in
28 cognitive behaviour therapy for chronic fatigue syndrome. Behaviour Research and
29 Therapy. 2013; 51(7):368-376
- 30 187. Heins MJ, Knoop H, Burk WJ, Bleijenberg G. The process of cognitive behaviour
31 therapy for chronic fatigue syndrome: which changes in perpetuating cognitions and
32 behaviour are related to a reduction in fatigue? Journal of Psychosomatic Research.
33 2013; 75(3):235-241
- 34 188. Heins MJ, Knoop H, Lobbestael J, Bleijenberg G. Childhood maltreatment and the
35 response to cognitive behavior therapy for chronic fatigue syndrome. Journal of
36 Psychosomatic Research. 2011; 71(6):404-410
- 37 189. Heins MJ, Knoop H, Prins JB, Stulemeijer M, van der Meer JW, Bleijenberg G.
38 Possible detrimental effects of cognitive behaviour therapy for chronic fatigue
39 syndrome. Psychotherapy and Psychosomatics. 2010; 79(4):249-256
- 40 190. Hives L, Bradley A, Richards J, Sutton C, Selfe J, Basu B et al. Can physical
41 assessment techniques aid diagnosis in people with chronic fatigue
42 syndrome/myalgic encephalomyelitis? A diagnostic accuracy study. BMJ Open. 2017;
43 7:e017521
- 44 191. Hodges LD, Nielsen T, Baken D. Physiological measures in participants with chronic
45 fatigue syndrome, multiple sclerosis and healthy controls following repeated exercise:
46 A pilot study. Clinical Physiology and Functional Imaging. 2018; 38(4):639-644

- 1 192. Holtzman CS, Bhatia S, Cotler J, Jason LA. Assessment of post-exertional malaise
2 (PEM) in patients with myalgic encephalomyelitis (ME) and chronic fatigue syndrome
3 (CFS): A patient-driven survey. *Diagnostics*. 2019; 9(1):1-13
- 4 193. Hughes AM, Hirsch CR, Nikolaus S, Chalder T, Knoop H, Moss-Morris R. Cross-
5 cultural study of information processing biases in chronic fatigue syndrome:
6 Comparison of Dutch and UK chronic fatigue patients. *International Journal of*
7 *Behavioral Medicine*. 2018; 25(1):49-54
- 8 194. Hughes JL. Illness narrative and chronic fatigue syndrome/myalgic encephalomyelitis:
9 A review. *The British Journal of Occupational Therapy*. 2002; 65(1):9-14
- 10 195. Huibers MJ, Beurskens AJ, Van Schayck CP, Bazelmans E, Metsemakers JF,
11 Knottnerus JA et al. Efficacy of cognitive-behavioural therapy by general practitioners
12 for unexplained fatigue among employees: Randomised controlled trial. *British*
13 *Journal of Psychiatry*. 2004; 184:240-246
- 14 196. Ickmans K, Meeus M, De Koning M, Lambrecht L, Pattyn N, Nijs J. Can recovery of
15 peripheral muscle function predict cognitive task performance in chronic fatigue
16 syndrome with and without fibromyalgia? *Physical Therapy*. 2014; 94(4):511-522
- 17 197. ICNIRP Project Group. ICNIRP statement on diagnostic devices using non-ionizing
18 radiation: Existing regulations and potential health risks. *Health Physics*. 2017;
19 112(3):305-321
- 20 198. Ingman T. A qualitative study investigating how people with myalgic
21 encephalomyelitis/chronic fatigue syndrome (ME/CFS) view recovery [Thesis].
- 22 199. Ingman T. A systematic literature review investigating the prognosis and predictors of
23 outcome following treatment for myalgic encephalomyelitis/chronic fatigue syndrome
24 (ME/CFS)
- 25 200. Ingman T, Ali S, Bhui K, Chalder T. Chronic fatigue syndrome: Comparing outcomes
26 in White British and Black and minority ethnic patients after cognitive-behavioural
27 therapy. *British Journal of Psychiatry*. 2016; 209:251-256
- 28 201. Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome:
29 Redefining an illness. Washington, DC. The National Academies Press. 2015.
30 Available from: <https://dx.doi.org/10.17226/19012>
- 31 202. ISRCTN. A randomised controlled trial of adaptive pacing, cognitive behaviour
32 therapy, and graded exercise, as supplements to standardised specialist medical
33 care versus standardised specialist medical care alone for patients with the chronic
34 fatigue syndrome/myalgic encephalomyelitis or encephalopathy. 2015. Available
35 from: <http://www.isrctn.com/ISRCTN54285094> Last accessed: 11/12/2019.
- 36 203. Jackson ML, Bruck D. Sleep abnormalities in chronic fatigue syndrome/myalgic
37 encephalomyelitis: A review. *Journal of Clinical Sleep Medicine*. 2012; 8(6):719-728
- 38 204. Janse A, Bleijenberg G, Knoop H. Prediction of long-term outcome after cognitive
39 behavioral therapy for chronic fatigue syndrome. *Journal of Psychosomatic Research*.
40 2019; 121:93-99
- 41 205. Janse A, Nikolaus S, Wiborg JF, Heins M, van der Meer JWM, Bleijenberg G et al.
42 Long-term follow-up after cognitive behaviour therapy for chronic fatigue syndrome.
43 *Journal of Psychosomatic Research*. 2017; 97:45-51
- 44 206. Janse A, van Dam A, Pijpers C, Wiborg JF, Bleijenberg G, Tummers M et al.
45 Implementation of stepped care for patients with chronic fatigue syndrome in

- 1 community-based mental health care: Outcomes at post-treatment and long-term
2 follow-up. *Behavioural and Cognitive Psychotherapy*. 2019; 47(5):548-558
- 3 207. Janse A, Wiborg JF, Bleijenberg G, Tummers M, Knoop H. The efficacy of guided
4 self-instruction for patients with idiopathic chronic fatigue: A randomized controlled
5 trial. *Journal of Consulting and Clinical Psychology*. 2016; 84(5):377-388
- 6 208. Janse A, Worm-Smeitink M, Bleijenberg G, Donders R, Knoop H. Efficacy of web-
7 based cognitive-behavioural therapy for chronic fatigue syndrome: Randomised
8 controlled trial. *British Journal of Psychiatry*. 2018; 212(2):112-118
- 9 209. Janse A, Worm-Smeitink M, Bussel-Lagarde J, Bleijenberg G, Nikolaus S, Knoop H.
10 Testing the efficacy of web-based cognitive behavioural therapy for adult patients with
11 chronic fatigue syndrome (CBIT): Study protocol for a randomized controlled trial.
12 *BMC Neurology*. 2015; 15:137
- 13 210. Jason L, Benton M, Torres-Harding S, Muldowney K. The impact of energy
14 modulation on physical functioning and fatigue severity among patients with ME/CFS.
15 *Patient Education and Counseling*. 2009; 77(2):237-241
- 16 211. Jason LA, Corradi K, Gress S, Williams S, Torres-Harding S. Causes of death among
17 patients with chronic fatigue syndrome. *Health Care for Women International*. 2006;
18 27(7):615-626
- 19 212. Jason LA, Fennell PA, Taylor RR, Fricano G, Halpert JA. An empirical verification of
20 the Fennell phases of the CFS illness. *Journal of Chronic Fatigue Syndrome*. 2000;
21 6(1):47-56
- 22 213. Jason LA, Jessen T, Porter N, Boulton A, Gloria-Njoku M, Friedberg F. Examining
23 types of fatigue among individuals with ME/CFS. *Disability Studies Quarterly*. 2009;
24 29(3):1-16
- 25 214. Jason LA, McManimen SL, Sunnquist M, Holtzman CS. Patient perceptions of post
26 exertional malaise. *Fatigue: Biomedicine, Health and Behavior*. 2018; 6(2):92-105
- 27 215. Jason LA, Taylor SL. Monitoring chronic fatigue syndrome. *Journal of Nervous and*
28 *Mental Disease*. 1994; 182(4):243-244
- 29 216. Jason LA, Timpo P, Porter N, Herrington J, Brown M, Torres-Harding S et al. Activity
30 logs as a measure of daily activity among patients with chronic fatigue syndrome.
31 *Journal of Mental Health*. 2009; 18(6):549-556
- 32 217. Jason LA, Torres-Harding S, Brown M, Sorenson M, Donalek J, Corradi K et al.
33 Predictors of change following participation in non-pharmacologic interventions for
34 CFS. *Japanese Society of Tropical Medicine*. 2008; 36(1):22-32
- 35 218. Jason LA, Zinn ML, Zinn MA. Myalgic Encephalomyelitis: Symptoms and Biomarkers.
36 *Current Neuropharmacology*. 2015; 13(5):701-734
- 37 219. Jelínek F, Pokorný J. Microtubules in biological cells as circular waveguides and
38 resonators. *Electro- and Magnetobiology*. 2001; 20(1):75-80
- 39 220. Jenkins M, Rayman M. Nutrient intake is unrelated to nutrient status in patients with
40 chronic fatigue syndrome. *Journal of Nutritional and Environmental Medicine*. 2005;
41 15(4):177-189
- 42 221. Jones DE, Hollingsworth KG, Jakovljevic DG, Fattakhova G, Pairman J, Blamire AM
43 et al. Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue
44 syndrome: A case-control study. *European Journal of Clinical Investigation*. 2012;
45 42(2):186-194

- 1 222. Josev EK, Malpas CB, Seal ML, Scheinberg A, Lubitz L, Rowe K et al. Resting-state
2 functional connectivity, cognition, and fatigue in response to cognitive exertion: a
3 novel study in adolescents with chronic fatigue syndrome. *Brain Imaging and*
4 *Behavior*. 2019;
- 5 223. Juutilainen J, Herrala M, Luukkonen J, Naarala J, Hore PJ. Magnetocarcinogenesis:
6 Is there a mechanism for carcinogenic effects of weak magnetic fields? *Proceedings:*
7 *Biological Sciences*. 2018; 285:20180590
- 8 224. Kapitein LC, Hoogenraad CC. Building the neuronal microtubule cytoskeleton.
9 *Neuron*. 2015; 87(3):492-506
- 10 225. Kasevich R. Cellphones radars & health. *IEEE Spectrum*. 2002; 39(8):15-16
- 11 226. Keller BA, Pryor JL, Giloteaux L. Inability of myalgic encephalomyelitis/chronic fatigue
12 syndrome patients to reproduce VO₂peak indicates functional impairment. *Journal of*
13 *Translational Medicine*. 2014; 12:104
- 14 227. Kempke S, Van Den Eede F, Schotte C, Claes S, Van Wambeke P, Van Houdenhove
15 B et al. Prevalence of DSM-IV personality disorders in patients with chronic fatigue
16 syndrome: A controlled study. *International Journal of Behavioral Medicine*. 2013;
17 20(2):219-228
- 18 228. Kenyon JN, Coe S, Izadi H. A retrospective outcome study of 42 patients with chronic
19 fatigue syndrome, 30 of whom had irritable bowel syndrome. Half were treated with
20 oral approaches, and half were treated with faecal microbiome transplantation.
21 *Human Microbiome Journal*. 2019; 13:100061
- 22 229. Kim JH, Lee JK, Kim HG, Kim KB, Kim HR. Possible effects of radiofrequency
23 electromagnetic field exposure on central nerve system. *Biomolecules &*
24 *Therapeutics*. 2019; 27(3):265-275
- 25 230. Kindlon T. Change in grey matter volume cannot be assumed to be due to cognitive
26 behavioural therapy. *Brain: A Journal of Neurology*. 2009; 132(1-2):e119
- 27 231. Kindlon T. Do graded activity therapies cause harm in chronic fatigue syndrome?
28 *Journal of Health Psychology*. 2017; 22(9):1146-1154
- 29 232. Kindlon T. Elements of rehabilitative strategies associated with negative outcomes in
30 CFS/ME: The need for further investigations. *Disability and Rehabilitation*. 2015;
31 37(5):466-467
- 32 233. Kindlon T. Harms of cognitive behaviour therapy designed to increase activity levels
33 in chronic fatigue syndrome: Questions remain. *Psychotherapy and Psychosomatics*.
34 2011; 80(2):110-111; author reply 112
- 35 234. Kindlon T. Internet-based CBT for adolescents with chronic fatigue syndrome. *The*
36 *Lancet*. 2012; 380(9841):561
- 37 235. Kindlon T. Objective compliance and outcome measures should be used in trials of
38 exercise interventions for chronic fatigue syndrome. *European Journal of Clinical*
39 *Investigation*. 2012; 42(12):1360-1361; author reply 1363-1365
- 40 236. Kindlon T. The PACE trial in chronic fatigue syndrome. *Lancet*. 2011;
41 377(9780):1833-1835
- 42 237. Kindlon T. Reporting of harms associated with graded exercise therapy and cognitive
43 behavioural therapy in myalgic encephalomyelitis/chronic fatigue syndrome. *Bulletin*
44 *of the IACFS/ME*. 2011; 19:59-111

- 1 238. Kindlon T. Response to: A pilot study of the process of change in a group chronic
2 fatigue syndrome management programme. Bulletin of the IACFS/ME. 2009; 17:84-
3 85
- 4 239. Kindlon T. Stratification using biological factors should be performed in more CFS
5 studies. Psychological Medicine. 2010; 40:352
- 6 240. Kindlon T, Baldwin A. Response to: Reports of recovery in chronic fatigue syndrome
7 may present less than meets the eye. Evidence-Based Mental Health. 2015; 18(2):e5
- 8 241. Kindlon T, Goudsmit EM. Graded exercise for chronic fatigue syndrome: Too soon to
9 dismiss reports of adverse reactions. Journal of Rehabilitation Medicine. 2010;
10 42(2):184-186
- 11 242. Kindlon T, Shepherd C. Treatment of myalgic encephalomyelitis/chronic fatigue
12 syndrome. Annals of Internal Medicine. 2015; 163(11):887-888
- 13 243. Kingdon CC, Bowman EW, Curran H, Nacul L, Lacerda EM. Functional status and
14 well-being in people with myalgic encephalomyelitis/chronic fatigue syndrome
15 compared with people with multiple sclerosis and healthy controls.
16 PharmacoEconomics Open. 2018; 2:381-392
- 17 244. Knoester M, Helfferich J, Poelman R, Van Leer-Buter C, Brouwer OF, Niesters HGM.
18 Twenty-nine cases of enterovirus-D68-associated acute flaccid myelitis in europe
19 2016: A case series and epidemiologic overview. Pediatric Infectious Disease
20 Journal. 2019; 38(1):16-21
- 21 245. Knoop H, Bleijenberg G, Gielissen MF, van der Meer JW, White PD. Is a full recovery
22 possible after cognitive behavioural therapy for chronic fatigue syndrome?
23 Psychotherapy and Psychosomatics. 2007; 76(3):171-176
- 24 246. Knoop H, Prins JB, Stulemeijer M, van der Meer JW, Bleijenberg G. The effect of
25 cognitive behaviour therapy for chronic fatigue syndrome on self-reported cognitive
26 impairments and neuropsychological test performance. Journal of Neurology,
27 Neurosurgery and Psychiatry. 2007; 78(4):434-436
- 28 247. Knoop H, Stulemeijer M, de Jong LW, Fiselier TJ, Bleijenberg G. Efficacy of cognitive
29 behavioral therapy for adolescents with chronic fatigue syndrome: long-term follow-up
30 of a randomized, controlled trial. Pediatrics. 2008; 121(3):e619-625
- 31 248. Knoop H, Stulemeijer M, Prins JB, van der Meer JW, Bleijenberg G. Is cognitive
32 behaviour therapy for chronic fatigue syndrome also effective for pain symptoms?
33 Behaviour Research and Therapy. 2007; 45(9):2034-2043
- 34 249. Knoop H, van der Meer JW, Bleijenberg G. Guided self-instructions for people with
35 chronic fatigue syndrome: Randomised controlled trial. British Journal of Psychiatry.
36 2008; 193(4):340-341
- 37 250. Knudsen AK, Henderson M, Harvey SB, Chalder T. Long-term sickness absence
38 among patients with chronic fatigue syndrome. British Journal of Psychiatry. 2011;
39 199:430-431
- 40 251. Kodama K. Application of broadband alternating current magnetic susceptibility to the
41 characterization of magnetic nanoparticles in natural materials. Journal of
42 Geophysical Research: Solid Earth. 2013; 118(1):1-12
- 43 252. Kreyberg S. Myalgic Encephalomyelitis/Postviral fatigue syndrome (G93.3). Basic
44 concepts and guidelines for the diagnosis. 2007.

- 1 253. Kreyberg SE. [Caring for seriously ill ME-patients: A small survey]. Norwegian Journal
2 of Nursing Research. 2007; 9(2):16-26
- 3 254. Kuehn B. Chronic fatigue care. JAMA. 2018; 320(8):750
- 4 255. Lacerda EM, Kingdon CC, Bowman EW, Nacul L. Using a participatory approach to
5 develop and implement the UK ME/CFS Biobank. Fatigue. 2018; 6(1):1-4
- 6 256. Lacerda EM, McDermott C, Kingdon CC, Butterworth J, Cliff JM, Nacul L. Hope,
7 disappointment and perseverance: Reflections of people with myalgic
8 encephalomyelitis/chronic fatigue syndrome (ME/CFS) and multiple sclerosis
9 participating in biomedical research. A qualitative focus group study. Health
10 Expectations. 2019; 22(3):373-384
- 11 257. LaManca JJ, Sisto SA, DeLuca J, Johnson SK, Lange G, Pareja J et al. Influence of
12 exhaustive treadmill exercise on cognitive functioning in chronic fatigue syndrome.
13 American Journal of Medicine. 1998; 105(3 Suppl. 1):59S-65S
- 14 258. Lapp CW. Initiating care of a patient with myalgic encephalomyelitis/chronic fatigue
15 syndrome (ME/CFS). Frontiers in Pediatrics. 2019; 6:415
- 16 259. Larun L, Odgaard-Jensen J, Brurberg KG, Chalder T, Dybwad M, Moss-Morris RE et
17 al. Exercise therapy for chronic fatigue syndrome (individual patient data). Cochrane
18 Database of Systematic Reviews 2014, Issue 4. Art. No.: CD011040. DOI:
19 <http://dx.doi.org/10.1002/14651858.CD011040>.
- 20 260. Leaman D. Magnetic rocks - Their effect on compass use and navigation in
21 Tasmania. Papers and Proceedings of the Royal Society of Tasmania. 1997; 131:73-
22 75
- 23 261. Leary S, Sylvester J, Shorter E, Moreno E. Your experience of ME services. Survey
24 Report by #MEAction UK. 2019. Available from: [https://www.meaction.net/wp-](https://www.meaction.net/wp-content/uploads/2019/10/Your-experience-of-ME-services-Survey-report-by-MEAction-UK.pdf)
25 [content/uploads/2019/10/Your-experience-of-ME-services-Survey-report-by-](https://www.meaction.net/wp-content/uploads/2019/10/Your-experience-of-ME-services-Survey-report-by-MEAction-UK.pdf)
26 [MEAction-UK.pdf](https://www.meaction.net/wp-content/uploads/2019/10/Your-experience-of-ME-services-Survey-report-by-MEAction-UK.pdf) [https://www.meaction.net/wp-content/uploads/2019/10/Your-](https://www.meaction.net/wp-content/uploads/2019/10/Your-experience-of-ME-services-Survey-report-by-MEAction-UK.pdf)
27 [experience-of-ME-services-Survey-report-by-MEAction-UK.pdf](https://www.meaction.net/wp-content/uploads/2019/10/Your-experience-of-ME-services-Survey-report-by-MEAction-UK.pdf)
- 28 262. Leone SS, Huibers MJ, Kant I, Van Schayck CP, Bleijenberg G, André Knottnerus J.
29 Long-term predictors of outcome in fatigued employees on sick leave: A 4-year
30 follow-up study. Psychological Medicine. 2006; 36(9):1293-1300
- 31 263. Lewis I, Pairman J, Spickett G, Newton JL. Clinical characteristics of a novel
32 subgroup of chronic fatigue syndrome patients with postural orthostatic tachycardia
33 syndrome. Journal of Internal Medicine. 2013; 273(5):501-510
- 34 264. Lien K, Johansen B, Veierod MB, Haslestad AS, Bohn SK, Melsom MN et al.
35 Abnormal blood lactate accumulation during repeated exercise testing in myalgic
36 encephalomyelitis/chronic fatigue syndrome. Physiological Reports. 2019;
37 7(11):e14138
- 38 265. Light AR, White AT, Huguen RW, Light KC. Moderate exercise increases expression
39 for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but
40 not in normal subjects. Journal of Pain. 2009; 10(10):1099-1112
- 41 266. Lincolnshire Partnership. Lincolnshire Chronic Fatigue Syndrome/ME Service.
42 Lincolnshire Partnership NHS Foundation Trust, 2019.
- 43 267. Liu X, Treister R, Lang M, Oaklander AL. IVIg for apparently autoimmune small-fiber
44 polyneuropathy: First analysis of efficacy and safety. Therapeutic Advances in
45 Neurological Disorders. 2018; 11:1-12

- 1 268. Lloyd S, Chalder T, Rimes KA. Family-focused cognitive behaviour therapy versus
2 psycho-education for adolescents with chronic fatigue syndrome: Long-term follow-up
3 of an RCT. *Behaviour Research and Therapy*. 2012; 50(11):719-725
- 4 269. Lloyd S, Chalder T, Sallis HM, Rimes KA. Telephone-based guided self-help for
5 adolescents with chronic fatigue syndrome: A non-randomised cohort study.
6 *Behaviour Research and Therapy*. 2012; 50(5):304-312
- 7 270. Loades ME, Read R, Smith L, Higson-Sweeney NT, Laffan A, Stallard P et al.
8 Depression and anxiety in adolescent chronic fatigue syndrome (CFS): A clinical
9 cohort study [Unpublished]. 2019;
- 10 271. Loades ME, Rimes KA, Ali S, Chalder T. Depressive symptoms in adolescents with
11 chronic fatigue syndrome (CFS): Are rates higher than in controls and do depressive
12 symptoms affect outcome? *Clinical Child Psychology and Psychiatry*. 2019;
13 24(3):580-592
- 14 272. Loades ME, Rimes KA, Ali S, Lievesley K, Chalder T. The presence of co-morbid
15 mental health problems in a cohort of adolescents with chronic fatigue syndrome.
16 *Clinical Child Psychology and Psychiatry*. 2018; 23(3):398-408
- 17 273. Loades ME, Sheils EA, Crawley E. Treatment for paediatric chronic fatigue syndrome
18 or myalgic encephalomyelitis (CFS/ME) and comorbid depression: A systematic
19 review. *BMJ Open*. 2016; 6:e012271
- 20 274. Loades ME, Smith L, Higson-Sweeney N, Beasant L, Stallard P, Kessler D et al.
21 Obstacles to recruitment in paediatric studies focusing on mental health in a physical
22 health context: The experiences of clinical gatekeepers in an observational cohort
23 study. *BMC Medical Research Methodology*. 2019; 19(1):89
- 24 275. Loy BD, O'Connor PJ, Dishman RK. Effect of acute exercise on fatigue in people with
25 ME/CFS/SEID: A Meta-analysis. *Medicine and Science in Sports and Exercise*. 2016;
26 48(10):2003-2012
- 27 276. Lyshevski SE, Tsouri GR. Molecular and biomolecular communication: Waveguides
28 and possible role of microtubules. 2011 11th IEEE International Conference on
29 Nanotechnology. 2011;
- 30 277. M.E. Group. Richmond & Kingston local area survey 2014. 2014.
- 31 278. M.E. Group. Richmond & Kingston local area survey 2019. 2019.
- 32 279. Maes M, Mihaylova I, De Ruyter M. Lower serum zinc in chronic fatigue syndrome
33 (CFS): Relationships to immune dysfunctions and relevance for the oxidative stress
34 status in CFS. *Journal of Affective Disorders*. 2006; 90(2-3):141-147
- 35 280. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Coenzyme
36 Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is
37 related to fatigue, autonomic and neurocognitive symptoms and is another risk factor
38 explaining the early mortality in ME/CFS due to cardiovascular disorder.
39 *Neuroendocrinology Letters*. 2009; 30(4):470-476
- 40 281. Maes M, Twisk FN, Ringel K. Inflammatory and cell-mediated immune biomarkers in
41 myalgic encephalomyelitis/chronic fatigue syndrome and depression: Inflammatory
42 markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in
43 depression. *Psychotherapy and Psychosomatics*. 2012; 81(5):286-295
- 44 282. Marshall PS, Forstot M, Callies A, Peterson PK, Schenck CH. Cognitive slowing and
45 working memory difficulties in chronic fatigue syndrome. *Psychosomatic Medicine*.
46 1997; 59(1):58-66

- 1 283. Marshall PS, Watson D, Steinberg P, Cornblatt B, Peterson PK, Callies A et al. An
2 assessment of cognitive function and mood in chronic fatigue syndrome. *Biological*
3 *Psychiatry*. 1996; 39(3):199-206
- 4 284. Mathew SJ, Mao X, Keegan KA, Levine SM, Smith EL, Heier LA et al. Ventricular
5 cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with
6 generalized anxiety disorder: An in vivo 3.0 T (1)H MRS imaging study. *NMR in*
7 *Biomedicine*. 2009; 22(3):251-258
- 8 285. May M, Emond A, Crawley E. Phenotypes of chronic fatigue syndrome in children
9 and young people. *Archives of Disease in Childhood*. 2010; 95(4):245-249
- 10 286. McCourt A, Maile E, Gregorowski A, Hargreaves D, Segal T. G599(P) Characteristics
11 of a patient population attending a specialist outpatient service for chronic fatigue
12 syndrome. *Archives of Disease in Childhood*. 2019; 104(Suppl 2):A242-A242
- 13 287. McDermott C, Richards SC, Thomas PW, Montgomery J, Lewith G. A placebo-
14 controlled, double-blind, randomized controlled trial of a natural killer cell stimulant
15 (BioBran MGN-3) in chronic fatigue syndrome. *QJM*. 2006; 99(7):461-468
- 16 288. McGregor NR, Armstrong CW, Lewis DP, Butt HL, Gooley PR. Widespread pain and
17 altered renal function in ME/CFS patients. *Fatigue: Biomedicine, Health and*
18 *Behavior*. 2016; 4(3):132-145
- 19 289. McGregor NR, Armstrong CW, Lewis DP, Gooley PR. Post-exertional malaise is
20 associated with hypermetabolism, hypoacetylation and purine metabolism
21 deregulation in ME/CFS cases. *Diagnostics*. 2019; 9(3):70
- 22 290. McManimen S, McClellan D, Stoothoff J, Gleason K, Jason LA. Dismissing chronic
23 illness: A qualitative analysis of negative health care experiences. *Health Care for*
24 *Women International*. 2019; 40(3):241-258
- 25 291. McManimen SL, Devendorf AR, Brown AA, Moore BC, Moore JH, Jason LA. Mortality
26 in patients with myalgic encephalomyelitis and chronic fatigue syndrome. *Fatigue*.
27 2016; 4(4):195-207
- 28 292. McPhee G, Baldwin A, Kindlon T, Hughes BM. Monitoring treatment harm in myalgic
29 encephalomyelitis/chronic fatigue syndrome: A freedom-of-information study of
30 National Health Service specialist centres in England. *Journal of Health Psychology*.
31 2019; <https://doi.org/10.1177/1359105319854532>
- 32 293. ME/cvs Vereniging. Report survey summary 'Zorg voor ME' (Care for ME). 2016.
33 Available from: [https://www.me-
34 cvsvereniging.nl/sites/default/files/documenten/Report%20Survey%20Summary%20
35 %27Zorg%20voor%20ME%27%20%28%E2%80%98Care%20for%20ME%E2%80%
36 99%29.pdf](https://www.me-cvsvereniging.nl/sites/default/files/documenten/Report%20Survey%20Summary%20%27Zorg%20voor%20ME%27%20%28%E2%80%98Care%20for%20ME%E2%80%99%29.pdf)
- 37 294. Meeus M, Hermans L, Ickmans K, Struyf F, Van Cauwenbergh D, Bronckaerts L et al.
38 Endogenous pain modulation in response to exercise in patients with rheumatoid
39 arthritis, patients with chronic fatigue syndrome and comorbid fibromyalgia, and
40 healthy controls: A double-blind randomized controlled trial. *Pain Practice*. 2015;
41 15(2):98-106
- 42 295. Melamed KH, Santos M, Oliveira RKF, Urbina MF, Felsenstein D, Opatowsky AR et
43 al. Unexplained exertional intolerance associated with impaired systemic oxygen
44 extraction. *European Journal of Applied Physiology*. 2019; 119(10):2375-2389

- 1 296. Mihelicova M, Siegel Z, Evans M, Brown A, Jason L. Caring for people with severe
2 myalgic encephalomyelitis: An interpretative phenomenological analysis of parents'
3 experiences. *Journal of Health Psychology*. 2016; 21(12):2824-2837
- 4 297. Miller RR, Reid WD, Mattman A, Yamabayashi C, Steiner T, Parker S et al.
5 Submaximal exercise testing with near-infrared spectroscopy in myalgic
6 encephalomyelitis/chronic fatigue syndrome patients compared to healthy controls: A
7 case-control study. *Journal of Translational Medicine*. 2015; 13:159
- 8 298. Millions Missing Canada. Iatrogenic harm: Spring survey results [Unpublished]. 2017.
- 9 299. Missen A, Hollingworth W, Eaton N, Crawley E. The financial and psychological
10 impacts on mothers of children with chronic fatigue syndrome (CFS/ME). *Child: Care,
11 Health and Development*. 2012; 38(4):505-512
- 12 300. Moneghetti KJ, Skhiri M, Contrepolis K, Kobayashi Y, Maecker H, Davis M et al. Value
13 of circulating cytokine profiling during submaximal exercise testing in myalgic
14 encephalomyelitis/chronic fatigue syndrome. *Scientific Reports*. 2018; 8:2779
- 15 301. Montoya JG, Anderson JN, Adolphs DL, Bateman L, Klimas N, Levine SM et al.
16 KPAX002 as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome
17 (ME/CFS): A prospective, randomized trial. *International Journal of Clinical and
18 Experimental Medicine*. 2018; 11(3):2890-2900
- 19 302. Montoya JG, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE et al.
20 Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a
21 subset of patients with chronic fatigue syndrome. *Journal of Medical Virology*. 2013;
22 85(12):2101-2109
- 23 303. Moore L. Chronic fatigue syndrome: All in the mind? An occupational therapy
24 perspective. *British Journal of Occupational Therapy*. 2000; 63(4):163-170
- 25 304. Moore R, Derry S, Aldington D, Cole P, Wiffen P. Amitriptyline for neuropathic pain in
26 adults. *Cochrane Database of Systematic Reviews* 2015, Issue 7. Art. No.:
27 CD008242. DOI: 10.1002/14651858.CD008242.pub3.
- 28 305. Morens DM, Folkers GK, Fauci AS. Acute flaccid myelitis: Something old and
29 something new. *mBio*. 2019; 10(2):e00521-00519
- 30 306. Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic
31 fatigue syndrome explained by activated immuno-inflammatory, oxidative and
32 nitrosative stress pathways. *Metabolic Brain Disease*. 2014; 29:19-36
- 33 307. Murdock KW, Wang XS, Shi Q, Cleeland CS, Fagundes CP, Vernon SD. The utility of
34 patient-reported outcome measures among patients with myalgic
35 encephalomyelitis/chronic fatigue syndrome. *Quality of Life Research*. 2017;
36 26(4):913-921
- 37 308. Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Advisory Committee. Report
38 to the NHMRC Chief Executive Officer. 2019. Available from:
39 [https://www.nhmrc.gov.au/about-us/publications/mecfs-advisory-committee-report-
40 nhmrc-chief-executive-officer#block-views-block-file-attachments-content-block-1](https://www.nhmrc.gov.au/about-us/publications/mecfs-advisory-committee-report-nhmrc-chief-executive-officer#block-views-block-file-attachments-content-block-1)
- 41 309. Nacul L, de Barros B, Kingdon CC, Cliff JM, Clark TG, Mudie K et al. Evidence of
42 clinical pathology abnormalities in people with myalgic encephalomyelitis/chronic
43 fatigue syndrome (ME/CFS) from an analytic cross-sectional study. *Diagnostics*.
44 2019; 9(2):1-16
- 45 310. Nacul L, Lacerda EM, Kingdon CC, Curran H, Bowman EW. How have selection bias
46 and disease misclassification undermined the validity of myalgic

- 1 encephalomyelitis/chronic fatigue syndrome studies? Journal of Health Psychology.
2 2019; 24(12):1765-1769
- 3 311. Nacul LC, Lacerda EM, Campion P, Pheby D, Drachler Mde L, Leite JC et al. The
4 functional status and well being of people with myalgic encephalomyelitis/chronic
5 fatigue syndrome and their carers. BMC Public Health. 2011; 11:402
- 6 312. Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S et al.
7 Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three
8 regions of England: a repeated cross-sectional study in primary care. BMC Medicine.
9 2011; 9:91
- 10 313. Nacul LC, Mudie K, Kingdon CC, Clark TG, Lacerda EM. Hand grip strength as a
11 clinical biomarker for ME/CFS and disease severity. Frontiers in Neurology. 2018;
12 9:992
- 13 314. Nagy-Szakal D, Barupal DK, Lee B, Che X, Williams BL, Kahn EJ et al. Insights into
14 myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through
15 comprehensive metabolomics. Scientific Reports. 2018; 8:10056
- 16 315. Natelson BH, Mao X, Stegner AJ, Lange G, Vu D, Blate M et al. Multimodal and
17 simultaneous assessments of brain and spinal fluid abnormalities in chronic fatigue
18 syndrome and the effects of psychiatric comorbidity. Journal of the Neurological
19 Sciences. 2017; 375:411-416
- 20 316. Natelson BH, Vu D, Coplan JD, Mao X, Blate M, Kang G et al. Elevations of
21 ventricular lactate levels occur in both chronic fatigue syndrome and fibromyalgia.
22 Fatigue. 2017; 5(1):15-20
- 23 317. National Centers for Environmental Information. Geomagnetism. Available from:
24 <https://www.ngdc.noaa.gov/geomag/geomag.shtml> Last accessed: 04/12/2019.
- 25 318. National Collaborating Centre for Primary Care. Chronic fatigue syndrome/myalgic
26 encephalomyelitis (or encephalopathy): Diagnosis and management of chronic
27 fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) in adults and
28 children. NICE clinical guideline 53. London. Royal College of General Practitioners,
29 2007. Available from: <http://guidance.nice.org.uk/CG53>
- 30 319. National Institute for Health and Care Excellence. Developing NICE guidelines: the
31 manual [Updated 2018]. London. National Institute for Health and Care Excellence,
32 2014. Available from:
33 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
- 34 320. Naviaux RK, Gordon E. Reply to Roerink et al.: Metabolomics of chronic fatigue
35 syndrome. Proceedings of the National Academy of Sciences. 2017; 114(6):E911
- 36 321. Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L et al. Metabolic
37 features of chronic fatigue syndrome. Proceedings of the National Academy of
38 Sciences of the United States of America. 2016; 113(37):E5472-5480
- 39 322. Newberry F, Hsieh SY, Wileman T, Carding SR. Does the microbiome and virome
40 contribute to myalgic encephalomyelitis/chronic fatigue syndrome? Clinical Science.
41 2018; 132(5):523-542
- 42 323. Newton JL, Mabillard H, Scott A, Hoad A, Spickett G. The Newcastle NHS Chronic
43 Fatigue Syndrome Service: Not all fatigue is the same. Journal of the Royal College
44 of Physicians of Edinburgh. 2010; 40(4):304-307
- 45 324. NHS North Bristol. Survey of patients attending NHS specialist CFS/ME Services
46 conducted April-July 2019. North Bristol NHS Trust, 2019.

- 1 325. Nijhof SL, Bleijenberg G, Uiterwaal CS, Kimpfen JL, van de Putte EM. Effectiveness of
2 internet-based cognitive behavioural treatment for adolescents with chronic fatigue
3 syndrome (FITNET): A randomised controlled trial. *Lancet*. 2012; 379(9824):1412-
4 1418
- 5 326. Nijhof SL, Bleijenberg G, Uiterwaal CS, Kimpfen JL, van de Putte EM. Fatigue In
6 Teenagers on the interNET--the FITNET Trial. A randomized clinical trial of web-
7 based cognitive behavioural therapy for adolescents with chronic fatigue syndrome:
8 Study protocol. *BMC Neurology*. 2011; 11:23
- 9 327. Nijhof SL, Priesterbach LP, Uiterwaal CSPM, Bleijenberg G, Kimpfen JLL, Van De
10 Putte EM. Internet-based therapy for adolescents with chronic fatigue syndrome:
11 Long-term follow-up. *Pediatrics*. 2013; 131(6):e1788-e1795
- 12 328. Nijhof SL, Rutten JM, Uiterwaal CS, Bleijenberg G, Kimpfen JL, Putte EM. The role of
13 hypocortisolism in chronic fatigue syndrome. *Psychoneuroendocrinology*. 2014;
14 42:199-206
- 15 329. Norfolk and Suffolk Service. Patient survey report. 2009. Available from:
16 <http://nandsme.blogspot.com/p/patient-survey.html>
- 17 330. Norris T, Hawton K, Hamilton-Shield J, Crawley E. Obesity in adolescents with
18 chronic fatigue syndrome: An observational study. *Archives of Disease in Childhood*.
19 2017; 102(1):35-39
- 20 331. Ocon AJ, Messer ZR, Medow MS, Stewart JM. Increasing orthostatic stress impairs
21 neurocognitive functioning in chronic fatigue syndrome with postural tachycardia
22 syndrome. *Clinical Science*. 2012; 122(5):227-238
- 23 332. Odoom JK, Adziati I, Quansah E, Attiku K, Ntim NAA, Arthur-Quarm J et al. High
24 serotype diversity of non-polio enteroviruses isolated in Ghana during acute flaccid
25 paralysis surveillance, 2010-2014. *Advances in Research*. 2018; 16(6):1-9
- 26 333. Office for National Statistics. Mentions of postviral fatigue syndrome (benign myalgic
27 encephalomyelitis), deaths registered in England and Wales, 2001 to 2016. 2018.
28 Available from:
29 <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/008461mentionsofpostviralfatiguesyndromebenignmyalgicencephalomyelitisdeathsregisteredinenglandandwales2001to2016> Last accessed: 29/11/2019.
- 32 334. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is
33 associated with severity of chronic fatigue immune dysfunction syndrome. *Clinical*
34 *Infectious Diseases*. 1994; 18(Suppl 1):S157-159
- 35 335. Oliver C. University Hospitals of Derby & Burton Foundation Trust: CFS service
36 outcomes 17-18 April. University Hospitals of Derby & Burton Foundation Trust, 2018.
- 37 336. Oxford Clinical Allied Technology and Trials Services Unit. Forward-ME Group CBT &
38 GET Survey. 2019.
- 39 337. PACE Trial participant dataset. Available from:
40 https://sites.google.com/site/pacefoir/pace-ipd_foia-qmul-2014-f73.xlsx Last
41 accessed: 03/12/2019.
- 42 338. Packer TL, Foster DM, Brouwer B. Fatigue and activity patterns of people with
43 chronic fatigue syndrome. *Occupational Therapy Journal of Research*. 1997;
44 17(3):186-199
- 45 339. Pakpoor J, Goldacre M. Neuroepidemiology: The increasing burden of mortality from
46 neurological diseases. *Nature Reviews: Neurology*. 2017; 13:518-519

- 1 340. Parslow R, Patel A, Beasant L, Haywood K, Johnson D, Crawley E. What matters to
2 children with CFS/ME? A conceptual model as the first stage in developing a PROM.
3 Archives of Disease in Childhood. 2015; 100(12):1141-1147
- 4 341. Parslow RM, Anderson N, Byrne D, Shaw A, Haywood KL, Crawley E. Adolescent's
5 descriptions of fatigue, fluctuation and payback in chronic fatigue syndrome/myalgic
6 encephalopathy (CFS/ME): Interviews with adolescents and parents. BMJ Paediatrics
7 Open. 2018; 2:e000281
- 8 342. Parslow RM, Harris S, Broughton J, Alattas A, Crawley E, Haywood K et al.
9 Children's experiences of chronic fatigue syndrome/myalgic encephalomyelitis
10 (CFS/ME): A systematic review and meta-ethnography of qualitative studies. BMJ
11 Open. 2017; 7:e012633
- 12 343. Parslow RM, Shaw A, Haywood KL, Crawley E. Important factors to consider when
13 treating children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME):
14 Perspectives of health professionals from specialist services. BMC Pediatrics. 2017;
15 17:43
- 16 344. Pastula DM, Aliabadi N, Haynes AK, Messacar K, Schreiner T, Maloney J et al. Acute
17 neurologic illness of unknown etiology in children - Colorado, August-September
18 2014. MMWR: Morbidity and Mortality Weekly Report. 2014; 63(40):901-902
- 19 345. Pates A. My life stopped ... voices from action for M.E. 2014 survey: severe M.E. time
20 to deliver report. Action for ME, 2014. Available from:
21 <https://www.actionforme.org.uk/uploads/pdfs/my-life-stopped-severe-ME-report.pdf>
- 22 346. Patient survey results for FDA drug development meeting for ME and CFS, April 25-
23 26, 2013 [Unpublished]. 2013.
- 24 347. Patrick Neary J, Roberts AD, Leavins N, Harrison MF, Croll JC, Sexsmith JR.
25 Prefrontal cortex oxygenation during incremental exercise in chronic fatigue
26 syndrome. Clinical Physiology and Functional Imaging. 2008; 28(6):364-372
- 27 348. Peci A, Winter A-L, Warshawsky B, Booth TF, Eshaghi A, Li A et al. Epidemiology of
28 Enterovirus D68 in Ontario. PloS One. 2015; 10(11):e0142841
- 29 349. Peckerman A, LaManca JJ, Dahl KA, Chemitiganti R, Qureishi B, Natelson BH.
30 Abnormal impedance cardiography predicts symptom severity in chronic fatigue
31 syndrome. American Journal of the Medical Sciences. 2003; 326(2):55-60
- 32 350. Pemberton S, Cox D. Perspectives of time and occupation: Experiences of people
33 with chronic fatigue syndrome/myalgic encephalomyelitis. Journal of Occupational
34 Science. 2014; 21(4):488-503
- 35 351. Pemberton S, Cox DL. Experiences of daily activity in chronic fatigue
36 syndrome/myalgic encephalomyelitis (CFS/ME) and their implications for
37 rehabilitation programmes. Disability and Rehabilitation. 2014; 36(21):1790-1797
- 38 352. Pemberton S, Dunn N, Bradley J, McKeever V. Survey of patient outcomes and
39 experience for adults and young people accessing a ME/CFS rehabilitation service.
40 2019.
- 41 353. Perrin RN. Chronic fatigue syndrome, a review from the biomechanical perspective.
42 British Osteopathic Journal. 1993; 11:15-23
- 43 354. Perrin RN, Edwards J, Hartley P. An evaluation of the effectiveness of osteopathic
44 treatment on symptoms associated with myalgic encephalomyelitis. A preliminary
45 report. Journal of Medical Engineering and Technology. 1998; 22(1):1-13

- 1 355. Perrin RN, Richards JD, Pentreath V, Percy DF. Muscle fatigue in chronic fatigue
2 syndrome/myalgic encephalomyelitis (CFS/ME) and its response to a manual
3 therapeutic approach: A pilot study. *International Journal of Osteopathic Medicine*.
4 2011; 14(3):96-105
- 5 356. Peterson PK, Schenck CH, Sherman R. Chronic fatigue syndrome in Minnesota.
6 *Minnesota Medicine*. 1991; 74(5):21-26
- 7 357. Peterson PK, Sirr SA, Grammith FC, Schenck CH, Pheley AM, Hu S et al. Effects of
8 mild exercise on cytokines and cerebral blood flow in chronic fatigue syndrome
9 patients. *Clinical and Diagnostic Laboratory Immunology*. 1994; 1(2):222-226
- 10 358. Pheby D, Saffron L. Risk factors for severe ME/CFS. *Biology and Medicine*. 2009;
11 1(4):50-74
- 12 359. Physios for M.E. An exploratory study of the experiences of M.E patients and
13 physiotherapy [Unpublished].
- 14 360. Plascencia-Villa G, Ponce A, Collingwood JF, Arellano-Jiménez MJ, Zhu X, Rogers
15 JT et al. High-resolution analytical imaging and electron holography of magnetite
16 particles in amyloid cores of Alzheimer's disease. *Scientific Reports*. 2016;
17 6(1):24873
- 18 361. Polli A, Van Oosterwijck J, Meeus M, Lambrecht L, Nijs J, Ickmans K. Exercise-
19 induce hyperalgesia, complement system and elastase activation in myalgic
20 encephalomyelitis/chronic fatigue syndrome - a secondary analysis of experimental
21 comparative studies. *Scandinavian Journal of Pain*. 2018; 19(1):183-192
- 22 362. Polo O, Pesonen P, Tuominen E. Low-dose naltrexone in the treatment of myalgic
23 encephalomyelitis/chronic fatigue syndrome (ME/CFS). *Fatigue: Biomedicine, Health
24 & Behavior*. 2019; 7(4):207-217
- 25 363. Preparing children for starting primary school. 2018. Available from:
26 [https://www.thetimes.co.uk/article/preparing-children-for-starting-primary-school-
27 6q6hv8nl3#](https://www.thetimes.co.uk/article/preparing-children-for-starting-primary-school-6q6hv8nl3#) Last accessed: 05/12/2019.
- 28 364. Prins J, Bleijenberg G, Rouweler EK, van der Meer J. Effect of psychiatric disorders
29 on outcome of cognitive-behavioural therapy for chronic fatigue syndrome. *British
30 Journal of Psychiatry*. 2005; 187:184-185
- 31 365. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL et al.
32 Cognitive behaviour therapy for chronic fatigue syndrome: A multicentre randomised
33 controlled trial. *Lancet*. 2001; 357(9259):841-847
- 34 366. Prokhorov BE, Förster M, Stolle C, Lesur V, Namgalagze AA, Holschneider M. The
35 ionospheric current system and its contribution to the Earth's magnetic field.
36 *Geophysical Research Abstracts*. 2016; 18
- 37 367. Puri BK, Gunatilake KD, Fernando KA, Gurusinghe AI, Agour M, Treasaden IH.
38 Increased tenderness in the left third intercostal space in adult patients with myalgic
39 encephalomyelitis: A controlled study. *Journal of International Medical Research*.
40 2011; 39(1):212-214
- 41 368. Quarmby L, Rimes KA, Deale A, Wessely S, Chalder T. Cognitive-behaviour therapy
42 for chronic fatigue syndrome: Comparison of outcomes within and outside the
43 confines of a randomised controlled trial. *Behaviour Research and Therapy*. 2007;
44 45(6):1085-1094

- 1 369. Raine R, Carter S, Sensky T, Black N. General practitioners' perceptions of chronic
2 fatigue syndrome and beliefs about its management, compared with irritable bowel
3 syndrome: Qualitative study. *BMJ*. 2004; 328(7452):1354-1357
- 4 370. Rand Corporation. 36-Item Short Form Survey Instrument (SF-36). Available from:
5 [https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/survey-
7 instrument.html](https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/survey-
6 instrument.html) Last accessed: 03/12/2019.
- 7 371. Rawlins M. De Testimonio: On the evidence for decisions about the use of
8 therapeutic interventions. *Clinical Medicine (London, England)*. 2008; 8(6):579-588
- 9 372. Reactive oxygen species in biology and human health. Ahmad SI. 1st ed. Boca
10 Raton. CRC Press. 2016.
- 11 373. Regland B, Forsmark S, Halaouate L, Matousek M, Peilot B, Zachrisson O et al.
12 Response to vitamin B12 and folic acid in myalgic encephalomyelitis and
13 fibromyalgia. *PLoS One*. 2015; 10(4):e0124648
- 14 374. Reynolds GK, Lewis DP, Richardson AM, Lidbury BA. Comorbidity of postural
15 orthostatic tachycardia syndrome and chronic fatigue syndrome in an Australian
16 cohort. *Journal of Internal Medicine*. 2014; 275(4):409-417
- 17 375. Richardson J. Myalgic encephalomyelitis: guidelines for doctors. *Journal of Chronic
18 Fatigue Syndrome*. 2002; 10(1):65-80
- 19 376. Rimes KA, Papadopoulos AS, Cleare AJ, Chalder T. Cortisol output in adolescents
20 with chronic fatigue syndrome: Pilot study on the comparison with healthy
21 adolescents and change after cognitive behavioural guided self-help treatment.
22 *Journal of Psychosomatic Research*. 2014; 77(5):409-414
- 23 377. Roberts AD, Papadopoulos AS, Wessely S, Chalder T, Cleare AJ. Salivary cortisol
24 output before and after cognitive behavioural therapy for chronic fatigue syndrome.
25 *Journal of Affective Disorders*. 2009; 115(1-2):280-286
- 26 378. Roberts D. Chronic fatigue syndrome and quality of life. *Patient Related Outcome
27 Measures*. 2018; 9:253-262
- 28 379. Roberts E, Wessely S, Chalder T, Chang CK, Hotopf M. Mortality of people with
29 chronic fatigue syndrome: A retrospective cohort study in England and Wales from
30 the South London and Maudsley NHS Foundation Trust Biomedical Research Centre
31 (SLaM BRC) Clinical Record Interactive Search (CRIS) Register. *Lancet*. 2016;
32 387(10028):1638-1643
- 33 380. Roe A. North of Tyne CFS/ME rehabilitation and management team: Service
34 evaluation 2016.
- 35 381. Roerink ME, Bredie SJH, Heijnen M, Dinarello CA, Knoop H, Van der Meer JWM.
36 Cytokine inhibition in patients with chronic fatigue syndrome: A randomized trial.
37 *Annals of Internal Medicine*. 2017; 166(8):557-564
- 38 382. Roerink ME, Knoop H, Bredie SJ, Heijnen M, Joosten LA, Netea MG et al. Cytokine
39 inhibition in chronic fatigue syndrome patients: Study protocol for a randomized
40 controlled trial. *Trials*. 2015; 16:439
- 41 383. Roerink ME, Knoop H, Bronkhorst EM, Mouthaan HA, Hawinkels LJAC, Joosten LAB
42 et al. Cytokine signatures in chronic fatigue syndrome patients: A case control study
43 and the effect of anakinra treatment. *Journal of Translational Medicine*. 2017; 15:267

- 1 384. Roma M, Marden CL, Flaherty MAK, Jasion SE, Cranston EM, Rowe PC. Impaired
2 health-related quality of life in adolescent myalgic encephalomyelitis/chronic fatigue
3 syndrome: The impact of core symptoms. *Frontiers in Pediatrics*. 2019; 7:26
- 4 385. Roor JJ, Knoop H, Dandachi-FitzGerald B, Peters MJV, Bleijenberg G, Ponds R.
5 Feedback on underperformance in patients with Chronic Fatigue Syndrome: The
6 impact on subsequent neuropsychological test performance *Applied*
7 *Neuropsychology*. 2020; 27(2):188-196
- 8 386. Ross SD, Estok RP, Frame D, Stone LR, Ludensky V, Levine CB. Disability and
9 chronic fatigue syndrome: a focus on function. *Archives of Internal Medicine*. 2004;
10 164(10):1098-1107
- 11 387. Rowe KS. Long term follow up of young people with chronic fatigue syndrome
12 attending a pediatric outpatient service. *Frontiers in Pediatrics*. 2019; 7:21
- 13 388. Rowe PC, Underhill RA, Friedman KJ, Gurwitt A, Medow MS, Schwartz MS et al.
14 Myalgic encephalomyelitis/chronic fatigue syndrome diagnosis and management in
15 young people: A primer. *Frontiers in Pediatrics*. 2017; 5:121
- 16 389. Ruggieri V, Paz MI, Peretti MG, Rugilo C, Bologna R, Freire C et al. Enterovirus D68
17 infection in a cluster of children with acute flaccid myelitis, Buenos Aires, Argentina,
18 2016. *European Journal of Paediatric Neurology*. 2017; 21(6):884-890
- 19 390. Santini SJ, Cordone V, Falone S, Mijit M, Tatone C, Amicarelli F et al. Role of
20 mitochondria in the oxidative stress induced by electromagnetic fields: Focus on
21 reproductive systems. *Oxidative Medicine and Cellular Longevity*. 2018;
22 2018:5076271
- 23 391. Šarić A, Buell AK, Meisl G, Michaels TCT, Dobson CM, Linse S et al. Physical
24 determinants of the self-replication of protein fibrils. *Nature Physics*. 2016; 12:874-
25 880
- 26 392. Scheeres K, Knoop H, Meer v, Bleijenberg G. Clinical assessment of the physical
27 activity pattern of chronic fatigue syndrome patients: A validation of three methods.
28 *Health & Quality of Life Outcomes*. 2009; 7:29
- 29 393. Scheeres K, Wensing M, Bleijenberg G, Severens JL. Implementing cognitive
30 behavior therapy for chronic fatigue syndrome in mental health care: A costs and
31 outcomes analysis. *BMC Health Services Research*. 2008; 8(175)
- 32 394. Scheeres K, Wensing M, Knoop H, Bleijenberg G. Implementing cognitive behavioral
33 therapy for chronic fatigue syndrome in a mental health center: A benchmarking
34 evaluation. *Journal of Consulting and Clinical Psychology*. 2008; 76(1):163-171
- 35 395. Scheeres K, Wensing M, Mes C, Bleijenberg G. The impact of informational
36 interventions about cognitive behavioral therapy for chronic fatigue syndrome on GPs
37 referral behavior. *Patient Education and Counseling*. 2007; 68(1):29-32
- 38 396. Schmalting KB, Patterson TL. The association of major life events with chronic fatigue.
39 *Journal of Psychosomatic Research*. 2019; 125:109810
- 40 397. Schweitzer R, Kelly B, Foran A, Terry D, Whiting J. Quality of life in chronic fatigue
41 syndrome. *Social Science and Medicine*. 1995; 41(10):1367-1372
- 42 398. Service related research project: a service evaluation of an eight-week lifestyle
43 management programme run by a chronic fatigue syndrome.
- 44 399. Service related research project: executive summary. A service evaluation of a
45 lifestyle management group programme at a chronic fatigue syndrome service. 2015.

- 1 400. Severens JL, Prins JB, van der Wilt GJ, van der Meer JW, Bleijenberg G. Cost-
2 effectiveness of cognitive behaviour therapy for patients with chronic fatigue
3 syndrome. *QJM*. 2004; 97(3):153-161
- 4 401. Shakespeare T, Watson N, Alghaib OA. Blaming the victim, all over again: Waddell
5 and Aylward's biopsychosocial (BPS) model of disability. *Critical Social Policy*. 2017;
6 37(1):22-41
- 7 402. Shan ZY, Finegan K, Bhuta S, Ireland T, Staines DR, Marshall-Gradisnik SM et al.
8 Brain function characteristics of chronic fatigue syndrome: A task fMRI study.
9 *NeuroImage: Clinical*. 2018; 19:279-286
- 10 403. Sharpe M, Goldsmith KA, Johnson AL, Chalder T, Walker J, White PD. Rehabilitative
11 treatments for chronic fatigue syndrome: Long-term follow-up from the PACE trial.
12 *The Lancet Psychiatry*. 2015; 2(12):1067-1074
- 13 404. Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A et al. A
14 report--chronic fatigue syndrome: Guidelines for research. *Journal of the Royal
15 Society of Medicine*. 1991; 84(2):118-121
- 16 405. Shukla SK, Cook D, Meyer J, Vernon SD, Le T, Clevidence D et al. Changes in gut
17 and plasma microbiome following exercise challenge in myalgic
18 encephalomyelitis/chronic fatigue syndrome (ME/CFS). *PloS One*. 2015;
19 10(12):e0145453
- 20 406. Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, Dyke JP et al.
21 Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical
22 glutathione and clinical symptoms implicate oxidative stress in disorder
23 pathophysiology. *NMR in Biomedicine*. 2012; 25(9):1073-1087
- 24 407. Smith ME, Haney E, McDonagh M, Pappas M, Daeges M, Wasson N et al. Treatment
25 of myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review for a
26 national institutes of health pathways to prevention workshop. *Annals of Internal
27 Medicine*. 2015; 162(12):841-850
- 28 408. Smith MEB, Nelson HD, Haney E, Pappas M, Daeges M, Wasson N et al. Diagnosis
29 and treatment of myalgic encephalomyelitis/chronic fatigue syndrome. Evidence
30 Report/Technology Assessment 2014; (219):1-433
- 31 409. Smith SN, Crawley E. Is there effective behavioural treatment for children with
32 chronic fatigue syndrome/myalgic encephalomyelitis? *Archives of Disease in
33 Childhood*. 2013; 98(7):561-563
- 34 410. Snell CR, Stevens SR, Davenport TE, Van Ness JM. Discriminative validity of
35 metabolic and workload measurements for identifying people with chronic fatigue
36 syndrome. *Physical Therapy*. 2013; 93(11):1484-1492
- 37 411. Snounou R, Woods N, Henry L, Adams JA. Focus group evaluation of an eight-week
38 group condition management programme for myalgic encephalomyelitis/ chronic
39 fatigue syndrome (ME/CFS).
- 40 412. Solomon-Moore E, Jago R, Beasant L, Brigden A, Crawley E. Physical activity
41 patterns among children and adolescents with mild-to-moderate chronic fatigue
42 syndrome/myalgic encephalomyelitis. *BMJ Paediatrics Open*. 2019; 3:e000425
- 43 413. Stahl D, Rimes KA, Chalder T. Mechanisms of change underlying the efficacy of
44 cognitive behaviour therapy for chronic fatigue syndrome in a specialist clinic: A
45 mediation analysis. *Psychological Medicine*. 2014; 44(6):1331-1344

- 1 414. Staud R, Boissoneault J, Craggs JG, Lai S, Robinson ME. Task related cerebral
2 blood flow changes of patients with chronic fatigue syndrome: An arterial spin labeling
3 study. *Fatigue*. 2018; 6(2):63-79
- 4 415. Staud R, Kizer T, Robinson ME. Muscle injections with lidocaine improve resting
5 fatigue and pain in patients with chronic fatigue syndrome. *Journal of Pain Research*.
6 2017; 10:1477-1486
- 7 416. Steffen TM, Hacker TA, Mollinger L. Age- and gender-related test performance in
8 community-dwelling elderly people: Six-Minute Walk Test, Berg Balance Scale,
9 Timed Up & Go Test, and gait speeds. *Physical Therapy*. 2002; 82(2):128-137
- 10 417. Stevelink SAM, Fear NT, Hotopf M, Chalder T. Factors associated with work status in
11 chronic fatigue syndrome. *Occupational Medicine*. 2019; 69(6):453-458
- 12 418. Stevens S, Snell C, Stevens J, Keller B, VanNess JM. Cardiopulmonary exercise test
13 methodology for assessing exertion intolerance in myalgic encephalomyelitis/chronic
14 fatigue syndrome. *Frontiers in Pediatrics*. 2018; 6:242
- 15 419. Stevens SR, Davenport TE. Functional outcomes of anaerobic rehabilitation in a
16 patient with chronic fatigue syndrome: Case report with 1-year follow up. *Bulletin of*
17 *the IACFS/ME*. 2010; 18(3):93-98
- 18 420. Stoll SVE, Crawley E, Richards V, Lal N, Brigden A, Loades ME. What treatments
19 work for anxiety in children with chronic fatigue syndrome/myalgic encephalomyelitis
20 (CFS/ME)? Systematic review. *BMJ Open*. 2017; 7(9):e015481
- 21 421. Stordeur S, Thiry N, Eyssen M. Chronisch Vermoeidheidssyndroom: Diagnose,
22 behandeling en zorgorganisatie. Brussel. Federaal Kenniscentrum voor de
23 Gezondheidszorg (KCE), 2008. Available from:
24 <https://kce.fgov.be/sites/default/files/atoms/files/d20081027358.pdf>
- 25 422. Strassheim VJ, Sunnquist M, Jason LA, Newton JL. Defining the prevalence and
26 symptom burden of those with self-reported severe chronic fatigue syndrome/myalgic
27 encephalomyelitis (CFS/ME): A two-phase community pilot study in the North East of
28 England. *BMJ Open*. 2018; 8:e020775
- 29 423. Strawbridge R, Sartor ML, Scott F, Cleare AJ. Inflammatory proteins are altered in
30 chronic fatigue syndrome-A systematic review and meta-analysis. *Neuroscience and*
31 *Biobehavioral Reviews*. 2019; 107:69-83
- 32 424. Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ et al. A
33 double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist
34 rintatolimod in severe cases of chronic fatigue syndrome. *PloS One*. 2012;
35 7(3):e31334
- 36 425. Strbak O, Kopcansky P, Frollo I. Biogenic magnetite in humans and new magnetic
37 resonance hazard questions. *Mesurament Science Review*. 2011; 11(3):85-91
- 38 426. Stulemeijer M, de Jong LW, Fiselier TJ, Hoogveld SW, Bleijenberg G. Cognitive
39 behaviour therapy for adolescents with chronic fatigue syndrome: Randomised
40 controlled trial. *BMJ*. 2005; 330(7481):14
- 41 427. Sumathipala A, Siribaddana S, Abeysingha MR, De Silva P, Dewey M, Prince M et al.
42 Cognitive-behavioural therapy v. structured care for medically unexplained
43 symptoms: Randomised controlled trial. *British Journal of Psychiatry*. 2008;
44 193(1):51-59
- 45 428. Sunnquist M, Jason LA. A reexamination of the cognitive behavioral model of chronic
46 fatigue syndrome. *Journal of Clinical Psychology*. 2018; 74(7):1234-1245

- 1 429. Sutton and St Helier Hospitals. Chronic Fatigue Service Sutton and St Helier
2 Hospitals Audit: Group programme satisfaction questionnaires. October 2006-May
3 2007.
- 4 430. Suvorov IM, Sushentsova TI, Posokhin VV, Chekodanova NV, Popova VI,
5 Kormushina VV. [Microwave radiation as a factor in altering the health of the
6 population]. *Medsina Truda i Promyshlennaia Ekologiya*. 1998; (11):29-30
- 7 431. Swinscow TDV. Correlation and regression. *Statistics at square one*. 9th ed. 1997.
- 8 432. Taylor AP. Environmental magnetite in the human brain. 2016. Available from:
9 [https://www.the-scientist.com/daily-news/environmental-magnetite-in-the-human-](https://www.the-scientist.com/daily-news/environmental-magnetite-in-the-human-brain-32901)
10 [brain-32901](https://www.the-scientist.com/daily-news/environmental-magnetite-in-the-human-brain-32901) Last accessed: 04/12/2019.
- 11 433. Taylor D. Clinical outcome evaluation for the Leeds and York CFS/ME Service 18/19
12 [Unpublished]. 2019.
- 13 434. Taylor RR. Quality of life and symptom severity for individuals with chronic fatigue
14 syndrome: Findings from a randomized clinical trial. *American Journal of*
15 *Occupational Therapy*. 2004; 58(1):35-43
- 16 435. Teitelbaum JE, Bird B, Greenfield RM, Weiss A, Muenz L, Gould L. Effective
17 treatment of chronic fatigue syndrome and fibromyalgia - A randomized, double-blind,
18 placebo-controlled, intent-to-treat study. *Journal of Chronic Fatigue Syndrome*. 2001;
19 8(2):3-28
- 20 436. Terzi M, Ozberk B, Deniz OG, Kaplan S. The role of electromagnetic fields in
21 neurological disorders. *Journal of Chemical Neuroanatomy*. 2016; 75(Pt B):77-84
- 22 437. The 25% ME Group. Analysis report. 2010. Available from:
23 www.25megroup.org/download/1819/?v=3069
- 24 438. The 25% ME Group. Exercise & ensuring patient safety [Unpublished]. 2014.
- 25 439. The 25% ME Group. Follow up survey on people with M.E., 2001. Available from:
26 <https://25megroup.org/factsheets-and-leaflets>
- 27 440. The 25% ME Group. Input to consultation on draft scope for the Guideline Myalgic
28 encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: Diagnosis and
29 management (in development). 2018.
- 30 441. The 25% ME Group. Input to consultation on NG74 'Intermediate care including
31 reablement'. 2017.
- 32 442. The 25% ME Group. M.E. family/household members survey questionnaire results.
33 2001. Available from: <https://25megroup.org/download/1819/?v=1830>
- 34 443. The 25% ME Group. M.E. generic members survey questionnaire results
35 [unpublished]. 2002.
- 36 444. The 25% ME Group. M.E. questionnaire results. 2000.
- 37 445. The 25% ME Group. Our newsletter. 2019. Available from:
38 <https://25megroup.org/our-newsletter> Last accessed: 11/12/2019.
- 39 446. The 25% ME Group. Severe myalgic encephalomyelitis: Understanding and
40 Remembrance Day (8th August) [pamphlet].
- 41 447. The 25% ME Group. Severely affected ME (myalgic encephalomyelitis) analysis
42 report on questionnaire issued January 2004. 2004.

- 1 448. The Consortium of Multiple Sclerosis Centers Health Services Research
2 Subcommittee. Multiple Sclerosis Quality of Life Inventory: A user's manual 1997.
3 Available from:
4 [https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochu](https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/MSQLI_-_A-User-s-Manual.pdf)
5 [res/MSQLI_-_A-User-s-Manual.pdf](https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/MSQLI_-_A-User-s-Manual.pdf)
- 6 449. The GK, Bleijenberg G, Buitelaar JK, van der Meer JW. The effect of ondansetron, a
7 5-HT3 receptor antagonist, in chronic fatigue syndrome: A randomized controlled trial.
8 Journal of Clinical Psychiatry. 2010; 71(5):528-533
- 9 450. The GK, Bleijenberg G, van der Meer JW. The effect of acclidine in chronic fatigue
10 syndrome: A randomized controlled trial. PLoS Clinical Trials. 2007; 2(5):e19
- 11 451. The ME Association. Managing my M.E. What people with ME/CFS and their carers
12 want from the UK's health and social services. The results of the ME Association's
13 major survey of illness management requirements. Buckinghamshire The ME
14 Association, 2010.
- 15 452. The ME Association. ME/CFS illness management survey results: No decisions about
16 me without me. Part 1. 2015. Available from: [https://www.meassociation.org.uk/wp-](https://www.meassociation.org.uk/wp-content/uploads/2015-ME-Association-Illness-Management-Report-No-decisions-about-me-without-me-30.05.15.pdf)
17 [content/uploads/2015-ME-Association-Illness-Management-Report-No-decisions-](https://www.meassociation.org.uk/wp-content/uploads/2015-ME-Association-Illness-Management-Report-No-decisions-about-me-without-me-30.05.15.pdf)
18 [about-me-without-me-30.05.15.pdf](https://www.meassociation.org.uk/wp-content/uploads/2015-ME-Association-Illness-Management-Report-No-decisions-about-me-without-me-30.05.15.pdf)
- 19 453. The Neurological Alliance, Quality Health. The National Neurology Patient Experience
20 Survey 2018/2019: Technical report. 2019. Available from:
21 [https://www.neural.org.uk/wp-content/uploads/2019/07/Neuro-Patience-Techincal-](https://www.neural.org.uk/wp-content/uploads/2019/07/Neuro-Patience-Techincal-Report.pdf)
22 [Report.pdf](https://www.neural.org.uk/wp-content/uploads/2019/07/Neuro-Patience-Techincal-Report.pdf)
- 23 454. Thomas M, Smith A. An investigation into the cognitive deficits associated with
24 chronic fatigue syndrome. Open Neurology Journal. 2009; 3:13-23
- 25 455. Tiersky LA, DeLuca J, Hill N, Dhar SK, Johnson SK, Lange G et al. Longitudinal
26 assessment of neuropsychological functioning, psychiatric status, functional disability
27 and employment status in chronic fatigue syndrome. Applied Neuropsychology. 2001;
28 8(1):41-50
- 29 456. Tillett A, Glass S, Reeve A, Burt A, Fisher M. Provision of health and education
30 services in school children with chronic fatigue syndrome. Ambulatory Child Health.
31 2000; 6(2):83-89
- 32 457. Timbol CR, Baraniuk JN. Chronic fatigue syndrome in the emergency department.
33 Open Access Emergency Medicine. 2019; 11:15-28
- 34 458. Togo F, Lange G, Natelson BH, Quigley KS. Attention network test: Assessment of
35 cognitive function in chronic fatigue syndrome. Journal of Neuropsychology. 2015;
36 9(1):1-9
- 37 459. Trabal J, Leyes P, Fernandez-Sola J, Forga M, Fernandez-Huerta J. Patterns of food
38 avoidance in chronic fatigue syndrome: Is there a case for dietary recommendations?
39 Nutrición Hospitalaria. 2012; 27(2):659-662
- 40 460. Tummers M, Knoop H, Bleijenberg G. Effectiveness of stepped care for chronic
41 fatigue syndrome: A randomized noninferiority trial. Journal of Consulting and Clinical
42 Psychology. 2010; 78(5):724-731
- 43 461. Tummers M, Knoop H, van Dam A, Bleijenberg G. Implementing a minimal
44 intervention for chronic fatigue syndrome in a mental health centre: A randomized
45 controlled trial. Psychological Medicine. 2012; 42(10):2205-2215

- 1 462. Tummers M, Knoop H, van Dam A, Bleijenberg G. Moderators of the treatment
2 response to guided self-instruction for chronic fatigue syndrome. *Journal of*
3 *Psychosomatic Research*. 2013; 74(5):373-377
- 4 463. Twisk F. Dutch Health Council Advisory report on myalgic encephalomyelitis and
5 chronic fatigue syndrome: Taking the wrong turn. *Diagnostics*. 2018; 8(2):34
- 6 464. Twisk F. Studies and surveys implicate potential iatrogenic harm of cognitive
7 behavioral therapy and graded exercise therapy for myalgic encephalomyelitis and
8 chronic fatigue syndrome patients. *Research on Chronic Diseases*. 2017; 1(2):13-14
- 9 465. Twisk F, Geraghty K. Deviant cellular and physiological responses to exercise in
10 myalgic encephalomyelitis and chronic fatigue syndrome. *Jacobs Journal of*
11 *Physiology*. 2015; 1(2):1-6
- 12 466. Twisk FN. Accurate diagnosis of myalgic encephalomyelitis and chronic fatigue
13 syndrome based upon objective test methods for characteristic symptoms. *World*
14 *Journal of Methodology*. 2015; 5(2):68-87
- 15 467. Twisk FNM. A definition of recovery in myalgic encephalomyelitis and chronic fatigue
16 syndrome should be based upon objective measures. *Quality of Life Research: An*
17 *International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation*.
18 2014; 23(9)
- 19 468. van Campen C, Rowe PC, Visser FC. Blood volume status in ME/CFS correlates with
20 the presence or absence of orthostatic symptoms: Preliminary results. *Frontiers in*
21 *Pediatrics*. 2018; 6:352
- 22 469. van Campen CM, Riepma K, Visser FC. Open trial of vitamin B12 nasal drops in
23 adults with myalgic encephalomyelitis/chronic fatigue syndrome: Comparison of
24 responders and non-responders. *Frontiers in Pharmacology*. 2019; 10:1102
- 25 470. Van Campen CMC, Visser FC. The abnormal cardiac index and stroke volume index
26 changes during a normal tilt table test in ME/CFS patients compared to healthy
27 volunteers, are not related to deconditioning. *Journal of Thrombosis and Circulation*.
28 2018:107
- 29 471. Van Den Eede F, Moorkens G, Hulstijn W, Maas Y, Schrijvers D, Stevens SR et al.
30 Psychomotor function and response inhibition in chronic fatigue syndrome. *Psychiatry*
31 *Research*. 2011; 186(2-3):367-372
- 32 472. van der Schaaf ME, De Lange FP, Schmits IC, Geurts DEM, Roelofs K, van der Meer
33 JWM et al. Prefrontal structure varies as a function of pain symptoms in chronic
34 fatigue syndrome. *Biological Psychiatry*. 2017; 81(4):358-365
- 35 473. van Der Schaaf ME, Schmits IC, Roerink M, Geurts DE, Toni I, Roelofs K et al.
36 Investigating neural mechanisms of change of cognitive behavioural therapy for
37 chronic fatigue syndrome: A randomized controlled trial. *BMC Psychiatry*. 2015;
38 15:144
- 39 474. van der Werf SP, de Vree B, Alberts M, van der Meer JW, Bleijenberg G, Netherlands
40 Fatigue Research Group Nijmegen. Natural course and predicting self-reported
41 improvement in patients with chronic fatigue syndrome with a relatively short illness
42 duration. *Journal of Psychosomatic Research*. 2002; 53(3):749-753
- 43 475. Van Konynenburg R, Nayhan N. Application of Yasko Protocol to the treatment of
44 chronic fatigue syndrome Boston. 2010.
- 45 476. van Kuppeveld FJ, de Jong AS, Lanke KH, Verhaegh GW, Melchers WJ, Swanink
46 CM et al. Prevalence of xenotropic murine leukaemia virus-related virus in patients

- 1 with chronic fatigue syndrome in the Netherlands: Retrospective analysis of samples
2 from an established cohort. *BMJ*. 2010; 340:c1018
- 3 477. VanNess JM, Snell CR, Stevens SR. Diminished cardiopulmonary capacity during
4 post-exertional malaise. *Journal of Chronic Fatigue Syndrome*. 2007; 14(2):77-85
- 5 478. VanNess JM, Stevens SR, Bateman L, Stiles TL, Snell CR. Postexertional malaise in
6 women with chronic fatigue syndrome. *Journal of Women's Health*. 2010; 19(2):239-
7 244
- 8 479. Velleman S, Collin SM, Beasant L, Crawley E. Psychological wellbeing and quality-of-
9 life among siblings of paediatric CFS/ME patients: A mixed-methods study. *Clinical
10 Child Psychology and Psychiatry*. 2016; 21(4):618-633
- 11 480. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G.
12 Prognosis in chronic fatigue syndrome: A prospective study on the natural course.
13 *Journal of Neurology, Neurosurgery and Psychiatry*. 1996; 60(5):489-494
- 14 481. Vercoulen JHMM, Swanink CMA, Zitman FG, Vreden SGS, Hoofs MPE, Fennis JFM
15 et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic
16 fatigue syndrome. *Lancet*. 1996; 347(9005):858-861
- 17 482. Vermeulen RC, Kurk RM, Visser FC, Sluiter W, Scholte HR. Patients with chronic
18 fatigue syndrome performed worse than controls in a controlled repeated exercise
19 study despite a normal oxidative phosphorylation capacity. *Journal of Translational
20 Medicine*. 2010; 8:93
- 21 483. Vermeulen RC, Vermeulen van Eck IW. Decreased oxygen extraction during
22 cardiopulmonary exercise test in patients with chronic fatigue syndrome. *Journal of
23 Translational Medicine*. 2014; 12:20
- 24 484. Vernon D, Stockport ME Group Members. Survey. 2004.
- 25 485. Verspaandonk J, Coenders M, Bleijenberg G, Lobbestael J, Knoop H. The role of the
26 partner and relationship satisfaction on treatment outcome in patients with chronic
27 fatigue syndrome. *Psychological Medicine*. 2015; 45(11):2345-2352
- 28 486. Vink M. Assessment of individual pace trial data: In myalgic
29 encephalomyelitis/chronic fatigue syndrome, cognitive behavioral and graded
30 exercise therapy are ineffective, do not lead to actual recovery and negative
31 outcomes may be higher than reported. *Journal of Neurology and Neurobiology*.
32 2017; 3(1):1-10
- 33 487. Vink M, Vink-Niese A. Cognitive behavioural therapy for myalgic
34 encephalomyelitis/chronic fatigue syndrome is not effective. Re-analysis of a
35 Cochrane review. *Health Psychology Open*. 2019; 6(1):1-23
- 36 488. Vink M, Vink-Niese A. Graded exercise therapy for myalgic encephalomyelitis/chronic
37 fatigue syndrome is not effective and unsafe. Re-analysis of a Cochrane review.
38 *Health Psychology Open*. 2018; 5(2):1-12
- 39 489. Vink M, Vink-Niese A. Multidisciplinary rehabilitation treatment is not effective for
40 myalgic encephalomyelitis/chronic fatigue syndrome: A review of the FatiGo trial.
41 *Health Psychology Open*. 2018; 5(2):1-8
- 42 490. Vink M, Vink-Niese F. Work rehabilitation and medical retirement for myalgic
43 encephalomyelitis/chronic fatigue syndrome patients. A review and appraisal of
44 diagnostic strategies. *Diagnostics*. 2019; 9(4):1-33

- 1 491. Wallis A, Ball M, Butt H, Lewis DP, McKechnie S, Paull P et al. Open-label pilot for
2 treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue
3 syndrome: Neuropsychological symptoms and sex comparisons. *Journal of*
4 *Translational Medicine*. 2018; 16:24
- 5 492. Wallis A, Butt H, Ball M, Lewis DP, Bruck D. Support for the microgenome:
6 Associations in a human clinical population. *Scientific Reports*. 2016; 6:19171
- 7 493. Wang H, Liu X, Lv B, Yang F, Hong Y. Reliable multi-label learning via conformal
8 predictor and random forest for syndrome differentiation of chronic fatigue in
9 traditional Chinese medicine. *PloS One*. 2014; 9(6):e99565
- 10 494. Wang H, Zhang X. Magnetic fields and reactive oxygen species. *International Journal*
11 *of Molecular Sciences*. 2017; 18(10):2175
- 12 495. Watt T, Oberfoell S, Balise R, Lunn MR, Kar AK, Merrihew L et al. Response to
13 valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and
14 Epstein-Barr virus IgG antibody titers. *Journal of Medical Virology*. 2012;
15 84(12):1967-1974
- 16 496. Wearden AJ, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S et al.
17 Nurse led, home based self help treatment for patients in primary care with chronic
18 fatigue syndrome: Randomised controlled trial. *BMJ*. 2010; 340:c1777
- 19 497. Wearden AJ, Emsley R. Mediators of the effects on fatigue of pragmatic rehabilitation
20 for chronic fatigue syndrome. *Journal of Consulting and Clinical Psychology*. 2013;
21 81(5):831-838
- 22 498. Wearden AJ, Riste L, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK et al.
23 Fatigue Intervention by Nurses Evaluation--the FINE Trial. A randomised controlled
24 trial of nurse led self-help treatment for patients in primary care with chronic fatigue
25 syndrome: study protocol. *BMC Medicine*. 2006; 4:9
- 26 499. Weatherburn GC, Goldsmith Lister A, Findley LJ. The feasibility of reviewing chronic
27 fatigue syndrome clients at a distance: a teleconference pilot study. *Journal of*
28 *Chronic Fatigue Syndrome*. 2007; 14(1):23-32
- 29 500. Webb CM, Collin SM, Deave T, Haig-Ferguson A, Spatz A, Crawley E. What stops
30 children with a chronic illness accessing health care: A mixed methods study in
31 children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *BMC*
32 *Health Services Research*. 2011; 11:308
- 33 501. Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. *Alternative*
34 *Medicine Review*. 2000; 5(2):93-108
- 35 502. White PD, Goldsmith K, Johnson AL, Chalder T, Sharpe M. Recovery from chronic
36 fatigue syndrome after treatments given in the PACE trial. *Psychological Medicine*.
37 2013; 43(10):2227-2235
- 38 503. White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC et al.
39 Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise
40 therapy, and specialist medical care for chronic fatigue syndrome (PACE): A
41 randomised trial. *Lancet*. 2011; 377(9768):823-836
- 42 504. White PD, Sharpe MC, Chalder T, DeCesare JC, Walwyn R, Pace Trial Group.
43 Protocol for the PACE trial: A randomised controlled trial of adaptive pacing, cognitive
44 behaviour therapy, and graded exercise, as supplements to standardised specialist
45 medical care versus standardised specialist medical care alone for patients with the

- 1 chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy. *BMC*
2 *Neurology*. 2007; 7:6
- 3 505. Whitehead L. The measurement of fatigue in chronic illness: A systematic review of
4 unidimensional and multidimensional fatigue measures. *Journal of Pain and*
5 *Symptom Management*. 2009; 37(1):107-128
- 6 506. Whitehead L, Champion P. Can general practitioners manage chronic fatigue
7 syndrome? A controlled trial. *Journal of Chronic Fatigue Syndrome*. 2002; 10(1):55-
8 64
- 9 507. Wiborg JF, Knoop H, Prins JB, Bleijenberg G. Does a decrease in avoidance
10 behavior and focusing on fatigue mediate the effect of cognitive behavior therapy for
11 chronic fatigue syndrome? *Journal of Psychosomatic Research*. 2011; 70(4):306-310
- 12 508. Wiborg JF, Knoop H, Stulemeijer M, Prins JB, Bleijenberg G. How does cognitive
13 behaviour therapy reduce fatigue in patients with chronic fatigue syndrome? The role
14 of physical activity. *Psychological Medicine*. 2010:1-7
- 15 509. Wiborg JF, van Bussel J, van Dijk A, Bleijenberg G, Knoop H. Randomised controlled
16 trial of cognitive behaviour therapy delivered in groups of patients with chronic fatigue
17 syndrome. *Psychotherapy and Psychosomatics*. 2015; 84(6):368-376
- 18 510. Wiborg JF, Wensing M, Tummers M, Knoop H, Bleijenberg G. Implementing
19 evidence-based practice for patients with chronic fatigue syndrome. *Clinical*
20 *Psychology & Psychotherapy*. 2014; 21(2):108-114
- 21 511. Wilshire C, Kindlon T, Matthees A, McGrath S. Can patients with chronic fatigue
22 syndrome really recover after graded exercise or cognitive behavioural therapy? A
23 critical commentary and preliminary re-analysis of the PACE trial. *Fatigue:*
24 *Biomedicine, Health and Behavior*. 2017; 5(1):43-56
- 25 512. Wilshire C, Kindlon T, McGrath S. PACE trial claims of recovery are not justified by
26 the data: A rejoinder to Sharpe, Chalder, Johnson, Goldsmith and White. *Fatigue:*
27 *Biomedicine, Health and Behavior*. 2017; 5(1):62-67
- 28 513. Wilshire CE, Kindlon T. Response: Sharpe, Goldsmith and Chalder fail to restore
29 confidence in the PACE trial findings. *BMC Psychology*. 2019; 7(1):19
- 30 514. Wilshire CE, Kindlon T, Courtney R, Matthees A, Tuller D, Geraghty K et al.
31 Rethinking the treatment of chronic fatigue syndrome-a reanalysis and evaluation of
32 findings from a recent major trial of graded exercise and CBT. *BMC Psychology*.
33 2018; 6(1):6
- 34 515. Worm-Smeitink M, Gielissen M, Bloot L, van Laarhoven HWM, van Engelen BGM,
35 van Riel P et al. The assessment of fatigue: Psychometric qualities and norms for the
36 Checklist individual strength. *Journal of Psychosomatic Research*. 2017; 98:40-46
- 37 516. Worm-Smeitink M, Janse A, van Dam A, Evers A, van der Vaart R, Wensing M et al.
38 Internet-based cognitive behavioral therapy in stepped care for chronic fatigue
39 syndrome: Randomized noninferiority trial. *Journal of Medical Internet Research*.
40 2019; 21(3):e11276
- 41 517. Worm-Smeitink M, Nikolaus S, Goldsmith K, Wiborg J, Ali S, Knoop H et al. Cognitive
42 behaviour therapy for chronic fatigue syndrome: Differences in treatment outcome
43 between a tertiary treatment centre in the United Kingdom and the Netherlands.
44 *Journal of Psychosomatic Research*. 2016; 87:43-49

- 1 518. Zablotskii V, Lunov O, Kubinova S, Polyakova T, Sykova E, Dejneka A. Effects of
2 high-gradient magnetic fields on living cell machinery. *Journal of Physics D: Applied*
3 *Physics*. 2016; 49(49):493003
- 4 519. Zablotskii V, Polyakova T, Dejneka A. Cells in the non-uniform magnetic world: How
5 cells respond to high-gradient magnetic fields. *Bioessays*. 2018; 40(8):1800017
- 6 520. Zhi W-J, Wang L-F, Hu X-J. Recent advances in the effects of microwave radiation on
7 brains. *Military Medical Research*. 2017; 4:29
- 8 521. Zielinski MR, Systrom DM, Rose NR. Fatigue, sleep, and autoimmune and related
9 disorders. *Frontiers in Immunology*. 2019; 10:1827

10